The Seed of Industrial Hemp (Cannabis sativa L.): Nutritional Quality and Potential Functionality for Human Health and Nutrition
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Keywords: THC, Cannabis sativa L. legislation, hempseed oil, hempseed proteins, hempseed minerals, antinutritional compounds, phenylpropionammides, bioactive peptides, hempseed dietary supplementation, hempseed-based food
Cannabis sativa L., commonly known as hemp, is an herbaceous, anemophilous plant belonging to the Cannabaceae family. It is considered one of the most ancient cultivated plants and due to its long history of cultivation, it is difficult to identify its exact centre of origin. According to phylogenetic studies based on molecular analysis and studies on sequence homology of ancient and modern DNA extracted from archaeobotanical and modern samples, respectively, most researchers agreed that this plant species originated in central Asia and was introduced in Europe as a cultivated and domesticated agricultural plant during the Bronze age (approximately, from the 22th until 16th century BC) [1,2]. Nevertheless, a recent work by McPartland and colleagues  provided evidence that C. sativa was indigenous also to Europe. Currently, there are no more traces of wild-type hemp and only domesticated (i.e., individuals of a species chosen and selected by humans for characteristics making them useful to people) and ruderal (i.e., forms growing outside of cultivation) hemp plants exist. Independently to its origin, the nowadays-domesticated form of C. sativa L. is widespread and cultivated not only in the Asian countries, but also in Canada, the United States (US), Europe, and Africa. It is a multipurpose, sustainable, and low environmental impact crop which can be useful for several application fields, from the agricultural and phytoremediation to food and feed, cosmetic, building, and pharmaceutical industries. Indeed, from this highly versatile plant, it is possible to obtain various products of industrial interest such as fibre and shives; bio-building and thermal insulated materials; seeds, flour and oil with important nutritional and functional features; and bioactive compounds of pharmacological interest  ( Figure 1 ).
The manifold applications of hemp plant: virtually, each part of this plant can be used in a specific industrial field. The seeds can be used in the food, feed, and cosmetical field as whole or dehulled, or it may be subjected to a cold press process to obtain an oil used in the food and cosmetic industries. From the stem, it is possible to obtain both shives and fibre, useful for animal, building, paper and textile applications. The hemp root system is highly developed in comparison to other herbaceous plants, and this feature is suitable for the phytoremediation of soil from heavy metals. Hemp flowers can be used for ornamental purposes or to obtain products of cosmetic and pharmaceutical interest, such as essential oils composed by delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) pure extracts.
Essentially, C. sativa L. can be grown for three main purposes: industrial, narcotic/recreational, and medicinal . Traditionally, C. sativa L. plants were cultivated primarily as a fibre crop for the production of textiles and ropes, especially in the western world. Despite their high nutritional value, the seeds of this plant were initially considered as a by-product of the fibre production, and hence, they were mainly used as animal feed. From the first half of the 21st century, the cultivation of this crop declined because of the progressive diffusion of synthetic fibres and the use of some narcotic strains of the C. sativa L. plant for the production of intoxicant drugs. Only since the last two decades, there has been a reintroduction of the the C. sativa L. cultivation exclusively for industrial purposes, and in this context, Canada has been the first western country to restore this crop, followed by Europe and the US. Nowadays, a growing interest for the seeds of the C. sativa L. plant, commonly named hempseeds, has been developed due to the increased knowledge about their high nutritional value and potential functionality. However, there is still a lack of awareness and much confusion between “industrial hemp” and “drug hemp” especially among the public opinion, so the research of the potential health benefits provided by hempseed is still penalized by the negative reputation of drug hemp, which daunts interests and investments. Moreover, although in scientific literature there is a fairly good amount of information about the nutritional composition of hempseeds, there is still a lack of studies regarding the nutritional and health benefits related to hempseed-based food products for human consumption. Hence, in this review, we overview the literature about the nutritional and functional properties of hempseeds belonging to those varieties of C. sativa L. that have been allowed for cultivation. These varieties contain a delta-9-tetrahydrocannabinol (THC) level less than 0.3% or 0.2% of the reproductive part of the female plant at flowering and are named “industrial hemp”. Next, the literature studies about animal and human hempseed supplementation is reviewed. For more clarity and awareness, in the first part of the work, we provide information regarding the main biochemical, genetic, and legislative aspects of the C. sativa L. species, important to outline and understand the difference between industrial hemp and drug hemp.
2. Biochemistry, Genetic, Taxonomy and Legal Status of C. sativa L.
2.1. The Cannabinoids Synthesis in C. sativa L.
The major discriminant factor related to the different intended uses of C. sativa L. is the level of the two major and more known phytochemicals characteristic of this crop, namely the only one psychoactive and toxicant compound of the plant, THC, and the non-psychoactive cannabidiol (CBD). Both of them belong to the cannabinoids’ class which includes over of 100 secondary metabolites belonging to the family of terpenophenolic compounds, typical of all C. sativa L. plants. These compounds are synthesized, collected, and stored in stalked glandular trichomes, that are specialized tiny secretory epidermal glands [5,6], which are essentially present and abundant on the inflorescence of the female plant, whilst are present in lower numbers on leaves and stems, and are absent on roots and seeds, therefore, these latter organs do not contain cannabinoids [4,7,8]. A possible presence of cannabinoids in hempseeds could occur during the harvesting process, as a result of physical contact with the resin secreted by the glandular trichomes located on the bracts that surround the seed [9,10]. Hence, the presence of cannabinoids in hempseed actually represents a contamination, and the level of this contamination depends on both the cultivar (cv) and the cleaning process of the seed. Reasonably, THC contamination in seeds from C. sativa L. varieties which produce a low-THC level—as the industrial hemp varieties—should be extremely low ; anyway, the adoption of a method for the quantification of the possible cannabinoid’s contamination and the level in hempseed products and food may be appropriate [11,12,13].
C. sativa L. plants grown for an industrial purpose, are cultivated to obtain fibre, seeds, and their derivatives. These plants are popularly called “industrial hemp” or “fibre-type” hemp, and they contain low-THC level (i.e., C. sativa L. plants cultivated for narcotic/recreational purposes are characterized by high-THC level and those cultivated for medicinal purposes are characterized by high-THC and high-CBD levels.
Several works clarified well the cannabinoids’ biosynthetic pathway [14,15,16,17,18,19]. According to these studies, a common precursor of all the main cannabinoids exists, and it is the cannabigerolic acid (CBGA). In the cytosol, CBGA is converted into the acidic form of the three main cannabinoids, from which other related cannabinoid compounds will originate, namely tetrahydrocannabinol acid (THCA), that in the acidic form has no psychoactive activity; cannabidiolic acid (CBDA); and cannabichromenic acid (CBCA). This conversion is catalysed by an oxidocyclase specific for each cannabinoid (THCA-synthase, CBDA-synthase, and CBCA-synthase, respectively) ( Figure 2 ). Finally, the acidic form of each cannabinoid undergoes non-enzymatic decarboxylation to their neutral and active form, i.e., THC with psychoactive activity, CBD, and CBC that is found at high levels in juvenile plants [20,21], respectively.
The cannabinoid synthetic pathway: cannabigerolic acid (CBGA) is the common precursor of all main cannabinoids. It is synthesized through an alkylation of the phenolic moiety of olivetolic acid with the terpenoid component of geranyl pyrophosphate (GPP). The reaction is catalysed by a geranylpyrophosphate:olivetolate geranyltransferase (GOT). Olivetolic acid is originated in the cytosolic polyketide pathway through an aldol condensation of hexanoyl-Coenzyme A (CoA) with three molecules of malonyl-CoA, that is catalysed by the polyketide synthase (PKS) enzyme in the presence of olivetolic acid cyclase (OAC). The GPP is synthesized by the plastidial methylerythritol phosphate (MEP) pathway. In the cytosol, CBGA is converted into the acidic form of the three main cannabinoids, tetrahydrocannabinol acid (THCA) that in the acidic form has no psychoactive activity, cannabidiolic acid (CBDA) and cannabichromenic acid (CBCA). GPS: geranyl pyrophosphate synthase; IPP: isopentenyl diphosphate; OAC: olivetolic acid cyclase.
2.2. Chemical Phenotype and Taxonomy of C. sativa L.
Elucidation of the cannabinoids’ biosynthetic pathway has been essential to demonstrate that the concentration of each cannabinoids in the plant is genetically determined, so that various genotypes related to different chemical phenotypes, diverging in types and concentration of cannabinoids (i.e., cannabinoids profile), exist. These phenotypes are known as “chemotypes” or “biotypes”, and three different principal chemotypes were commonly identified [8,20,22] on the basis of the two main cannabinoids (i.e., THC and CBD) content and ratio:
Chemotype I is characterized by a low CBD/THC ratio (0.00–0.05), due to high THC content (>0.3% of dry weight of the reproductive part of the female plant at flowering). This chemical phenotype is also known as “drug type”, “THC-predominant”, or C. sativa L. subsp. Indica and the varieties belonging to this chemotype are those commonly grown for narcotic/recreational purposes.
Chemotype II has both the two main cannabinoids, CBD and THC, in a content ratio (CBD/THC) close to the unity (0.5–3.0), usually with a slight prevalence of CBD. This chemical phenotype is also named “intermediate type” or “THC-intermediate”, and the varieties belonging to this chemotype are mainly grown for medicinal use.
Chemotype III is characterized by high CBD/THC ratio (15–25) due to high CBD amount and low THC content, not over than 0.3% of dry weight of the reproductive part of the female plant at flowering. This chemical phenotype is also known as “non-drug type”, “fibre-type”, “THC-predominant”, or C. sativa L. subsp. Sativa, and the varieties belonging to this chemotype are cultivated for industrial purposes, namely, for fibre, seeds, and their derivatives.
De Meijer and colleagues  for the first time gave a clear genetic meaning to the tripartite distribution of the chemotypes within the C. sativa L. population. Indeed, studying the inheritance of the chemotype traits of C. sativa L. plants, they identified the existence of a single locus named B locus, with two co-dominant alleles, named BT and BD, each of which codes for the THCA- and CBDA-synthases, respectively. Hence, according to this model, the THC-predominant phenotype (chemotype I) is related to the BT/BT genotype, the CBD-predominant phenotype (chemotype III) is determined by the BD/BD genotype, and the intermediate phenotype (chemotype II) is induced by the heterozygous state BT/BD. The same authors also showed that the value of the CBD/THC ratio in the heterozygous hybrids obtained from cross between parental homozygous pure-THC and pure-CBD, unexpectedly differed significantly and deviated from the expected 1.0 value. Therefore, they speculated that some heritable factor could affect the balance between THCA- and CBDA-synthase in their competition to convert the CBGA precursor. In particular, the authors hypothesized that the BT and BD alleles could be part of a wider allelic series coding for several isoenzymatic forms of THCA- and CBDA-synthase, respectively, with differential affinities for the CBGA substrate, resulting in significantly different CBD/THC ratios observed in the heterozygotes. Further studies pointed out the existence of several allelic variants of BD [7,20,24] and BT [7,8,24,25] genes coding for less or totally non-functional CBDA- and THCA-synthase, respectively, and which therefore, influence the cannabinoid profile of the plant and, from a practical point of view, also represent an useful genetic marker to differentiate the drug-type from the fibre-type C. sativa L. plants. Interestingly, a higher number of allelic variants of wild-type BD locus was found in comparison to the BT locus. Hence, considering the high number of the cannabinoid synthase genes’ allelic variants and the higher mutation rate of the CBDA-synthase allele, Onofri and colleagues  proposed a phylogenetic hypothesis according to which it is possible to consider all cannabinoids’ allelic variants as a gene family and to speculate that the wild-type CBDA-synthase allele may be the ancestral form of this gene family, from which events of duplication would have led to a higher CBDA-synthase variation, resulting in the formation of the CBDA-synthase pseudogenes (i.e., the CBDA-synthase allelic variants) and to the rise of a new sequence coding for a new enzyme able to convert the CBDA substrate in a new product, the THCA. According to this evolutionary theory, it has also been hypothesized that the low-functionally THCA-synthase allele found in some fibre type (CBD-predominant) plants , could be an evolutionarily intermediate between the CBDA-synthase ancestor and the fully functional THCA-synthase allele.
The high intrinsic genetic variability rate of C. sativa L. has been further accentuated by the long history of its domestication. Indeed, the different intended uses of the C. sativa L. cultivation’s products have led over the years, to an artificial phenotypic selection of specific features of the domesticated plants, useful for increasing the yield and/or the quality of the commercial interest’s cultivation products . The direct consequence of this selection was the unaware artificial creation of the C. sativa L. varieties, each with specific genotypic and phenotypic features, which at first, induced the taxonomists and botanists to erroneously recognize two or three different species of C. sativa L., embracing a polytypic concept of the Cannabis genus . To further complicate the taxonomic classification of the Cannabis genus, there has been also the fact that C. sativa L. is a crop which tends to exist in “crop-weed complexes”, that is complexes of domesticated forms in cultivation and related ruderal (weedy) forms growing outside of cultivation, developing morphological characteristics also very different from those of the domestic progenitor, as a consequence of adaptation to the wild environment . However, it must be considered that, despite the high genetic variability of C. sativa L., the varieties that genotypically and phenotypically differ, are interfertile. Therefore, taking into account the Darwinian definition of biological species, “a group of organisms that can reproduce with one another in nature and produce fertile offspring”, C. sativa L. varieties cannot be consider as different species of the Cannabis genus. For this reason, to date, the polytypic concept has been definitely given up and replaced by the monotypic one. According to this, a single species of Cannabis genus exists, namely C. sativa L., which includes several varieties or cultivars (cvs) that genotypically and phenotypically differ, but they all are interfertile and therefore, they belong to the same species [29,30].
From a practical point of view, the main discrimination factor among the C. sativa L. cvs is the THC content, which, essentially for legal reasons, as described in the next paragraph, is an useful tool to discriminate between the drug-type plants with high THC content, used for medical or recreational purposes, and the fibre-type plants with low THC content, commonly named industrial hemp.
2.3. Legislation of C. sativa L.
Historically, industrial hemp or simply, hemp, that is, C. sativa L. plants grown for fibre and/or seeds, was frequently cultivated over the world, mainly for the production of technical textiles, until the first half of the 21st century. In the US, hemp was widely grown from the colonial period into the mid-1800s. In the early 1900s and prior to the late 1950s, hemp continued to be grown, being considered as an agricultural commodity: the US Department of Agriculture (USDA) supported its production, and USDA researchers continued to publish information related to hemp production and also reported on hemp’s potential for use in textiles and in paper manufacturing . In Europe, at the end of the 1950s, Italy was the second country in the world after Russia for the areas under hemp cultivation (over 100,000 hectares) and was the world’s best for the quality of the obtained products . However, following the discovery of the psychotropic activity of THC, and the increasing awareness of its deleterious effects on human health, many countries began to take measures in an effort to stem the use of C. sativa L. plants’ flowers and leaves for their psychotropic effects. The first provision was taken in the US and Canada. In the US, between 1914 and 1933, 33 states passed laws restricting legal production to medicinal and industrial purposes only. In 1937, the Marihuana Tax Act defined hemp as a narcotic drug, without any distinguishing between low THC plants (hemp) and high THC (drug hemp or simply, marijuana) ones: both were considered schedule I controlled substances, and it was required that farmers growing hemp hold a federal registration and special tax stamp. This effectively limited further production expansion; in fact, after 1943, production of hemp started to decline until the late 1950s when no production was recorded. Finally, in 1970, The Controlled Substances Act (CSA) was issued, and it placed the control of selected plants, drugs, and chemical substances under federal jurisdiction. Among the selected plants, there were also C. sativa L. ones to which were given the statutory definition of marijuana and were put in the Drug Enforcement Administration (DEA) schedule of controlled substances . In Canada, the cultivation of hemp has been prohibited due to the presence of THC, in 1938 with the Canadian Opium and Narcotics Act [33,34]. In 1961, the United Nation (UN) endorsed and adopted the single convention on narcotic drugs, which established a universal system for limiting the cultivation, production, distribution, trade, possession, and use of narcotic substances to medical and scientific purposes, with a special focus on plant-derived substances, among which is cannabis. In the article 28, paragraph 2 of this convention, cannabis was defined as “the flowering or fruiting tops of the C. sativa L. plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated”. The same article described a system of control required if a country decides to permit the cultivation of C. sativa L. that is not for industrial or horticultural purposes [4,35]. Ten years later, in 1971, the UN endorsed the convention on psychotropic substances which established an international control system for psychotropic substances, among which is THC . In line with these directives, in 1975 the Italian Republic issued the law n. 685/1975, introducing cannabis (intended as a drug product obtained from C. sativa L. plants) in the schedule of controlled substances.
The better knowledge of the biochemical and biomolecular features of the C. sativa L. species has made it possible to understand the genetics and biochemical mechanisms previously described, which are the basis of the cannabinoids’ synthesis and, in particular, of THC. Furthermore, thanks to the development of specific analysis techniques (e.g., gas chromatography or gas chromatography-mass spectrometry), it is now possible to resolutely and accurately quantify the THC content of C. sativa L. plants in order to distinguish between cvs with high and low THC contents. For these reasons, nowadays, the cultivation of industrial hemp has been reintroduced either in the US, Canada, and Europe. Canada was one of the first country to restore industrial hemp cultivation. Indeed, in 1994, it began to issue licenses for hemp as a research crop and then, in 1998, the cultivation of hemp varieties containing less than 0.3% THC of the dry weight of leaves and flowering parts was legalized, and it is currently permitted, provided that a license from the Office of Controlled Substances of Health Canada has been acquired. To date, Canada is the major hemp-producing and -exporting country, particularly of hemp-based foods, ingredients, and other related products . In the EU, the hemp cultivation reintroduction took place in 2013 with the EU regulation n. 1307/2013 that allowed the growth of C. sativa L. plants for industrial purposes only for those plants with low levels of THC. According to this regulation, the granting of payments under the Common Agricultural Policy (CAP) is conditional upon the use of certified seeds of specific hemp varieties, that is, C. sativa L. cvs with a THC content not exceeding 0.2% of the dry weight of leaves and flowering parts . Thus, the EU has adopted more stringent parameters compared to Canada, to ensure the safety of and to protect the health of citizens. Different genotypes of industrial hemp with a THC content < 0.2% have been selected and registered, and currently, there are about 70 allowed industrial hemp varieties listed in the European Plant Variety Database as agricultural species (Table 1 ) [37,38]. Some of these cvs are dioecious as the C. sativa L. plant naturally occurs; other cvs are monoecious and are obtained by ancestral breeding . Often, but not always, the monoecious varieties are adopted for seed production since they give a higher yield of the product of interest, whereas the dioecious cvs are mainly adopted for fibre production. Moreover, the industrial hemp varieties listed in the EU plant variety database are constantly updated based on the results of the annual THC-content’s monitoring and on the possible request for the introduction of new cvs with a low THC amount.
Industrial hemp cultivars registered and listed in the European Union Plant Variety Database and their origin. All these varieties are certified to contain less than 0.2% of THC of dry weight of leaves and flowering parts of the plant, according to the EU regulation 1307/2013.
|No||Registered Varieties||Origin||No||Registered Varieties||Origin|
|4||Austa SK||Latvia||36||KC Virtus||Hungary|
|8||Cannakomp||Hungary||40||Kompoliti Hibrid TC||Hungary|
|17||Earlina 8 FC||France||49||Santhica 23||France|
|18||Eletta Campana||Italy||50||Santhica 27||France|
|19||Epsilon 68||France||51||Santhica 70||France|
|20||Fedora 17||Switzerland||52||Secuieni Jubileu||Romania|
|27||Futura 83||France||59||Uniko B||Hungary|
Nowadays the EU is the world’s largest hemp-producing market second only to Canada, with France, the Netherlands, Lithuania, and Romania as the major production centres . According to the EU guidelines, also in Italy, the cultivation of industrial hemp has been recently restored through the law n. 242/2016, and the subsequent circular of the Ministry of Agricultural, Food and Forestry Policies (MIPAAF) published on 14 January 2017 that has delineated the conditions for hemp production, its commercialization, and its utilization for specific industrial purposes .
Finally, in the US, the federal policy regarding hemp was significantly altered with the 2014 Farm Bill (Agricultural Act of 2014) that allowed the USDA and certain research institutions to grow hemp under an agricultural pilot program. Despite this act, industrial hemp continued to be a niche crop. The great novelty was four years later with the 2018 Farm Bill that has established a new federal hemp regulatory system under the USDA with the aim to facilitate the commercial cultivation, processing, and marketing of hemp and to essentially treat hemp like any other agricultural commodity. Indeed, it removed hemp (i.e., C. sativa L. varieties with a THC content C. sativa L.) through the entry into force of the Cannabis Act, Bill C-45 . In Figure 3 , the main highlights about the C. sativa L. legislation in Canada, the US, the EU and Italy among the EU states, are illustrated.
The main points of the legislation about C. sativa L. (industrial hemp) cultivation in the US, Canada, and the EU with a focus on the Italian Republic among the EU states. The red line separates the legislation related to the prohibition of C. sativa L. cultivation (left part of the red line) from that allowed the reintroduction of growing of this crop (right part of the red line). For more details, see Section 2.3. US: United States; UN: United Nations; THC: delta-9-tetrahydrocannabinol; EU: European Union; USDA: United Stated Department of Agricultural.
3. C. sativa L. Seed
As mentioned above, the C. sativa L. crop has a prehistoric use as an important source of industrial interest’s plant fibre. Nevertheless, in the last decades, there has been a growing interest in the seed of the plant which is the fruit of hemp, commonly named seed, even if it is technically an achene, namely an one-seeded dry fruits in which the pericarp is not as tightly joined to the seed, essentially similar to the cereal caryopsis . Normally, the seeds of hemp grown for fibre production were considered as a waste product, and at most, they were mainly used as animal feed [34,41]. However, in recent times, with the growing recognition of their nutritional features and health benefits, the production of hempseeds has been increased and these seeds have become a product with an important and growing potential market . Therefore, the literature about the nutritional and functional features related to this product has been reviewed in the next sections.
3.1. Hempseed Nutritional Features
Hempseed has commonly been claimed as one of the most nutritionally complete food sources due to its high nutritive traits. It can be consumed as such (whole, hulled seed) or dehulled (hempseed kernel), as well as its processing products, including oil, flour, and protein powder. Despite the fact that some studies highlighted high variability in the hempseed composition according to the genotypes and environmental factors [3,32,34,39,43,44,45,46], it typically contains 25–35% lipids with a unique and perfectly balanced fatty acids (FAs) composition; 20–25% proteins easy to digest and rich in essential amino acids; 20–30% carbohydrates, a great part of which are constituted in dietary fibre, mainly insoluble; as well as vitamins, and minerals ( Table 2 ).
Hempseed nutritional characteristics (mg/100 g).
|Moisture||Fat||Proteins||CHO||Total DF||Insoluble DF||Soluble DF||Ash||Ref|
|6.7 ± 0.5||34.6 ± 1.2||25.6 ± 0.6||34.4 ± 1.5||33.8 ± 1.9||30.9 ± 1.5||2.9 ± 0.4||5.4 ± 0.3|||
|8.4 ± 0.02||33.3 ± 0.1||22.5 ± 0.2||n.a.||n.a.||n.a.||n.a.||5.9 ± 0.03|||
|7.3 ± 0.1||24.5 ± 2.0||24.8 ± 1.1||38.1 ± 2.5||n.a.||n.a.||n.a.||5.3 ± 0.6|||
Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available; CHO: carbohydrates; DF: Dietary Fibre.
In addition to its nutritional value, hempseed is also rich in natural antioxidants and other bioactive components such as bioactive peptides, phenolic compounds, tocopherols, carotenoids, and phytosterols, the content of which appears to be mostly affected by the environmental and agronomic factors and, to a lesser extent, by genetic variability . Moreover, hempseed contains also some antinutritional compounds that could negatively influence its nutritional value. In the following subsections, these nutritional and antinutritional hempseed’s components are discussed in detail.
3.1.1. Hempseed Fat
Fatty Acid Composition
Fat represents the most important component of hempseeds, particularly from an industrial point of view. Indeed, since hempseeds are oilseeds, the oil is the main food product of industrial interest that it is possible to obtain from them. For this reason, hempseed’s fat is commonly called oil. Several studies [34,39,44,45,46,47,48,49] demonstrated that the oil content of hempseeds belonging to different cvs ranges from 25 to 35% of the whole seed ( Table 2 ). Galasso and colleagues  and Irakly and co-workers , analysing the seeds belonging to different industrial hemp cvs, highlighted that this variation is mainly due to the genotype. In addition, Irakli and colleagues  also observed that even environmental conditions such as geography, climatic conditions, and local agronomic factors have an effect on the total oil content, though slighter than genotype. This evidence is in accordance with the findings of Kriese and colleagues  and Mihoc and co-workers . In this latter study, the authors, analysing the oil content of five Romanian industrial hemp cvs grown in two consecutive years in the same site, found that environmental conditions such as high monthly average temperature of 25–26 °C and a low rainfall level (223 mm during the flourishing of plants) resulted in an incomplete maturation of hempseeds and in a decrease in oil content.
As regards the chemical composition of the hempseed’s fat, it is needed to consider that most publications on this argument are referred to the oil extracted from hempseed through specific industrial methods, rather than to the whole seed, because of the high industrial relevance attributable to hempseed oil. However, in this review, we have been focused primarily on the whole hempseed, so, except in the case of a lack of literature data about whole hempseed, we have considered only the publications about this matrix, excluding those specifically concerning the oil. The literature data about the FA composition of the fat component of whole hempseed are reported in Table 3 .
Hempseed fatty acid profile (% of oil).
|7.0 ± 0.3||2.8 ± 0.4||12.7 ± 1.3||56.2 ± 3.5||2.9 ± 0.4||15.0 ± 1.1||n.a.||10.9 ± 0.5||13.1 ± 1.3||75.1 ± 3.7||4.0|||
|5.6 ± 0.5||3.9 ± 0.4||16.2 ± 6.2||54.7 ± 4.1||n.a.||16.2 ± 4.0||0.5 ± 0.01||10.9 ± 0.7||17.5 ± 6.3||72 ± 4.3||3.2|||
Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. PA: Palmitic Acid (16:0); SA: Stearic Acid (18:0); OA: Oleic Acid (18:2, n-9); LA: Linoleic Acid (18:2, n-6); GLA: γ-Linolenic Acid (18:3, n-6); ALA: α-Linolenic Acid (18:3, n-3); SDA: Stearidonic Acid (18:4, n-3); ∑-SFA: Total Saturated Fatty Acid; ∑-MUFA: Total Monounsaturated Fatty Acid; ∑-PUFA: Total Polyunsaturated Fatty Acid; n.a.: not available.
Overall, the literature data showed that hempseed oil is characterized by high polyunsaturated fatty acids (PUFAs) content and low saturated fatty acids (SFAs) amounts. More precisely, based on genotype and environmental factors, hempseed oil contained up to 90% unsaturated fatty acids , of which from 70% to over 80% is composed by PUFAs. The major monounsaturated fatty acid (MUFA) was Oleic Acid (18:1, n-9, OA) which has been shown to reach the highest value (18.78%) in the Canadian cv Joey , whereas the lowest OA content (8.42%) was found in the Finola cv grown in Italy . Generally, the amount of OA in hempseed oil is shown to be higher than those found in chia seed (7%)  and comparable to those present in linseed (15%) . Among PUFAs, Linoleic Acid (18:2, n-6, LA) was the most representative FA in hempseed oil of all analysed genotypes, accounting for more than half of the total FA. The second prominent PUFAs was α-linolenic acid (18:3, n-3, ALA). Hence, hempseed oil represents an especially rich source of these two fatty acids which are known as Essential Fatty Acids (EFAs), since they cannot be synthesized by mammals and, therefore, must be acquired by diet because they are necessary to maintain healthy human life. Indeed, LA and ALA are the precursors of the n-6 and n-3 PUFAs biologically active in animals, including humans, namely the long-chain PUFAs Arachidonic Acid (20:4, n-6, AA) which derived by the conversion of LA; and Docosahexaenoic Acid (22:6, n-3, DHA) and Eicosapentaenoic Acid (20:5, n-3, EPA) obtained from the ALA precursor. These biologically active forms of EFAs are necessary for many physiological processes, including maintenance of cell membrane structure, and cardiovascular health, the regulation of metabolic and inflammatory processes through the synthesis of prostaglandins and leukotrienes, skin integrity, as well as proper regulation of the brain’s development and function. In this context, it is important to note that the conversion of both LA and ALA into their biologically active PUFAs derivatives occurs at a low conversion rate. Several studies [3,34,39,47] highlighted that the Finola cv was the hemp variety with the highest ALA amount compared to other cvs. The highest ALA content in the Finola cv was found by Callaway (22%)  and the lowest was found by Irakli and colleagues (15.3%) .
In addition to the absolute concentration of PUFAs in the diet, the n-6/n-3 ratio represents an important index to ensure the maintenance of an optimal state of health, and to prevent the onset of chronic-degenerative diseases characterized by a chronic inflammation status, like cardiovascular and neurodegenerative diseases, as well as cancer . Despite the existence of different lines of thought about the healthiest n-6/n-3 ratio, according to the European Food and Safety Authority (EFSA) , the ideal n-6/n-3 ratio has been established as 3:1 to 5:1, that is also the ratio found in the traditional Japanese and Mediterranean diets, where the incidence of coronary disease has been historically low . The levels of LA and ALA found in the fat component of hempseeds make them a food matrix with the ideal, low n-6/n-3 ratio ranging precisely from 3:1 to 5:1, which is useful for reducing the n-6/n-3 ratio in diets, especially of industrialized countries, where there is an unhealthy average n-6/n-3 ratio of about 10:1, due to the too high n-6 and too low n-3 amount in the people’s diets . In addition to LA and ALA, among n-6 and n-3 FAs, hempseed oil also contains their respective biologic metabolites γ-Linolenic Acid (18:3, n-6, GLA) and Stearidonic Acid (18:4, n-3, SDA) that allow to bypass the first critical enzymatic step of δ-6-desaturase, facilitating the conversion into the biologically active form of long-chain PUFAs. Even in this case, Finola cv appeared as the hemp variety with the highest content of both GLA and SDA [3,34,39,47]. Furthermore, GLA performs also an anti-inflammatory activity since it is rapidly converted in Dihomo-γ-Linolenic Acid (DGLA; 20:3, n-6) in the human body. DGLA is located in the cell membrane, where it can act as a precursor of anti-inflammatory metabolites and can compete with AA for the synthesis of metabolites involving in the inflammatory response . In this context, it is important to consider that hempseed oil is not the only one source of GLA, neither the plant source with the highest amount of GLA, in fact, one of the most representative sources of this FA is the borage oil (19–23% of GLA) which however lacks n-3 PUFAs differently from hempseed oil . As regard the SFAs, studies reported that the total amount of them is not over than 12% ( Table 3 ), with a consequent recommended high (>10) PUFA/SFA ratio, considered beneficial to reduce the risk of atherosclerosis and coronary heart disease . The principal SFA was the Palmitic Acid (16:0, PA) with an amount ranging from 2 to 9%, followed by Stearic Acid (18:0, SA).
Concerning the variability in the hempseed oil’s FAs content, in literature there are some conflicting data. Particularly, a common evidence is that the FAs composition differs among cvs. Irakli and co-workers  demonstrated that, similarly to the oil content, the FAs profile of hempseeds is drastically affected by genotype. The same authors found that the content of FAs of seven industrial hemp cvs approved for cultivation in Greece and grown in the same site for three consecutive years, was most affected by genotype for ALA primarily, followed by OA and PA (genotype contribution on the variance, 99.6%, 91.2%, and 86.2%, respectively), whereas LA was the FA least affected (genotype contribution on the variance, 42%). Similar data were found by Vonapartis and colleagues  for ten Canadian industrial hemp cvs, which did not obtain significant differences among the analysed cvs for LA, but they found noticeable differences in the ALA concentration. Contrarily, Galasso et al.  detected high and significant variability for both LA and ALA contents of twenty hempseed accessions and cvs.
The Unsaponifiable Matter
Generally, any oil matrix is composed of saponifiable and unsaponifiable matter. The former consists of all the oil substances containing an ester portion that can be removed by treatment with irreversible alkaline hydrolysis, including mono-, di-, and tri-acylglicerols and phospholipids. The latter, according to the International Organization for Standardization (ISO) 18609:2000 definition, consists in all the substances dissolved in the product which cannot be saponified by the caustic alkalis but are soluble in the ordinary fat solvent (e.g., hexane). The unsaponifiable matter includes sterols, aliphatic and terpenic alchols, as well as fat-soluble vitamins. Literature data about the composition of the unsaponifiable matter of the fat component of whole hempseed are very scarce; in fact, almost all of them concern the oil of hempseed. One of the first reports in which the unsaponifiable matter of the oil of hempseed has been investigated in detail was the work of Montserrat-De La Paz and colleagues . They demonstrated that the unsaponifiable matter of hempseed oil represents from 1.8 to 1.92% of the total oil, and the most relevant compounds of this oil fraction are tocopherols and phytosterols. Tocopherols are naturally occurring, fat-soluble compounds with high antioxidant activity. They include the different isomers α-, β-, γ-, and δ-tocopherol and represent the dominant antioxidants in hempseed oil, protecting it from oxidation thanks to their ability to scavenge free radicals. As said, most publications in which the tocopherol content has been assessed concern the oil of hempseed instead of whole hempseed, and in fact, the obtained results are expressed referring to the oil (e.g., mg/100 g of oil) rather than to the seed (e.g., mg/100 g of seeds). Anyway, they provide important information about the content of these functional compounds, and considering the lack of data referred to whole hempseed, these publications have been considered in this specific case. The literature data obtained from the studies that evaluated the tocopherol profile of hempseed and hempseed oil are reported in Table 4 , where the results expressed per 100 g of seeds have been separated from those expressed per 100 g of oil.
Hempseed oil unsaponifiable matter: tocopherol profile.
|Type of Analyzed Sample||Total Tocopherols||α-Tocopherol||β-Tocopherol||γ-Tocopherol||δ-Tocopherol||Ref.|
|mg/100 g seed|
|Whole seed||n.a.||0.35 ± 0.09||n.a.||0.55 ± 0.13||n.a.|||
|mg/100 g oil|
|Oil||n.a.||2.78 ± 0.01||n.a.||56.41 ± 0.02||n.a.|||
|Oil||80.28 ± 4.50||3.22 ± 0.65||0.81 ± 0.16||73.38 ± 2.86||2.87 ± 0.83|||
|Oil||n.a.||2.56 ± 0.06||0.60 ± 0.005||59.79 ± 1.21||3.97 ± 0.15|||
|Oil||97.13||4.32 ± 0.65||n.a.||89.26 ± 1.92||3.55 ± 0.25|||
|Oil||92.97||4.71 ± 0.54||n.a.||84.11 ± 1.74||4.15 ± 0.44|||
1 β-tocopherol + γ-tocopherol. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available.
Obviously, when the values are reported per 100 g of oil, the tocopherol amounts are higher in comparison to the values referring to 100 g of seeds, as a consequence of the concentration of these compounds in the extracted oil. In any case, all works reported γ-tocopherol as the most abundant isomer, followed by α-, δ- and β-tocopherols. Among these isomers, γ-tocopherol has been suggested to be the most active antioxidant in lipids , and therefore, it contributes together with other antioxidant compounds like polyphenols to provide high oxidative stability to hempseed and, especially, to its oil, whereas, the α-isoform is considered as the only one tocopherol bioactive form, namely the form with vitamin E activity in the human body . Regarding the daily intake of vitamin E as α-tocopherol, EFSA has set an average intake (AI) of 13 mg/day for males and 11 mg/day for females . According to literature data ( Table 4 ), the α-tocopherol content in whole hempseed can reach up to 5 mg/100 g of seeds . A serving portion of hempseed corresponds to 30 g ; hence, the daily intake of a serving portion of whole hempseed can contribute to satisfying up to 14% for women and 12% for men for the vitamin E AI, whereas, the γ-tocopherol content found in the oil of hempseed has been shown to be higher than those found in both linseed and canola seed oils .
The total tocopherol amount in hempseed oil has been shown to be higher than that found in sunflower, sesame, and amaranth oil . It can reach even values higher than 90 mg/100 g of oil based on the type of extraction process used to obtain oil from the seed. Indeed, on an industrial scale, various oil extraction techniques exist, each of which can differ in performance in terms of economic costs, extraction yield, and composition and physicochemical quality of the extracted oil . One of these techniques is the cold-pressing method which, however, has low extraction efficiency and leads to obtaining an oil with high chlorophyll levels, probably due to intensive mechanical destruction of hempseed cells during the pressing and the consequent release of the pigments from chloroplasts. High amounts of chlorophyll negatively influence the oil quality and shelf-life, since it can lead to oil photooxidation due to the chlorophyll’s role as a sensitizer . To obtain a qualitatively better oil, it is possible to use an alternative extraction process such as supercritical fluid extraction (SFE), ultrasound assisted extraction (UAE), or microwave assisted extraction (MAE). SFE is based on the use of a gaseous medium above or near its critical temperature and pressure to recover extracts from solid matrices. Carbon dioxide (CO2) is the most commonly supercritical fluid used in the food industry for extraction from plant materials. Aladìc and colleagues  demonstrated that this method of extraction can extract more efficiently the tocopherols than the traditional cold-pressing, leading to two- or three-fold higher γ-tocopherol content in the extracted oil. Another alternative extraction process that has been shown to improve both the yield and nutritional quality of the hempseed oil was the enzyme-assisted cold-pressing (EACPM) method. Indeed, Latif and co-workers  found that, by using this extraction technique, the level of total tocopherols in the hempseed oil increased from 4.8 to 14.1% (based on the enzyme’s type) in comparison to that obtained by the cold-pressing method. Finally, UAE and MAE resulted even more efficient in increasing the extraction not only of tocopherols (+17% and +11%, respectively) but also of other oil-soluble antioxidant compounds present in the hempseeds, such as polyphenols, since the oil obtained through these techniques were shown to have higher oxidation stability and antioxidant capacity than that extracted by SFE. This has been attributed either to the capacity of both UAE and MAE processes to extract oil at a lower extraction temperature and a shorter process time [60,61]. These methods can extract oil and oil-soluble components from seeds using the effect of ultrasounds and microwaves, respectively, on the seeds. The ultrasounds, propagating through the cells, generate the phenomenon of cavitation, which provides a greater solvent penetration into the sample matrix, increasing the contact between the sample and the solvent, and thereby, enhancing the efficiency (yield) and reducing the time of extraction, whereas, the microwaves can easily penetrate into the sample pores causing the solvent trapped in the pores to heat evenly and rapidly; in this way, the kinetics of extraction increases, leading to shorter extraction times, higher extraction rates, lower costs, and less solvent use.
The extraction technique can have an influence on the tocopherol amount of the oil but not on that of the whole hempseed. Factors that mainly affect the tocopherols amount in the seeds and indirectly, also in the derived oil, are both genotype and, above all, environmental factors. About this, Irakli and colleagues  observed that the differences found in the tocopherols amount of seven industrial hemp cvs grown in Greece in three consecutive years, were mainly due to the effect of growing year (71% of the total variance) than the genotype (24% of the total variance). This, adding to the use of different extraction techniques used for the tocopherol analysis from hempseed, could explain the much lower tocopherol amount found by the authors in comparison to the very high tocopherols concentration obtained by Vonapartis and co-workers .
Phytosterols are fat-soluble compounds found only in plants; they cannot be synthesized in human and are characterized to have a structure similar to that of cholesterol. Thanks to this chemical feature, when phytosterols are ingested, in the intestine, they are able to reduce the cholesterol solubility, excluding it from lipid micelles and to compete with free cholesterol uptake, thereby preventing the cholesterol intestinal absorption. To date, only three reports are investigated the phytosterols content and profile of whole hempseed [49,50] or hempseed oil  ( Table 5 ).
Hempseed oil unsaponifiable matter: phytosterol profile.
|Type of Analysed Sample||Total Phytosterols||β-Sitosterol||Stigmasterol||Campesterol||Ref.|
|mg/100 g seed|
|Whole seed||n.a.||53.61 ± 3.15||2.47 ± 0.25||11.54 ± 1.03|||
|Whole seed||124 ± 12||79.7 ± 0.1||3.4 ± 0.9||7.3 ± 0.6|||
|mg/100 g oil|
|Oil||279.37 ± 12.43||190.5 ± 5.93||10.02 ± 0.75||50.57 ± 3.20|||
Data are expressed as mean ± standard deviation. n.a.: not available.
As noted for tocopherol content, the total phytosterol content is more concentrated when expressed for hempseed oil rather than for whole seeds. Anyway, the most abundant phytosterol has been shown to be β-sitosterol with a value of 190.5 mg/100 g for hempseed oil  and 79.7  and 53.61 mg/100 g  for the whole hempseed belonging to two different cvs. β-sitosterol in the seed plays an important role in the fluidity of plant cell and membrane and has a role in cellular differentiation. In humans, it can be effective to reduce hypercholesterolemia; can have favorable effects against colon cancer; and possesses antiviral, antifungal, and anti-inflammatory properties . According to Vecka and colleagues , the amount of β-sitosterol in whole hempseed is higher than in linseed (79.7 vs. 55.4 mg/100 g seeds) and it is similar to the richest source of β-sitosterol analysed in the same study, namely pistachio (85.9 mg/100g seeds). The other two main phytosterols found in hempseed are campesterol and stigmasterol. The latter was described as a compound able to inhibit several pro-inflammatory factors and potentially effective in the prevention of osteoarthritis .
Finally, the other still little explored components of the unsaponifiable matter of hempseed oil are carotenoid. Analysis of total carotenoids has been performed only bya few papers [48,64,66] on the hempseed oil obtained by CO2 SFE and cold-pressing process, whereas data on the carotenoids profile on whole hempseed are reported only by Irakli and colleagues . According to these papers, the total carotenoids of hemp oil has been found to range from 7.8 to 8.2 mg/100 g for oil obtained by two different cold-pressing methods applied on Hlesiia cv  and amount to 3.15 or 12.54 mg/100 g for oil obtained by cold-pressing and CO2 SFE, respectively . In another work , the amount of total carotenoids in hemp oil obtained by CO2 SFE was 3.42 mg/100 g. These differences may be due to the adoption of different CO2 SFE parameters as well as genotype and environmental factors as reported in the publication of Irakli and colleagues . As said, this is the only one report that analysed the carotenoid profile of whole hempseeds belonging to seven different cvs, showing that all analysed varieties contained the three main carotenoids lutein, zeaxanthin, and β-carotene, with lutein as the most abundant carotenoid ranging from 1.4 to 3.4 mg/100 g seeds, followed by β-carotene (0.2–0.8 mg/100 g seeds) and zeaxanthin (0.2–0.5 mg/100 g seeds). In this case, the total carotenoid content was found ranging from 1.4 to 4.3 mg/100 g seeds with values significantly affected by both genotype and growing year.
3.1.2. Hempseed Proteins
The protein content of whole hempseed can vary from 20 to 25% ( Table 2 ) according to variety and environmental factors. This amount can further increase in some hempseed-processed products such as dehulled seed and hempseed meal or cake (also called hempseed flour), that is, the remaining fraction of hempseed obtained after expelling its oil fraction [45,46,48,49]. Mattila and colleagues  demonstrated that in hempseed the proteins are mostly located in the inner layer of the seed, in fact they found only a low quantity of total proteins in the hull. Therefore, the increase in the protein content of processed products can be explained as a consequence of protein concentration after removing some component of the whole seed that totally or almost lacks in protein, such as the hull, where most of the fibre is located and the removal of which leads to a 1.5 times increase in both protein and oil amount. More proteins are also present when both hull and oil (the major component of whole hempseed) are removed. Indeed, their removal leads to obtaining the hempseed-processed product with the highest protein (up to over 50%) and the lowest fat content (even less than 10%, based on the type of extraction methods used) .
Research about the hempseed proteins originated from the early 20th century and highlighted that the two main proteins of hempseed are the storage protein albumin, a globular protein, and edestin, a legumin. This latter is the most abundant component, constituting about 82% of total hemp protein content. It is a hexamer of about 300 KDa composed by six identical subunits, each of which is in turn made up of an acidic (AS) and a basic (BS) subunit with molecular weights of about 33.0 and 20.0 KDa, respectively, that are linked by one disulphide bond [67,68]. In addition to edestin, the other components that have been found were albumin components (13% of total protein) and β-conglycinin (a vicilin-like protein) (up to 5% of total protein), the presence of which has been recently confirmed also by Pavlovic and co-workers  and in a recent genome-wide study  in which two albumin and one vicilin-like encoding genes in addition to three edestin isoforms where identify, each encoded by a different gene, differing for the amount of sulphurated amino acids that are particularly abundant in the isoform-type 3. Nevertheless, in the report of Pavlovic and co-workers , the authors found that edestin amounted to about 65% of total hempseed proteins. This result is in line with what was found from the HPLC and MS/MS analysis performed by Mamone and colleagues , but it is less than what was obtained in the previous studies by Tang and colleagues  and by Wang and co-workers . Moreover, these latter authors also found that the solubility of hempseed proteins at acidic pH was lower than that of soy proteins, and this may be due to the formation of covalent disulphide bonds among individual molecules of edestin, resulting in insoluble protein aggregates. Another physio-chemical property investigated was the thermal one. It was found that the denaturation temperature of hempseed proteins was 92 °C. This evidence is in agreement with what was observed by Raikos and colleagues  about the effect of heat treatment (80 °C or over) on the structural characteristics of hempseed proteins and consequently, on their digestibility. Indeed, high temperatures can lead the proteins to unfold and to expose their hydrophobic groups, favouring protein-protein interactions instead of the protein-water ones, and, hence, the formation of insoluble protein aggregates to which digestive enzymes cannot access. In this context, Wang and co-workers , investigating on the in vitro digestibility of hempseed protein isolates, had previously shown that untreated hempseed proteins were much more digestible compared to soy proteins. The high digestibility of hempseed proteins has been confirmed also by Mamone and colleagues , who observed that only a handful of peptides survived to an in vitro digestion process. On the contrary, Lin and colleagues  observed that heat pre-treatment on hempseed proteins at 100 °C for 15 or 30 min, improved their digestibility. The authors explained this evidence as a consequence of the improvement in the digestive enzymes’ bioaccessibility on target proteins through increased exposure of susceptible peptide bonds after protein unfolding.
Regarding the nutritional value of hempseed proteins, it is important to consider that the nutritional quality of a protein is defined by its amino acid composition and by its digestibility and bioavailability. The protein’s amino acid composition along with the individual’s amino acid requirement, are important to establish the amino acid score, which is the relative contribution that the amino acids contained in the protein meet the individual’s amino acid requirement, whereas, the protein digestibility is closely related to the bioavailability of its amino acids, since it measures the degree to which the protein is digested and their components—the amino acids—are absorbed by the gastrointestinal tract and, hence, introduced into the human body. Several authors investigated the hempseed proteins’ amino acid composition [45,46,47,67,68,73]. Some of them analysed the protein extracted from whole hempseed while others examined commercial hempseed protein isolate, so the obtained results are expressed on either a whole seed basis (g of amino acids per 100 g of seeds), or total protein basis (g of amino acids per 100 g of protein). In Table 6 , the literature data about the amino acid composition for whole hempseed are reported.
Hempseed protein amino acid content (g/100 g seed).
|Ala||Arg||Asp||Cys||Glu||Gly||His *||Ile *||Leu *||Lys *||Met *||Phe *||Pro||Ser||Thr *||Trp *||Tyr||Val *||Ref.|
* Essential amino acids. Ala: alanine; Arg: arginine; Asp: asparagine; Cys: cysteine; Glu: glutamate/glutamine; His: histidine; Iso: isoleucine; Leu: leucine; Lys: lysine; Met: methionine; Phe: phenylalanine; Pro: proline; Ser: serine; Thr: threonine; Trp: tryptophan; Tyr: tyrosine; Val: valine; n.a.: not available.
Amino acid composition obtained for hempseed proteins by various authors, are in good agreement and highlighted (1) that hempseed proteins contain all essential amino acids (EAAs) required by humans, and (2) that the most abundant amino acid is glutamic acid (3.74–4.58% of whole seed) followed by arginine (2.28–3.10% of whole seed). As previously anticipated, several authors [47,67,68] compared the amino acid composition of hempseed proteins to that of soy proteins and casein. The soy proteins have been chosen since they are one of the most important and commonly used plant sources of high-quality proteins , whereas casein is a highly digestible animal protein, considered a complete protein source, and therefore, it is commonly used as a reference protein to assess the nutritional quality of other proteins . Moreover, soy proteins and casein are considered good sources of amino acids for infants. From this comparison, it emerged that hempseed proteins have a good amount of sulphur-containing amino acids, higher than both casein and soy proteins. Furthermore, in comparison to soy proteins, the amino acid content of hempseed proteins was higher or similar, except for aspartic acid, glutamic acid, and lysine that resulted in being higher in soy proteins, whereas, if compared to casein, the amino acid content of hempseed proteins was higher or similar, except for tyrosine, leucine, methionine, and lysine that were more abundant in casein. Among EAAs, only three (isoleucine, lysine, and phenylalanine) resulted in being lower in hempseed proteins in comparison to casein, while the others appeared to be higher or similar and the proportion of EAAs to the total amino acids for hempseed proteins resulted in being higher than soy proteins and similar to casein. However, to understand if a protein can satisfy the human nutritional requirement, it is necessary to estimate the amino acid score for each amino acid element. The amino acid score for hempseed proteins has been calculated in different papers [46,67,68] based on the Food and Agriculture Organization/World Health Organization (FAO/WHO) amino acid suggested requirements for children 2–5 years old. The results obtained from all reports agree with the evidence that lysine was one of the limiting amino acids since its score was lower than 1 (0.75 in ; 0.72 in ; and 0.62 in ). Instead, conflicting results were found for other limiting amino acids of hempseed proteins. In both the papers of Tang and Wang and colleagues [67,68], others limiting amino acids were shown to be the sulphur-containing amino acid (methionine + cysteine) with an amino acid score of 0.65  and 0.62 . Hence, comparing the sulphurated amino acid score with the lysine amino acid score, the former resulted in the first limiting amino acid followed by lysine. Contrarily, House and co-workers  found that lysine was the first limiting amino acid followed by tryptophan (amino acid score, 0.87) and leucine (amino acid score, 0.94) and the limitation in the lysine content of hempseed proteins, ranks hempseed in the same range of the main cereal grains. These differences in the results may be related to the fact that the analyses were performed on different type of samples (i.e., commercial hempseed protein isolates and proteins extracted from whole hempseed). Tang and colleagues  have also calculated the amino acid score based on the FAO/WHO amino acid suggested requirements for children 10–12 years old and for adults, showing that, in these cases, there are no limiting amino acids.
House and colleagues  investigated the in vivo digestibility of hempseed proteins using a rat bioassay for protein digestibility, with the aim to evaluate the actual amino acid bioavailability. The authors observed that the in vivo protein digestibility of hempseed proteins collocates hempseed in the same range as the major pulse protein sources, such as lentils, and above cereal grain products. Furthermore, they also found that the presence of hull in the seed negatively affects the digestibility of the hempseed proteins. In fact, removal of the hull fraction from the hempseed led to an average increase in the protein digestibility from 85.2 to 94.9%. The authors supposed that the high fibre content of the hull may exert an influence on the digestibility of the proteins, but it is also possible that this decrease is, almost in part, due to the presence of some antinutritional factors such as phytate and trypsin inhibitors [39,74,75], with a different distribution in the various parts of the whole hempseed (see Section 3.1.5).
Overall, whole hempseed can be considered a rich-protein source containing a protein amount higher or similar than other protein-rich products, such as quinoa (13.0%) , chia seeds (18.2–19.7%) , buckwheat seeds (27.8%)  and linseeds (20.9%) . Nutritionally, the protein fraction of hempseed is highly digestible, has a good profile of EAAs required for infants similar to those of casein except for lysine that is the first limiting amino acid in hempseed proteins, even if this limitation is related only for the amino acid requirement for infants up to 5 years old who require a larger proportion of lysin. Furthermore, in addition to EAA profile, it is important to consider also the benefits provided by the amount of other non-EEAs such as arginine. In fact, arginine is a dietary precursor for the formation of nitric oxide (NO), a potent mediator of vascular tone, and therefore it is very important for the health of the cardiovascular system. Additionally, arginine and NO specifically, have been linked to optimal immune function and to muscle repair , so from this point of view, the proteins of hempseed represent an important source of digestible arginine. Hence, whole hempseed or their derived products such as hempseed meal or hempseed protein isolate can be considered a good viable, vegetable-based protein source for human diet.
3.1.3. Hempseed Carbohydrate and Dietary Fibre
Dietary fibre is defined as the part of plant material in the diet, which is resistant to enzymatic digestion and that includes cellulose, non-cellulosic polysaccharides such as hemicellulose, pectin, gums, mucilage and a non-carbohydrate component, namely lignin. Nutritionally, the dietary fibre is considered an integral part of the carbohydrate fraction of a food matrix. As previously said, the total carbohydrate content of hempseed can range between 20 and 30% ( Table 2 ). Actually, only a few literature reports analysed the total carbohydrate and fibre of hempseed. Among these, Callaway  found that the total carbohydrate content of the whole hempseed belonging to the Finola cv amounted to 27.6 g/100 g of seeds, whereas Mattila and colleagues  by analysing the nutritional value of some commercial protein-rich seeds, among which is hempseed, found that the total carbohydrate content of whole hempseed was similar to those found in the whole flaxseed (34.4 ± 1.5 g/100 g of seeds and 29.2 ± 2.5 g/100 g of seeds, respectively). However, the most interesting result obtained in both studies was that a great part of the total carbohydrate of the analysed hempseed was constituted by dietary fibre, the most of which was the insoluble fraction ( Table 2 ). In particular, Callaway found a Total Dietary Fibre content (TDF) of 27.6 g/100 g of seeds , demonstrating that the entire carbohydrate fraction consisted in dietary fibre, whereas in the study of Mattila and co-workers , the TDF of hempseed amounted to 33.8 ± 1.9 g/100 g of seeds, representing the 98% of the total carbohydrate. Since the remaining carbohydrate after excluding the amount of TDF is essentially starch, it is possible to assert that hempseed represents a low-starch content food matrix and a good source of dietary fibre, above all, the insoluble fraction. The high content of Insoluble Dietary Fibre (IDF) was found also by Multari and co-workers  for hempseed flour, which resulted in an IDF content of 25.49 g/100 g, whereas the Soluble Dietary Fibre (SDF) content was 0.16 g/100 g, thus highlighting that hempseed is one of the richest sources of IDF among several high-protein crops such as green pea, buckwheat, and fava bean (IDS, 8.69 ± 0.07 g/100 g, 6.98 ± 0.01 g/100 g, and 9.39 ± 0.30 g/100 g, respectively). These results were rather consistent with those obtained by Callaway (IDF, 22.2 g/100 g; SDF, 5.4 g/100 g)  and by Mattila and colleagues (IDF, 30.9 ± 1.5 g/100g; SDF, 2.9 ± 0.4)  for the amount of SDF and IDF in whole hempseed.
An estimate of the IDF could be obtained also through the analysis of Neutral Detergent Fibre (NDF), which measures the amount of the cell wall components, namely, hemicellulose, cellulose and lignin. Vonapartis and colleagues  reported that the average concentration of NDF in hempseed of ten industrial hemp cvs grown in Canada, was 35.7 g/100 g and this result was in good agreement to that obtained by House and colleagues (NDF, 32.1 g/100 g) . To note, it has been demonstrated that much of the fibre fraction of whole hempseed is located in the hull, as the fibre content obtained for dehulled hempseed was significantly lower than that found for the whole hempseed [45,46].
As previously said, the high fibre content of whole hempseed can negatively affect the protein digestibility; however, it is also important to take into account that the consumption of dietary fibre provides several health benefits in the human body. Indeed, dietary fibre, including the insoluble fraction, is considered a functional product acting as a probiotic, among others. In particular, it has been shown that it can improve insulin sensitivity; can reduce appetite and food intake, thus decreasing the risk of obesity and diabetes; and can lower the blood total cholesterol and low-density lipoprotein (LDL); moreover, because of the dietary fibre resists to digestion in the small intestine, it reaches the large intestine, where it is fermented by the gut microbiota, to produce short chain fatty acids with anti-carcinogenic and anti-inflammatory properties .
Hence, considering the health benefits derived by the ingestion of dietary fibre together with the considerable amount of fibre in hempseed, it would merit consideration as an ingredient to enrich the fibre content of foods, thereby improving their nutritional value. In this context, it should be taken into account that the use of whole hempseed (as it or defatted) would be more appropriate since almost all the fibre is located in the hempseed hull.
3.1.4. Hempseed Minerals
The total mineral content of a food matrix is indicated by the amount of ash that is the inorganic matter of the sample. Minerals are considered as micronutrients because their dietary requirement is relatively low (1–2500 mg/day depending on the mineral’s type); nevertheless, they are needed to maintain optimal health, playing physiological and structural essential roles. Based on their dietary requirements, minerals can be classified as macro-elements (i.e., minerals needed in amount of >50 mg/day), including phosphorous, potassium, magnesium, calcium; and sodium, and as micro-elements or in-trace elements (i.e., minerals needed in amounts of
Although different authors analysed the total ash amount in several varieties of hempseeds ( Table 2 ), highlighting that they are a good source of total minerals also considering other oilseeds like chia seeds  and linseeds  (4.9–6/100 g for hempseeds, 4.56–5.07 g/100 g for chia seeds and 3.5 g/100 g for linseeds), only a few authors investigated their minerals profile [43,44,45,47,48,49] showing that they can be considered a good source of useful macro- and micro-elements. The results obtained by these authors are reported in Table 7 .
Hempseed mineral composition value (mg/100 g) of different industrial hemp cultivars.
|P 1||K 1||Mg 1||Ca 1||Na 1||Fe 2||Mn 2||Zn 2||Cu 2||Cd 2||Ref.|
1 Macro-element. 2 In-trace element. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. P: phosphorous; K: potassium; Mg: magnesium; Ca: calcium; Na: sodium; Fe: iron; Mn: manganese; Zn: zinc; Cu: copper; Cd: cadmium. n.a.: not available.
In general, the mineral profile of seeds can widely vary based on environmental condition, mineral soil composition, the use or not of fertilizers, the type of fertilizer if used, as well as the plant variety. However, except to Siano and colleagues , other authors who have investigated the mineral profile of hempseeds belonging to different varieties and grown in various countries, obtained consistent and comparable values [43,44,47,48]. The major macro-elements found in hempseeds were phosphorous (P), potassium (K), magnesium (Mg), calcium (Ca), and sodium (Na), whereas among the in-trace elements, iron (Fe), manganese (Mn), zinc (Zn), and copper (Cu) have been reported.
Considering either EFSA’s Dietary Reference Value (DRV)  and the Food and Nutrition Board of the Institute of Medicine’s Dietary Reference Intake (DRI) , and the mineral content of hempseeds reported for different hemp cvs, it is possible to claim that hempseeds represent an excellent natural source of P, K, Mg, Ca, Fe, Zn, Cu, and Mn. Particularly, the amount of P, the most abundant mineral found in hempseeds, resulted in being higher also than that found in niger seeds (Guizotia abyssinica (L.f.) Cass.) and linseeds (Linum usitatissimum L.), which are oilseeds like hempseeds and are considered optimal phosphorous’ sources (P average content, 784.64 mg/100 g and 461.35 mg/100 g, respectively) . The level of K in hempseeds is in general higher compared to that found in linseeds (568.91 mg/100 g) , and is equivalent to that observed in hazelnut (863 mg/100 g), thought to be an optimal source of this macro-element . Interestingly, the high K amount along with a relatively low Na content, leads to a high K/Na ratio, which is believed to be related to cardioprotective effects as it promotes a high K intake considered to be inversely related to blood platelet aggregation and stroke incidence. Mg also contributes to hearth function and health, so that a Mg deficiency can lead to cardiac dysfunction. The amount of this mineral in hempseeds results in being similar to walnut (Mg range: 381–443 mg/100 g) which is one of the most important sources of Mg . Among the in-trace elements, Fe is of particular importance considering its essential role for human health and its widespread dietary deficiency. Interestingly, the hempseed’s Fe content resulted to be exceptionally high in the study of Mihoc and colleagues  in comparison to others works ( Table 7 ), but this may be due to the very high Fe level in the experimental growth soil (1900–2043 mg/100 g). Lan and co-workers  highlighted that the hempseed’s Fe content is much higher than cereal grains, and for this, hempseeds could be used to enrich cereal food products, ameliorating iron deficiency. In the same study, the authors have also calculated the percent contribution of minerals per serving of hempseeds (30 g of seeds) to Reference Daily Intake (RDI) for adult males from age 19 to 30, finding that the highest % RDI supplied by hempseeds of the analysed industrial hemp cvs, was for Fe and Mn (average % RDI, 46.68 and 169.14, respectively), concluding that all analysed varieties represent an excellent sources especially of Fe, Mn, Cu, Zn, P, and Mg. Additionally, it has been shown an increase in the content of some minerals in hempseed kernel after dehulling. Particularly, in the Hungarian Hlesiia cv, hull removal led to an increase in phosphorous (1.5 times), iron (1.25 times), and zinc (2 times) . Whereas Mattila and co-workers  observed that whole hempseed held 30–65% fewer macro-elements and Zn among in-trace elements in comparison to hemp hulls, whilst Cu and Mg were more evenly distributed in both the seed’s kernel and hull.
It is known that hemp plant with its wide root system is among the plants appropriate for phyto-depuration, namely decontamination of soil from the high and toxic level of heavy metals such as cadmium (Cd). For the non-smoking population, the major source of exposure to Cd is food and among the most important Cd food sources can be mentioned integral cereals, potatoes, seafood, fungi, and oilseeds. A dietary exposure to Cd in humans leads to a relatively low, but efficient absorption of the metal in the kidney and liver, where it has a very long biological half-life ranging from 10 to 30 years. Cd is primarily toxic to the kidney, especially to the proximal tubular cells, where it accumulates over time and may cause renal dysfunction. Cd can also cause bone demineralization, either through direct bone damage or indirectly, as a result of renal dysfunction. Moreover, the International Agency for Research on Cancer has classified Cd as a human carcinogen (group 1) after that data on human exposure to Cd in the general population have been statistically associated with increased risk of some cancer types such as lung, endometrium, bladder, and breast cancers . Taking into account the high capacity of hemp to absorb minerals from soil, including heavy metals, Mihoc and colleagues  evaluated the hemp plant capacity to translocate the absorbed Cd into the seeds in a soil with high Cd content (>0.3 mg/100 g) in the absence or presence of one of two different fertilizers (K and P fertilizers). They analysed the seeds belonging to five industrial hemp cvs approved for growth in Romania and they showed that hemp is able to absorb and translocate to the seeds from 130 to 400 µg/100 g of Cd, with the highest values obtained for plants treated with both K and P fertilizers. Considering the highly cadmium toxicity for human health, the European Food Safety Authority’s Panel on contaminants in the food chain  has set the tolerable weekly intake (TWI) for cadmium at 2.5 µg/Kg of body weight, whereas the FAO/WHO recommended 100 µg/Kg in cereals and legumes and up to 300 µg/Kg in medicine as the cadmium upper limit for safe human consumption . Hence, the value of Cd found in hempseeds by Mihoc and colleagues  far exceeds the upper limit set by the FAO/WHO, even if according to the EFSA TWI value, for an adult man with an average body weight of 70 Kg, the TWI for Cd is 175 µg, and 30 g (a serving portion) of hempseeds belonging to plants grown in a soil with high Cd content, has a Cd level below the TWI (39–120 µg of Cd). In addition, the medium Cd content in soil is generally of 0.05–0.08 mg/100 g, namely from 6 to 37.5 times lower than that used in the work by Mihoc and colleagues . Indeed, in another work investigating the heavy metal content in twenty-one hempseed samples collected from north western Turkey, the Cd content in the samples was found to be within the range of 0.5–2.3 µg/100 g, much lower than the upper limit recommended from the FAO/WHO . Similarly, Mattila and colleagues  observed that the Cd level in whole hempseed was 1.5 µg/100 g. In their study, Mihoc and co-workers  also investigated whether and how the minerals’ soil composition, the presence or absence of different fertilizers and the seeding distance could influence the minerals profile of the analysed hempseeds. They observed that both fertilizers at different levels of administration, decreased the absorption of Zn and Mn due to both the soil’s pH increase which limited the availability of minerals from soil, and the mineral-phosphate complexes forming for the P excess owing to the use of fertilizer. Furthermore, the authors showed that the content of Ca, Mg, and K in the seeds was mainly affected by varieties. The uptake of Ca by the plants was disturbed also by fertilizer, whereas K uptake was influenced also by further factors, such as seeding distance and environmental factors such as soil moisture and temperature.
3.1.5. Hempseed Antinutritional Compounds
The antinutritional factors are biological compounds present in human or animal foods that reduce nutrients’ bioavailability or food intake, or the metabolism of which may lead to the release of toxic products, thereby contributing to impaired gastrointestinal and metabolic performance. Generally, compounds such as saponins, phytic acid, alkaloids, certain oligosaccharides, protease inhibitors, cyanogenic glycosides, glucosinolates, and tannins are traditionally incorporated into this group. Referring to hempseed, only a few reports [39,73,74,75] investigated about the antinutritional compounds in this seed, and the antinutritional factors that have been considered were phytic acid, trypsin inhibitors, condensed tannins, cyanogenic glycosides, and saponins. The literature data about these analyses are shown in Table 8 .
Hempseed antinutritional compounds.
|Phytic Acid 1||Condensed Tannins 2||Trypsin Inhibitors 3||Cyanogenic Glycosides 4||Sapoins 2||Ref.|
|4.5–7.6 *||n.a.||10.8–27.8 *||n.a.||n.a.|||
|6.2–7.7 *||214.0–456.0 *||10.8–27.7 *||50.0–170.0 *||47.0–70.0 *|||
|5.3 ± 0.4 *||105.0 ± 4.0 **||n.a.||n.a.||n.a.|||
|6.1–7.4 *||135.0–214.0 *||18.2–28.4 *||60.0–240.0 *||5.9–8.1 *|||
1 g/100 g. 2 mg/100 g. 3 U/mg. 4 ppm. * On defatted matter. ** On whole seed. Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. n.a.: not available.
Phytic acid is a natural plant compound acting as the major storage form of P as well as the primary P reserve for the plant. Indeed, it constitutes 60 to 70% of the total P in cereal grains, oilseeds, and legumes and generally comprises 1–5% weight in cereals, oilseeds, legumes, and nuts . From a chemical point of view, PA is a myo-inositol hexakisphosphate (IP6) composed by an inositol ring esterified with six phosphate groups that are not internally connected; hence it has up to 12 replaceable protons allowing it to bind with multivalent cations (i.e., Zn 2+ , Fe 2+/3+ , Ca 2+ , Mg 2+ , Mn 2+ , and Cu 2+ ), positively charged proteins, and in some cases, starch through hydrogen bonds , forming insoluble complexes known as phytates. Both phytate-mineral and phytate-protein complexes are not readily absorbed by monogastric animals including humans because of their inability to metabolize phytic acid due to the lack of a sufficient level of phytate-degrading enzymes in their digestive tract. Thus, these complexes negatively affect the bioavailability of dietary and endogenous minerals and proteins as well as the digestive enzymes’ activity; therefore, for these reasons, phytic acid is considered an antinutrient. However, phytic acid may also have beneficial effects in the prevention and treatment of several pathological conditions related to oxidation and cancer , maybe due to its ability to chelate Fe ions, that lead phytic acid to inhibit iron-driven hydroxyl radical (–OH • ) formation and, hence, to strongly suppress lipid peroxidation and the oxidation of other biomolecules. Hence, for optimum physiological benefit of phytic acid, the phytate content in the upper part of the gut should be low to avoid negative effects on mineral and protein absorption and bioavailability, but at the same time, it should be high enough to use its antioxidant and anticancer activity. However, to date, accurate and clear information on the phytate dosage required to elicit beneficial effects in human is still limited. In accordance with Russo and Reggiani , to increase the safety for feed and food formulation, it is preferable to reduce the phytic acid content to at least 0.45 g/100 g of defatted sample. According to literature data, the results obtained by different authors about the phytic acid content in hempseed ( Table 8 ) are in good agreement and show that the level of this antinutritional compound ranges between 4 and 8% of the dry weight of the defatted matter. Galasso and colleagues  found a significant variability in the phytate content among different hemp cvs, and Russo  showed that French monoecious varieties had lower content than Italian dioecious ones, but this evidence is exactly the opposite of what Galasso and co-workers  found analysing twenty hempseed cvs and accessions of different origin, among which, the French varieties have been to be those with the highest phytic acid content. These differences in the results could be explained by the significant influence of genotype, growing year and the interaction between these two factors on the antinutritional compounds’ amount, phytic acid included . Compared to other seeds, the content of phytic acid in hempseed seems to be higher. For example, Russo and Reggiani, and Russo and co-workers [73,75] highlighted that the phytic acid content of hempseed was higher than those found in soy bean (2%), and Mattila and colleagues , comparing different type of oilseed, legumes, and pseudo-cereal grains, observed that oilseeds in general, including hempseed, linseed, and rapeseed, form a group with a higher phytic acid content in comparison to other legumes (e.g., fava bean and lupin) and pseudo-cereal grains (e.g., quinoa and buckwheat), and among the analysed oilseeds, whole hempseed was that with the highest phytic acid level.
Condensed tannins (CTs) are phenolic compounds (flavonoid oligomers, specifically), ubiquitous in the plant kingdom, designated as proanthocyanidins. They are considered as antinutritional compounds because of their ability to form insoluble complexes with proteins and minerals, negatively affecting nitrogenous compounds uptake and absorption of minerals , and thus reducing the nutritional value of foods. Moreover, based on their concentration, CTs can affect the palatability of the meal. Nevertheless, being phenolic compounds, in the monomeric form, they also have some beneficial effects on health acting not only as antioxidants, but also as anticarcinogenic, cardioprotective, anti-microbial and anti-diabetic compounds . According to Russo , the attention threshold for CTs is 1% of dry weight of the product. Although the amount of CTs found in hempseed meal ( Table 8 ) has been shown to be higher than other plant sources, for example soy (10 mg/100 g), the hempseed meal’s CTs content is however below than the attention threshold, so it neither is toxic, nor affects the hempseed meal palatability . Russo and Reggiani  found significant variability for the CTs content in monoecious and dioecious cvs, with a double level in the monoecious varieties than dioecious ones. Mattila and co-workers  evaluating the amount of CTs in whole hempseed and in the hull of hempseed, observed that the hull had slightly higher CTs content than whole hempseed, even if the difference was rather small (105 ± 4 mg/100 g and 144 ± 5 mg/100 g, respectively). The same authors also found that CTs in hempseed were essentially epi-catechin polymers (i.e., procyanidins).
Trypsin inhibitors (TIs) are a type of endogenous antinutritional factor commonly present in various crops, seeds, and vegetables, among which are pulses and legume seeds, nuts, oilseeds, and cereal grains. They can have a negative impact on the nutritional value of food and feed products as they affect protein utilization and digestion in human and animals. Their role in the plant is to protect the plant against microbial proteinases and to regulate the activity of endogenous proteinases. From a nutritional point of view, the ingestion of TIs reduces the digestibility of food proteins and the bioavailability of amino acids because they can pass unaltered through the stomach as they are stable against pepsin and at low pH , and in the small intestine, they are able to inhibit the biological activity of the digestive enzymes trypsin and chymotrypsin—both important for the digestion of protein in living organisms—by competitive binding and in this way, they lead to the formation of an irreversible trypsin/chymotrypsin enzyme-TI complex. TIs have been largely studied mainly in legume seeds, particularly in soybean, as it is one of the richest sources of these antinutrients. Guillamòn and colleagues , investigating the TIs content in different types and varieties of legume seeds, identified three groups of legume seeds according to the TIs content:
the highest content group including different soy (Glycine max) cvs with a TIs content ranging from 43 to 84 U/mg of the sample;
the medium content group corresponding to common bean (Phaseolus vulgaris) varieties containing from 17 to 51 U/mg of the sample; and
the lowest content group including lentil (Lens culinaris) and fava bean (Phaseolus vulgaris) cvs containing from 3 to 10 U/mg of the sample.
Although most of the works regarding TIs are performed on soy and legume seeds in general, some literature data about the amount of these antinutritional compounds in oilseeds such as Sacha inchi (Plukenetia volubilis L.)  and linseed  are also reported. The TIs amount in hempseed meal reported by different authors ( Table 8 ) was found to range between 10.8 and 28.4 U/mg, and the differences in the TIs content is probably due to both genotype and growth conditions [39,74,75]. These values are similar to those found for the TIs content obtained for linseed meal (13.8–24.7 U/mg) by Russo and Reggiani  and, considering the grouping made by Guillamòn, they would place both linseed and hempseed in the medium content group of TIs. Interestingly, Pojić and co-workers  highlighted that the inner fraction of hempseed, containing predominantly cotyledon particles, is the part of the seed with the highest TI activity compared to the fraction containing the hull particles. By contrast, Mattila and colleagues  found that the TI activity between whole hempseed and hempseed hull was similar, indicating that TIs are equally located through the hempseed’s kernel and hull.
Cyanogenic glycosides are nitrogen-containing secondary metabolites that serve to the plant as a protective device against predators such as the herbivores. The level of cyanogenic glycosides produced by the plant is dependent upon the age and variety of the plant, as well as the environmental factors . They are considered toxicants for humans because, structurally, they are glycosides of 2-hydroxynitriles that can be hydrolysed by the enzyme β-glucosidase into cyanohydrin, which is unstable and thus dissociates, leading to the toxic hydrocyanic acid. Although this is a violent poison, oral intake of cyanogenic glycosides (e.g., via food) is not necessarily toxic, particularly in the short-term intake. Indeed, hydrolysis of the cyanogenic glycosides in the digestive tract or by the liver leads to a slow release of hydrocyanic acid that is readily detoxified by the body. According to Russo , at levels below 100 ppm, the cyanogenic glycosides are not harmful to health. The amount of these antinutrients in hempseed has been investigated only in two reports [73,75], showing that, in the hempseed meal, their level significantly varies according to genotypes  and monoecious or dioecious cvs, with monoecious varieties containing lower cyanogenic glycosides than dioecious ones . Moreover, these studies highlighted that the hempseed meal of some hemp cvs has a cyanogenic glycosides content above the safety limit, but since this value refers to hempseed meal, it is resulted to be more concentrated compared to the whole seed.
Finally, saponins comprise a large family of structurally related compounds containing a steroid or triterpenoid aglycone (sapogenin) linked to one or more water-soluble oligosaccharide moieties. At larger quantities, these compounds are gastric irritants, and they can exert toxic properties causing haemolysis of red blood cells. However, at low doses, they may have a plasma cholesterol lowering effect in humans, as well as strong cytotoxic effects against cancer cell lines, and are important in reducing the risk of many chronic diseases . The FAO/WHO established a safety limit of 12% of saponins for quinoa seeds which are among the main saponins’ plant sources . Russo and Reggiani [73,75] found that the saponins amount in hempseed meal of different cvs was well below than 12%, and lower than other plant sources such as linseed and soy, despite the results they obtained from two separate studies being very different, with the level of saponins showed in one work  almost ten-fold higher than that obtained in the other work .
Concluding, among the various antinutritional compounds analysed in hempseed, TIs and, above all, phytic acid were the most abundant, based on a comparison with other edible seeds. Overall, it has been highlighted that all the analysed antinutritional compounds are positively correlated, and therefore, it is possible that the biosynthetic pathways of these compounds in hemp are expressed simultaneously during the seed’s development .
3.2. Hempseed Functional Features
The functional properties of hempseeds are related not only to their high nutritional value which awards them important beneficial features for human health, but also to the presence of different bioactive compounds, among which are unique phenolic compounds with antioxidant, anti-inflammatory, and neuroprotective actions, as well as bioactive peptides that will be discussed in detail in the next sections.
3.2.1. Hempseed Phenolic Compounds
Phenolic compounds are plant-derived secondary metabolites that are commonly produced by the plants as defence agents against biotic and abiotic stress, such as the attack of predatory species and UV light, respectively. These compounds, thanks to their chemical structures, have intrinsic antioxidant activity; therefore, they may protect cell constituents against oxidative damage and, hence, limit the risk of various degenerative diseases associated with oxidative stress. Indeed, in the human body they can exert a multitude of physiological activities, among which are cardioprotective and anti-inflammatory effects. Often, literature values about total antioxidant capacity and total phenolic content of a matrix are difficult to absolutely compare, due to the variety of analytical and extraction methods and the wide use of different reference compounds in the quantitation. Hence, in this review, we quantitatively compared the literature data obtained about these parameters by different authors, only if possible.
The first investigations about the antioxidant power and the total phenolic content (TPC) of hempseed were performed on hempseed oil. As previously said, the most abundant antioxidants in this product are tocopherols, especially the γ-isoform which confers to this oil a high oxidative stability despite the high level of unsaturated fatty acids that are highly susceptible to oxidation. However, together with tocopherols, also phenolic compounds contribute to the high oxidative stability of hempseed oil [52,58,95,96]. Indeed, it has been shown that hempseed cold-pressed oil represents a good dietary source of antioxidants which could have potential application in health promotion and disease prevention from oxidative damage, and therefore, it could be used to improve the quality and stability of food products. Smeriglio and colleagues  evaluating in detail the polyphenolic profile and the antioxidant properties of cold-pressed hempseed oil of the Finola cv, found that this product contained significant amounts of polyphenols, especially flavonoids such as flavanones, flavonols, flavanols, and isoflavones, the most representative and abundant of which were naringenin, kaepferol-3-O-glucoside, epicatechin, and daidzein, respectively. The presence of flavonoids in hempseed cold-press oil was demonstrated also by Faugno and co-workers  who investigated the polyphenol profile of cold-pressed oil of Uso 31 cv. The authors used the LS-ESI-MS/MS technique to assess the polyphenol qualitative and quantitative compositions of the oil and to investigate the influence of some agronomic practices on the quantitative variability of polyphenolic compounds. They found that, among phenols, the most representative compounds were dihydroxybenzoic acid, caffeoyl-tartaric acid isomers, p-coumaric acid, N-caffeoyltyramine, and N-feruoyltyramine, whereas, among the flavonoid subfamily, they found the glycosides of quercetin, kaempferol and isorhamnetin. Moreover, the authors observed that the highest production of polyphenols has been obtained without pre-seeding fertilization and with 60-plant/m 2 crop density, whereas when the plant density was halved, the abundance of phenolic compounds was compromised. In general, as said, the quantitative variability of polyphenols is affected by the influence of multiple biotic and abiotic factors, which take place in the biosynthetic pathway of these compounds, as reported also by Irakli and colleagues , who highlighted that the amount of phenolic compounds in the whole hempseed is affected by genotype, growing year, and the interaction between these factors. However, the growing year and so, the environmental and agronomical conditions, were the factor that most affected the variability of the TPC (contribution to total variance, 59%). In Table 9 , the literature data about the TPC extracted by different methods but analysed by the same technique (Folin–Ciocolteau) and expressed using the same reference compound (gallic acid) are reported, and they show the high variability of the parameters.
Total phenolic content (mg Gallic Acid Equivalent (GAE)/g) of hempseed cold-pressed oil or whole hempseed.
|Type of Sample||TPC||Ref.|
|Whole hempseed||0.77 ± 0.04|||
|Cold-pressed oil||1.88 ± 0.003|||
|Whole hempseed||0.96 ± 0.35|||
|Cold-pressed oil||2.68 ± 0.09|||
|Cold-pressed oil||0.44 ± 0.001|||
|Whole hempseed||0.92 ± 0.04|||
|Whole hempseed||2.33 ± 0.07|||
Where more than one cultivar has been analysed, the maximum and minimum values of the obtained data range are shown. Where only one cultivar has been analysed, the mean ± standard deviation is reported. TPC: Total Phenolic Content.
Although tocopherol was reported as the main antioxidant for hempseed oil, it would not be the same for the whole hempseed. Indeed, Irakli and co-workers  observed a significant positive correlation between the TPC and antioxidant activity of hempseeds belonging to seven industrial hemp cvs approved for cultivation in Greece and only weak correlation between γ-tocopherol and antioxidant activity, concluding that the antioxidant capacity of hempseed is due, mainly, to phenolic compounds rather than to the tocopherols. The high positive relation between the TPC and the radical scavenging activity of hydroalcoholic hempseed extract was also reported by Chen and colleagues . These results can be explained by the fact that polyphenols are polar, hydro-soluble compounds and, thus, that only a few of them are isolated during oil extraction whereas most remain associated to the hemp cake . Conversely, the tocopherols, that are fat-soluble, are extracted more efficiently, and hence, are more abundant in oil. This is in accordance with the results of Siano and co-workers  and Moccia and colleagues  who have analysed and compared the TPC and the radical scavenging activity of whole hempseed, hempseed flour, and hempseed oil of Fedora cv, showing that, although the values obtained for whole hempseed and hempseed flour were similar for both evaluated parameters, those for hempseed oil were significantly lower. Regarding the TPC of whole hempseed, Galasso and colleagues  highlighted that the value obtained for hempseed were slightly higher than those found for linseed (5.88–10.63 mg Caffeic Acid Equivalent (CAE)/g of dry weight of defatted hempseed vs. 4.64–9.40 mg CAE/g of dry weight of defatted linseed), which is considered a matrix rich in total phenols among the oilseeds . In addition, the TPC and the total antioxidant capacity of whole hempseed could increase consequently the germination of seed, leading to a derived product–the hempseed sprouts—enriched with beneficial bioactive compounds [99,102].
Various authors found that in whole hempseed, polyphenols are mainly located in the hull rather than in the kernel [74,92,100] and that the main phenolic compounds that have been detected in C. sativa L. seeds are lignans, phenols derived from the shikimic acid biosynthetic pathway. Particularly, they originate from cinnamic acid derivatives which are biochemically related to the metabolism of phenylalanine. Lignans detected in hempseed are also called phenylpropionamides due to their chemical components and belong to two main groups known as phenolic amides and lignanamides . The first ones are made by an ammine moiety (tyramine, derived from the tyrosine oxidative decarboxylation) linked to a phenolic moiety (a hydroxycinnamic acid, such as coumaric, caffeic or ferulic acid). The second ones are derived by a random polymerization of phenolic amides. Some of these phenols are found exclusively in the C. sativa L. plant. More than 20 kinds of phenylpropionamides, most of which are lignanamides, have been isolated from hempseed. Chen and co-workers  isolated and identified two hempseed lignans with strong in vitro antiradical activity and protective effect against in vitro oxidation of human LDL in an ethanol extract of hempseed hull. These compounds were the phenolic amide N-trans-caffeolyltyramine and the lignanammide cannabisin B, which were identified as the most abundant phenolic compounds in the hull fraction of hempseed also by Pojić and colleagues  who in addition, showed that the most abundant polyphenols in the cotyledon inner fraction of hempseed were catechin and p-hydroxybenzoic acid. The other phenylpropionamides identified as the most abundant in hempseed of different varieties were the lignanamides cannabisin A , cannabisin F, and grossamide . Also, Yan and co-workers  isolated and identified a total of 14 phenolic compounds characteristic of the hempseed, twelve of which were lignanamides. Further phenylpropionamides recently isolated from hempseed were cannabisin I , cannabisin Q, and coumaroylaminobutanol glucopyranoside (CLG) , corresponding to the glycoside of 4-((E)-p-coumaroylamino)butan-1-ol previously described by Yan and colleagues .
Concerning the functional effect, most of the phenolic compounds isolated from hempseed have been shown to have high radical scavenging activity compared to quercetin, and, in addition, the phenolic amide N-trans-feryoryltyramine and especially, the lignanamides 3,3′-demethyl-grossamide and 3,3′-demethylheliotropamide were also able to in vitro inhibit the acetylcholinesterase (AChE) enzyme at a concentration of 100 µg/mL, thus exhibiting properties similar to the medicines used for the treatment of mild to moderate Alzheimer’s disease (AD) such as galanthamine . Bourjot and co-workers  found that, among the phenolic amides they have extracted from hempseed flour, N-trans-caffeoyltyramine had the highest antioxidant and arginase inhibitor activities. In this regard, the inhibition of arginase could raise NO bioavailability that ameliorates endothelial functionality and it can also reduce oxidative stress which plays a central role in the onset and progression of endothelial dysfunction involved in various diseases, including cardiovascular ones. However, the most important biological effects attributable to hempseed phenylpropionamides are the anti-inflammatory and neuroprotective activities. In this context, Zhu and co-workers  had recently isolated and characterized the chemical and functional features of two unique hempseed bioactive compounds named sativamides A and B. According to the authors, from a chemical point of view, they are non-lignanamide compounds characterized by a benzo-angular triquinane core (i.e., a core consisting of fused five-membered hydrocarbon rings and arranged in an angular position), derived from N-trans-caffeoyltyramine. Interestingly, it has been shown that pre-treating of the SH-SY5Y human neuroblastoma cell line with 50 µM of sativamides A or B, reduced the cell death caused by endoplasmic reticulum stress that has been shown to play an important role in neurodegenerative diseases, such as Parkinson’s disease and AD. The same cell line was also used by Maiolo and colleagues  to create a cellular model of Parkinson’s disease, on which the neuroprotective effect of various natural compounds, among which is N-trans-caffeoyltyramine extracted from hempseed, was tested. The obtained results highlighted that 150 µM of the hempseed’s phenolic amide was able to prevent the cell death induced by up to 150 µM of H2O2 treatment and due to oxidative stress and mitochondrial dysfunction caused by this toxic compound. Oxidative stress and mitochondrial dysfunction are thought to contribute to cell death in Parkinson’s disease; therefore, the resulting effect of 150 µM N-trans-caffeoyltyramine can be considered as potentially neuroprotective.
The neuroprotective effect of different hempseed phytochemicals has been shown to be related particularly to the anti-inflammatory and antioxidant action of some of these compounds on microglia cells which are immune cells of the central nervous system that are involved in regulating the immune responses in the brain, thus playing an important role in brain infection and inflammation. The persistent and/or over-activation of these cells is often related to neuronal damage and onset of neurodegenerative diseases, such as AD and Parkinson’s disease, and multiple sclerosis, that in fact, are characterized by chronic inflammation and oxidative stress. About this, Zhou and colleagues  investigated the anti-neuroinflammatory and neuroprotective action of each of the twenty phenolic compounds that they have isolated from hempseed, on the release of the inflammatory cytokine TNF-α from Lipopolysaccharide (LPS)-stimulated BV2 microglia cells, treated with 15 µM of each interest compounds. The authors highlighted that, among the analysed phenylpropionamides, those with a higher inhibitory activity on the Tumor Necrosis Factor α (TNF-α release were lignanamides and compared to resveratrol—the positive control—the much stronger inhibitory action was found for the CLG. To understand the molecular mechanism underlying the neuroprotective action of the most bioactive hempseed phenylpropionamides, various studies were performed by different authors. More specifically, to date, the investigated compounds were CLG , grossamide , and cannabisin F . In all cases, BV2 microglia cells were pre-treated with 5, 10, or 15 µM of each tested compound 1 h before the addition of 100 ng/mL of LPS for 24 h. After 24 h of LPS exposure, it has been shown that all three lignanamides were able to decrease the release of the inflammatory cytokines IL-1β, IL-6, and TNF-α in a dependent-manner by the inactivation at different level of the NF-κB inflammatory pathway. Moreover, CLG and cannabisin F were also found to have the ability to promote the expression of nuclear factor erythroid 2-related factor 2 (Nfr-2), a protein important in modulating redox homeostasis, in regulating the cellular antioxidant response against reactive oxygen species (ROS) and in attenuating oxidative stress. Normally, this protein is located in the cytoplasm, but in response to oxidative stimuli, Nrf2 transferred to the nucleus and activated downstream genes involved in the antioxidant defence. Although LPS stimulation leads to an increased production of ROS by microglia-stimulated cells, it has been demonstrated that the pre-treatment with CLG or cannabisin F upregulated the Nfr-2 pathway, thus exerting a beneficial antioxidant effect [108,110]. In addition, it has also shown that cannabisin F was able to enhance its inhibitory action on the NF-κB transcription factor even by inhibiting the downregulation of the silent information regulator transcript-1 (SIRT1) induced by LPS. SIRT1 is a histone deacetylase that inhibits NF-κB transcriptional activity through deacetylation of its p65 subunit, thus leading to the reduction of inflammatory cytokines. LPS stimulation induces the downregulation of SIRT1, increasing the inflammatory status, but this can be counteracted by cannabisin F . The anti-neuroinflammatory and neuroprotective effect of hempseed phenols was observed also in vivo on an LPS-induced neuroinflammatory model mice . In particular, the beneficial effects were obtained after three weeks of treatment with 1 g/Kg/day of hempseed extract (concentration of the extract, 233.52 ± 2.50 µg/mg) and consisted of a reduced expression of the inflammatory cytokines IL-1β, IL-6, and TNF-α in the brains and the prevention of LPS-induced damage to the hippocampal nerve cells as well as an improvement in the animal’s learning, memory, and their cognitive function. The phenylpropionamides isolated from hempseed and the literature studies about their biological action are listed in Table 10 .
Hempseed phenylpropionamides and their biological effect.
|N-trans-caffeolyltyramine||Strong in vitro scavenging DPPH radical and ORAC antioxidant activity;
LDL protection against in vitro oxidation;
In vitro AChE and arginase inhibitory activity;
In vivo anti-neuroinflammatory action;
In vitro prevention of H2O2-induced cell death.
|N-trans-feryoryltyramine||In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
|N-trans-caffeolyoctopamine||In vivo anti-neuroinflammatory action.|||
|N-trans-cumaroyltyramine||In vivo anti-neuroinflammatory action.|||
|Cannabisin A||In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
|Cannabisin B||Strong in vitro scavenging DPPH radical and ORAC antioxidant activity;
LDL protection against in vitro oxidation;
In vitro arginase inhibitory activity.
|Cannabisin C||In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
|Cannabisin D||In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
|Cannabisin E||In vivo anti-neuroinflammatory action|||
|Cannabisin F||In vitro scavenging DPPH radical and ORAC antioxidant activity;
In vivo anti-neuroinflammatory action;
In vitro inhibition of the NFκB inflammatory pathway, activation of Nfr-2 antioxidant pathway and upregulation of SIRT1.
|Cannabisin M||In vitro scavenging DPPH radical activity;
In vivo anti-neuroinflammatory action.
|Isocannabisin N||In vivo anti-neuroinflammatory action|||
|Grossamide||In vitro inhibition of the NFκB inflammatory pathway.
In vivo anti-neuroinflammatory action;
|3,3′-demethyl-grossamide||In vitro scavenging DPPH radical activity;
In vitro AChE inhibitory activity;
In vivo anti-neuroinflammatory action.
|3,3′-demethylheliotropamide||In vitro AChE and arginase inhibitory activity.|||
|Sativamides A||In vitro reduction of ER stress-induced cell death.|||
|Sativamides B||In vitro reduction of ER stress-induced cell death.|||
|4-((E)-p-coumaroylamino)butan-1-ol||In vitro inhibition of TNF-α release.|||
|Cumaroylaminobutanol glucopyranoside||In vitro inhibition of TNF-α release;
In vitro inhibition of the NFκB inflammatory pathway and activation of Nfr-2 antioxidant pathway.
3.2.2. Hempseed Bioactive Peptides
Together with phenolic compounds, other kinds of hempseed’s functional compounds are the bioactive peptides. The evidence of the existence of these peptides has been demonstrated by the findings about the bioactive features observed for the products obtained by the hydrolysis of hempseed proteins. Indeed, it has been shown that, although hempseed proteins have limited bioactive properties, their hydrolysis provides hydrolysates with higher bioactivity [112,113,114], including antioxidant [72,112,113,114,115,116,117,118], antihypertensive [114,119], antiproliferative [72,112], hypocholesterolemic [120,121], anti-inflammatory, and neuroprotective [113,122] effects. This evidence suggests that bioactive peptides are encrypted in the protein native structure and are released during the hydrolysis process. Depending on the hydrolysis conditions (i.e., type of proteases used, period, and time of hydrolysis), hydrolysates with different kinds and efficiency degrees of activity can be obtained. This is due to the fact that hydrolysis conditions can influence the type of obtained peptides, namely the size and the amino acid profile—and hence, the structure—which in turn, influence the activity and the function of peptides. In this context, literature data agree that important factors which affect the bioactivities of the peptides are their molecular weight and amino acid composition. In general, low-molecular weight peptides are more bioactive than the high-molecular weight ones, since they more easily escape enzymatic degradation in the gastrointestinal tract, and therefore, they can be absorbed and introduced as such into the blood stream than larger peptides. Moreover, small peptides are likely more easily able to interact with specific target sites, such as an enzyme’s active site, in comparison to larger peptides. Instead, the peptide’s amino acid composition is fundamental to define its structure and, therefore, to influence the strength and the efficiency of the interaction with the peptide’s target site; in fact, the amino acids composition is the basis of the peptide’s structure-function relationship.
About hempseed protein hydrolysates, different reports [114,115,116,119,122] confirmed that the type and level of proteases used as well as the time of hydrolysis affect the degree of hydrolysis, the amino acids profile, and the molecular weight of the obtained peptides due to the fact that different proteases have different specificities, and therefore, they will produce different types of peptides with different activities. Moreover, these publications demonstrated that, overall, independently to the hydrolysis’ type, hempseed proteins are highly susceptible to proteolysis and most of the liberated bioactive peptides have a molecular weight less than 10 KDa and a high hydrophobicity rate. More specifically, Tang and colleagues  and Wang and co-workers  observed that hempseed hydrolysates with a higher degree of hydrolysis, a higher amount of hydrophobic amino acids, and a higher surface hydrophobicity possessed higher in vitro antioxidant activity (particularly, the α, α-diphenyl-β-picrylhydrazyl (DPPH) radical scavenging and Fe 2+ chelating abilities). Their results were consistent with those obtained by Logarušić and colleagues , who also found that the obtained hydrolysates showed cytotoxic and antiproliferative activity on HeLa cancer cells and a stimulatory effect on the proliferation of normal HaCaT cells. However, the effective concentration at which the hydrolysates exerted these functional activities depended on the hydrolysis condition, thus highlighting that different hydrolysis methods generate peptides with different structure and, hence, different activity. Similar results were obtained also by Rodriguez-Martin and colleagues , who in addition to the in vitro antioxidant activity demonstrated that specific hempseed hydrolysates’ fractions possessed neuroprotective action, being able to down-regulate the expression levels of TNF-α and IL-6 inflammatory cytokines and to increase the mRNA levels of the anti-inflammatory IL-10 gene at the concentration of 100 μg/mL in LPS-stimulated BV2 microglia cells. Furthermore, Malomo and colleagues investigated both in vitro and in vivo hypotensive  and in vitro neuroprotective  activity of hempseed protein hydrolysates obtained by different hydrolysis methods, highlighting that the hydrolysates’ activity was determined mostly by the type and sequence of peptides’ amino acids rather than by the degree of hydrolysis that is related to the level of the proteases used and the time of the hydrolysis process. Particularly, the authors observed that the hypotensive effect of hempseed protein hydrolysates was due to their angiotensin-converting enzyme (ACE) and renin-inhibitory activity, which seemed to be related to high proline and phenylalanine content, respectively, though also other additional peptides’ structural factors were likely to be involved in the overall functional effect. In the other work , the authors showed that hempseed hydrolysates exert an in vitro neuroprotective action through inhibition of the activity of the acetylcholinesterase enzyme (AChE) and observed that the most active hydrolysates were those with the highest negatively charged amino acids amount. Also, arginine was the second most abundant amino acid found in the hydrolysates with higher AChE inhibitory action, and according to the authors, this was probably due to the fact that it is responsible for binding the peripheral anionic site (PAS) of AChE that is believed to be an important enzyme binding site for inhibitors, thus highlighting the importance of the structure-function relationship. Nevertheless, none of these reports that have investigated the bioactive features of hempseed protein hydrolysates elucidated the amino acids profile and structural features of peptides responsible for the investigated functional effects, nor the specific relationship between their function and structure.
In this regard, Aiello and co-workers  found that hempseed peptides with a hypocholesterolemic effect contained 8−10 amino acid residues and were characterized by a high hydrophobicity rate, a hydrophobic N-terminus, and a negatively charged C-terminus. These were identified as features essential to interact with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCoAR), the enzyme that mediates the rate-limiting step of the intracellular cholesterol production. These peptides seemed to be generated especially through peptic hydrolysis of hempseed proteins because it has been observed that, in comparison to hydrolysates obtained using other peptidases, the peptic hydrolysate exerted a significantly higher hypocholesterolemic activity on HepG2 cells already at a concentration of 0.25 mg/mL . This hypocholesterolemic effect has been attributed to a statin-like mechanism, since like statins, the peptic hempseed hydrolysate was able to decrease the cholesterol level (1) by acting as direct inhibitor of HMGCoAR and (2) by increasing the level of sterol-responsive element binding protein 2 (SREBP2), a transcription factor playing a crucial role in the regulation of genes involved in the cholesterol homeostasis, such as the low-density lipoprotein receptor (LDLR) coding gene. Therefore, the increase in the SREBP2 level leads to an increase in the LDLR expression on the HepG2 surface and to a consequent increase in the circulating cholesterol uptake.
As said, another bioactive property attributed to hempseed protein hydrolysate was the anti-hypertensive activity . Publications investigating the structural features of the hydrolysate’s component peptides found that most bioactive peptides able to inhibit renin and/or ACE contained three or four amino acids and some particular structural characteristics related to its sequence. They had a good hydrophobicity/hydrophilicity balance; contained hydrophobic amino acids at the C-terminal, aromatic, or branched-chain amino acid residues near the C-terminal; and hydrophobic residues at the N-terminal. Moreover, when a branched-chain, hydrophobic amino acid residue and/or an ionizable functional group were present at the N-terminal or near it, the ACE-inhibitory activity may be enhanced [121,123,124,125]. Hempseed peptides with these structural features that has been shown to possess in vitro ACE-inhibitory activity were the Glycine-Valine-Leucine-Tyrosine (GVLY), Leucine-Glycine-Valine (LGV) , Tryptophan-Valine-Tyrosine-Tyrosine (WVYY), and Proline-Serine-Leucine-Proline-Alanine (PSLPA) peptides, whereas the peptides Tryptophan-Tyrosine-Threonine (WYT), Serine-Valine-Tyrosine-Threonine (SVYT), and Isoleucine-Proline-Alanine-Glycine-Valine (IPAGV) showed dual inhibition of ACE and renin enzymes , with the tripeptide WYT exhibiting the strongest renin inhibition related to the presence in its sequence of the main structural features characteristics of renin-inhibitor peptides, namely one hydrophobic side chain (tryptophan) at the N-terminal, bulky chains (tyrosine) at the C-terminal, one hydrogen bond donor (tryptophan), and two hydrogen bond acceptors (threonine and tyrosine) . Girgih and colleagues  found that the hempseed peptides inhibited ACE through a mixed-type model of enzyme inhibition, implying that peptides bound to both active and non-active sites, thus blocking the substrate binding or producing changes in the enzyme’s conformation, which reduced the substrate affinity with the active site. These interactions between peptide and ACE were mainly stabilized by electrostatic and hydrophobic interactions and hydrogen bond formation. Whereas the hempseed peptides inhibited renin enzyme by an uncompetitive model of enzyme inhibition, implying that peptides bound to the renin−substrate complex, causing reduction in the reaction velocity as well as the catalytic efficiency. Also in this case, the main involved interactions were the electrostatic and hydrophobic ones, as well as multiple hydrogen bonds. Of note, these bioactive peptides originated by simulated gastrointestinal digestion of hempseed proteins. In addition, the in vivo hypotensive ability of the WVYY, PSLPA, WYT, SVYT, and IPAGV peptides were assessed after oral administration of 0.5 mg/mL of each peptide to spontaneously hypertensive rats. The results demonstrated that all analysed peptides were able to significantly reduce the systolic blood pressure (SBP) of animals, but PSLPA, SVYT, and IPAGV exerted a long-lasting SBP-lowering effect, indicating a more efficient absorption coupled with strong binding to target enzymes and resistance to structural inactivation by gastrointestinal tract or blood circulatory system proteases .
Hydrophobicity represents a particularly important feature for all bioactive peptides in general and for the antioxidant ones in particular. Indeed, along with the short length of the peptides, hydrophobicity is essential to facilitate the crossing of the intestinal barrier and to enhance the peptides permeability through the cell membrane via hydrophobic association with the lipid bilayer, and in antioxidant peptides, it promotes the effective interaction with free radicals and their inhibition, thus achieving potent antioxidant effects . It has been shown that the hydrophobic amino acids such as valine, alanine, and leucine, represent 50% of the total amino acids in antioxidant hempseed peptides and that they are distributed on both sides of the peptide chain . The hydrophobic, aromatic amino acids such as phenylalanine and tryptophan are also abundant since they can enhance the metal chelating ability due to the several binding sites on their aromatic rings . Another amino acid residue recurring in the sequence of antioxidant peptides, is histidine, especially located at the N- or C-terminal where it can enhance the radical scavenging activity due to its imidazole ring that is effective in metal-ion chelation [126,127].
Finally, Ren and co-workers  identified two hempseed peptides with α-glucosidase inhibitory activity and therefore, with antidiabetic property. These peptides were the dipeptide Leucine-Arginine (LR) and the pentapeptide Proline-Leucine-Methionine-Leucine-Proline (PLMLP). Even in this case, the hydrophobic amino acids gave a great contribution to the performance in the inhibition of α-glucosidase activity, and the P and L residues seemed to be particularly important; in fact, they were been considered as vital amino acids playing α-glucosidase inhibitory action separately or synergistically.
In conclusion, it is important to highlight that, although the in vitro and, in part, in vivo (animal) studies have demonstrated the functional effects of hempseed protein hydrolysates and of single isolated peptides, human studies investigating the peptides’ stability into the gastrointestinal tract and their bioavailability, namely the capacity to reach the target site in the active and functional form, are still lacking and they should be investigated.
4. Hempseed Dietary Supplementation
Considering the antioxidant and anti-inflammatory properties related to the hempseed’s components, different authors investigated whether hempseed food supplementation could have the ability to counteract chronic-degenerative diseases characterized by chronic inflammatory and oxidative stress conditions, such as cardiovascular and neurodegenerative diseases. Until now, most of the studies have been conducted on animal models and only a few literature reports have been found on humans, underlining the requirement to investigate the effects of the supplementation with hempseeds and their derivatives on human health and to understand their potentiality as ingredient for functional foods. With this in mind, in the following subsections, literature publications about the effects of hempseed- and hempseed products-based supplementation in animals’ and humans’ studies have been reviewed.
4.1. Animal Studies
According to the WHO, cardiovascular diseases (CVDs) are the first cause of worldwide death . Atherosclerosis, hypercholesterolemia, and hypertension represent among the major risk factors of CVDs and both hypercholesterolemia and hypertension, along with chronic inflammation and oxidative stress, are considered as the factors that promote the process of atherosclerosis ; hence, their prevention would reduce the risk of atherosclerosis and CVDs onset. Diet represents an important non-pharmacological tool that can reduce cardiovascular risk and, thus, improve health outcomes of people at risk, and in this context, the antioxidant and anti-inflammatory properties of whole hempseed could represent an effective and efficient dietary intervention to promote the treatment and prevention of the CVDs. Therefore, some authors investigated the potential anti-hypercholesterolemic, anti-hypertensive, and anti-atherosclerotic ability of hempseeds or hempseed derived products such as hempseed oil, hempseed flour, or hempseed protein hydrolysate, after dietary administration, mainly on rats’, mice’s, or rabbits’ CVDs models.
Regarding this, Kaushal and colleagues  evaluated whether 1 month of supplementation of 10% whole hempseeds in Wistar rats fed high-fat, pro-hypercholesterolemic diet had the ability to ameliorate hypercholesterolemia-associated cardiovascular effects. The obtained results highlighted that when 10% whole hempseeds was added to a normal, balanced diet, it did not caused any changes in the serum lipid parameters, the aorta’s wall histology, and the redox and inflammatory status of the animals in comparison to the control (i.e., rats fed a normal, balanced diet without hempseeds supplementation), however, the supplementation of a high fat diet with 10% hempseeds led to a significantly ameliorated effect of serum parameters (i.e., decreased total cholesterol, LDL, and triglycerides levels), redox and inflammatory status, as well as the prevention in the development of the aortic changes related to atherosclerosis. As said, inflammation and oxidative stress are involved in the atherosclerosis changes. It is known that high-fat diet is responsible for the activation of the inflammation inducible genes such as cyclooxygenase-2 (COX-2), which lead to increase the expression of pro-inflammatory prostaglandins Prostaglandin E (PGE). The COX-2 inflammatory pathway is closely related to the redox status because it can be activated by oxidative stress and vice versa (i.e., the COX-2 inflammatory pathway can generate oxidative stress). Based on the obtained results, the authors asserted that 10% hempseeds supplementation was able to exert the anti-hypercholesterolemic effects through redox-sensitive modulation of the inflammatory pathway of PGs biosynthesis. In particular, it would seem that the antioxidant properties of hempseed, which include the ability to scavenge free radicals, to chelate metal ions, and to inhibit the LDL oxidation, may improve the redox status in the high-fat diet induced hypercholesterolemic rats, and thus, it can induce a redox shift of the COX-2 pathway toward the production of anti-inflammatory PGs of D- and J-series.
The beneficial effect of the short-term (20 days) hempseed feeding in Wistar rats on the prevention of hypercholesterolemia and coronary artery disease was observed also by Karimi and co-workers . Indeed, they found that the hempseed dietary treatment did not significantly affect the mean fasting triglyceride, total cholesterol and albumin levels, but it was able to improve the blood lipid and protein profiles, since it significantly decreased the mean fasting serum LDL level, and significantly increased the mean fasting serum HDL and total protein levels. These actions were attributed to the high and low contents of PUFAs and SFAs, respectively, in hempseeds, as well as to their relatively high amount of phytosterols, especially β-sitosterol. Actually, Seo and colleagues  showed that also hydrophilic components of hempseeds could exert an anti-atherosclerotic effect. In their study, the authors treated via intragastric inoculation Apo-E Knock Out (KO) mice atherosclerotic animal models, with a hempseed water extract for 14 weeks. The lack of Apo-E in these genetically modified mice led to increase in total plasma cholesterol and triglycerides and decrease of serum HDL-cholesterol level and, as consequence, generated atherosclerotic lesions similar to those found in humans. The treatment with hempseed water extract reduced the atherosclerotic plaque formation, as well as the serum level of total cholesterol and LDL-cholesterol and increased the serum HDL-cholesterol level. Moreover, a reduction in the serum level of the inflammatory cytokine TNF-α demonstrating a decrease in the inflammatory status related to atherosclerosis was found also. As previously said, all these findings have been generally attributed to the hempseed lipidic fraction, that is missing in the hempseed water extract used in this study, and therefore, the authors concluded that some hydrophilic compounds of hempseed, presumably phenolics, possessed the observed anti-atherosclerotic action, but the specific compounds and the molecular mechanisms by which they exerted this protective action have still to be elucidated.
The ability of the dietary hempseeds supplementation to reduce the dietary cholesterol uptake in the presence of an enriched-cholesterol diet, was observed also by Lee and co-workers  in Drosophila melanogaster and was attributed to the ability of some hempseed components, PUFAs LA and ALA in primis, to down-regulate the expression of the Niemann-Pick C1-Like 1 (NPC1L1) gene, coding for a key intestinal cholesterol absorption protein. By contrast, Prociuk and colleagues  found that 8 weeks of 10% hempseeds supplementation of a cholesterol-enriched diet in albino New Zealand rabbits did not decrease the cholesterol plasma level but led to an approximately 12-fold increase in the plasma GLA level, resulting in a normalization of the platelet aggregation. Indeed, it was shown that the enriched-cholesterol diet without hempseeds supplementation increased the cholesterol plasma level and the platelet aggregation, raising the risk of acute coronary syndrome. The addition of hempseeds to the diet was however able to inhibit the platelet aggregation despite the presence of high circulating cholesterol, and this effect was exactly attributed to the high GLA plasma level. All these results that showed an overall beneficial effect of hempseeds dietary supplementation on atherosclerosis are still in contrast to those found by Gavel and co-workers . Indeed, they found, by investigating the effect of the addition of 10% hempseeds to the cholesterol-enriched diet of albino New Zealand rabbits on atherogenesis and aortic contractile function, that this dietary supplementation would not be able to protect the aortic vessel from the atherosclerotic plaque formation. In this case, the hempseeds supplementation provided only mildly beneficial effects against contractile disfunction associated with atherosclerotic vessel.
In female subjects, the risk of coronary heart disease and other CVDs related to the rise of the concentration of circulating total cholesterol and LDL-cholesterol, can also increase as a consequence of menopause, which is associated also to other relative complications related to the estrogen deficiency, like depression, anxiety, and possibly impaired cognition. In this context, Saberivand and colleagues  demonstrated that whole hempseeds dietary supplementation (until 10%) in a balanced diet of the ovariectomized rat model of menopause, may improve the menopausal complications including the cardiovascular ones. In particular, the authors have shown that 3 weeks of dietary supplementations with 1%, 2%, or 10% of hempseeds were able to conserve the triglycerides and total cholesterol plasma level close to the control group (non-ovariectomized rats), preventing the dyslipidemia and the weight gain that usually occurs after ovariectomy (or menopause) as a consequence of the decline of the estrogen levels. Indeed, it was found that the decline of plasma estrogen levels was prevented by the hempseeds dietary treatment, probably thanks to the presence of phytoestrogens, such as β-sytosterol, in hempseeds. In addition, the authors even observed that the hempseeds dietary supplementation was also capable of exerting an antidepressant activity, as well as of preventing the accrual of blood calcium and thus preventing the bone loss and promoting the bone homeostasis.
As previously underlined, along with hypercholesterolemia, hypertension represent another main CVDs risk factor. It is defined as a systolic blood pressure (SBP) higher than 140 mmHg or a diastolic blood pressure (DBP) higher than 90 mmHg . The in vitro studies which demonstrated the existence of hempseed peptides with anti-hypertensive properties (see Section 3.2.2) led some researchers to evaluate the in vivo hypotensive ability of hempseed products on the spontaneously hypertensive rats (SHRs). This animal model is characterized by high plasma ACE and renin enzyme activities as well as a decrease in the antioxidant defence and higher oxidative stress in comparison to the normotensive rats. It has been shown that a diet supplemented with 1% of hempseed proteins hydrolysate was effective both to prevent the hypertension development in SHRs and to act as treatment to reduce the SBP in SHRs with still established hypertension through the reduction of the plasma ACE activity . Moreover, the same supplemented diet led also to a reduction of the oxidative stress in SHRs normalizing the plasma total antioxidant capacity, which reached a value similar to normotensive rats, and enhancing the cellular antioxidant defences, namely the catalase and superoxide dismutase enzymes’ activity . The anti-hypertensive and antioxidant effects were not so marked in the SHRs fed a diet supplemented with 1% hempseed protein isolate instead of the hempseed protein hydrolysate. This evidence was explained with the fact that the already hydrolysed peptides are more bioactive or more bioavailable than those obtained by the gastrointestinal digestion of hempseed proteins [117,138], suggesting the advantage of the use of hempseed protein hydrolysate rather than whole hempseed or hempseed proteins isolate as an ingredient to formulate functional foods or nutraceuticals for the prevention and treatment of hypertension. Interestingly, the hypotensive effect of these hempseed products was not observed in normotensive rats, suggesting an action directly related to the higher ACE plasma activity than the physiological level .
Others animal studies were performed to explore the potential beneficial effect of the dietary intake of hempseeds and their products on neurodegenerative diseases, generally associating with aging, oxidative stress, and neuroinflammation, such as AD, cognitive deficit, memory impairments and multiple sclerosis (MS). Most of these studies were carried out after that epidemiological evidence highlighted that some Chinese population, habitual consumers of hempseeds which make up an integral part of their daily diet, are characterized by significant numbers of long-lived centenarians’ individuals with good cognition and few health problems [139,140]. About this, Lee and co-workers  found that a Drosophila melanogaster model of AD reared in a hempseed meal media, significantly suppressed the cytotoxicity of amyloid β42 (Aβ42) peptides accumulation, ameliorating the eye degenerative phenotype, and this neuroprotective effect of hempseed meal was attributed to the PUFAs LA and ALA. Further evidence has demonstrated that the daily inclusion and long-term consumption of hempseeds into the diet may promote the longevity and the lifespan extension; may improve cognitive function; and may prevent age-related diseases, including obesity, diabetes, and cancer in old mice, as a consequence of the adjustment of some nutritional imbalances typical of the western diet (e.g., the n-6/n-3 PUFAs ratio), and the capability to regulate the expression of genes involved in the regulation of 5′AMP-activated protein kinase (AMPK) signalling that can reduce the oxidative stress and can inhibit the inflammatory response induced by the NF-κB pathway . It has been also shown that daily oral administration of hempseed oil on an MS mice model can have positive effects on the treatment of this chronic-inflammatory and neurodegenerative disease characterized by wide demyelination, since it can exert immunomodulatory action, in particular the anti-inflammatory one, and can improve the re-myelination of neuronal myelin sheath in the brain, with a protective effect on the central nervous system (CNS) . This protective effect of hempseed oil in CNS tissues seems to be a consequence of the increase in the intake of n-3 PUFAs and the n-6 anti-inflammatory GLA and of the reduction of the n-6/n-3 PUFAs ratio and of SFAs intake, all of which are factors able to regulate the mTOR signalling pathway in order to shift the immune response from pro- to anti-inflammatory one, thus reducing the chronic inflammation, which is an important factor for MS onset and development [141,142]. However, in many of the reports that demonstrated the neuroprotective effect of hempseeds or derivatives dietary supplementation, the hempseeds’ supplement was not the only one administrated. In fact, hempseeds were often administrated in combination with other products such as bitter vegetable (Sonchus oleraceus)  or evening primrose oil [141,142], and therefore, based only on these data, it is not possible to understand whether the beneficial effects can be obtained also with the solely ingestion of the hempseeds supplement or whether they are closely related to a co-operative action of the both administrated supplements.
Hence, although different evidence of an effective beneficial action of hempseeds or hempseed derivatives on CVDs and neurodegenerative disease animal models is present in scientific literature ( Table 11 ), further studies are still needed to clarify the exact molecular mechanisms involved as well the type and the doses of the more efficient hempseed product necessary to exert the in vivo beneficial function, that are all essential factors to develop a potentially functional food.
Literature studies on the effect of hempseed or hempseed products’ dietary supplementation on animal models.
|Supplement Type||Purpose||Experimental Design||Results||Ref.|
|Hempseed meal hydrolysate (HMH)||Evaluation of the antioxidant ability of an HMH-containing diet to attenuate the plasma levels of some oxidative stress markers in growing and adult SHRs rats.||8-week old SHRs (n = 8) fed control or 1% HMH-containing diets ad libitum for 8 weeks (for analysing the preventive effect).
20-week old SHRs (n = 4) fed control or HPH-containing diets ad libitum for 4 weeks (for analysing the treatment effect).
|Dietary intervention with a specific HMH on young and adults SHRs exerted an antioxidant action by:
• The increase of the SOD and CAT activities in both growing and adult SHRs;
• The significant decrease of the TPx plasma level in both growing and adult SHRs and NTRs.
|Hempseed||Investigation of the aspects of dietary hempseed against hyperlipidemia-associated CV risks.||1 month of 10% hempseed supplemented high fat-diet on Wistar rats.||The 10% hempseed dietary treatment had an anti-hyperlipidaemic effect by inducing:
• The serum level decreases of the cholesterol, LDL and triglycerides;
• The increase of the HDL serum level;
• A significant reduction in the aorta thickness;
• Less intima damage foam cells formation and smooth muscle cell proliferation;
• The remarkable decrease in the lipid deposition, plaque size, and lesion surface area distribution;
• The decrease of the pro-inflammatory PGEs expression;
• The increase of the anti-inflammatory PGDs expression.
|Hempseed||Evaluation of the effect of hempseed feeding on lipid and protein profiles.||20-days of hempseed supplementation (free access) on Wistar rats.||Short-term hempseed dietary intake can have hepatoprotective properties and beneficial effect on the prevention of CVD by favouring:
• The decrease of the mean fasting serum LDL level;
• The increase of the mean fasting serum HDL and total protein levels.
|Hempseed water extract (HWE)||Evaluation of the anti-atherosclerotic activity of hempseed water extract in ApoE KO mice.||14-days of intragastric inoculation of 300 µL of hempseed water extract or distilled water (control) to six-week-old, male ApoE KO (n = 7).||Dietary HWE ingestion exerted an anti-atherosclerotic effect through:
• The reduction of the atherosclerotic plaque formation in the aortic sinuses;
• The reduction of the serum GOT concentration, demonstrating less liver damage after the treatment;
• The decrease of total serum cholesterol and LDL, and the increase of serum HDL;
• The significant decrease of TNF-α serum level.
|Hempseed Meal (HSM)||Investigation of the protective effects of the dietary intake of HSM and its LA and ALA components on AD and CVD Drosophila melanogaster models.||GMR-Aβ42 Drosophila melanogaster line (AD model) reared in cornmeal-soybean standard media with the LA, ALA, and GLA amounts present in the HSM (for the effect on AD phenotype).
Wild-type Drosophila melanogaster larvae reared in HSM media with 35.1 μg/mL of cholesterol (for the CV effect).
|Thanks to their LA and ALA contents, HSM dietary uptake may exert beneficial effects on AD and CVD through:
• The suppression of suppressed Aβ42 cytotoxicity in the GMR-Aβ42 flies’ line reared on HSM mean (beneficial effect on AD);
• The reduction of dietary cholesterol uptake observed in the wild-type flies reared on the cholesterol media (beneficial effect on CVD).
|Hempseed||Investigation of the ability of dietary hempseed to reduce platelet aggregation under hypercholesterolemia.||Male New Zealand rabbits fed 125 g/day of control diet supplemented with 10% of hempseed and 0.5% of cholesterol for 8 weeks.||Hempseed supplementation to a hypercholesterolemic diet is able to normalize the platelet aggregation by increasing the GLA plasma level.|||
|Hempseed||Investigation of the dietary hempseed ability to inhibit atherosclerosis and the associated vascular contractile dysfunction in a cholesterol-induced rabbit model.||Male albino New Zealand rabbits fed 125 g/day of control diet supplemented with 10% of hempseed and 0.5% of cholesterol (to induce atherosclerotic plaque formation) for 8 weeks.||Dietary hempseed supplementation did not generate protection against atherosclerotic plaque formation in hypercholesterolemic diet, but it provided mildly beneficial effects against contractile dysfunction associated with atherosclerotic vessels.|||
|Hempseed||Investigation of the ability of hempseed dietary intake on the prevention of ovarian hormone deficiency-induced hypercholesterolemia in ovariectomized rats and on the complications of estrogen deficiency such as depression, anxiety, and bone loss problems.||Bilateral ovariectomized six-month-old female Wistar rats (n = 5) fed 1%, 2%, or 10% hempseed supplemented diets or a control diet (standard commercial diet) for 3 weeks.||Until 10% of hempseed dietary supplementation improved the post-ovariectomized complications in rats since it:
• Prevented the accrual of blood calcium, preventing the bone loss;
• Prevented the body weight gain induced by ovariectomy;
• Conserved the TGs and TC plasma levels as those of the non-ovariectomized rats, preventing dyslipidaemia;
• Resulted in an antidepressant activity.
|Hempseed meal hydrolysate (HMH)||Evaluation of the effect of HMH-containing diet on the prevention and treatment of hypertension in growing SHRs and in SHRs with established hypertension.||8-week old SHRs (n = 8) fed control or 1% HMH-containing diets ad libitum for 8 weeks (for the preventive effect).
20-week old SHRs (n = 4) fed control (without HPH) or HPH-containing diets, ad libitum for 4 weeks (for analysing the treatment effect).
|Dietary intervention with a specific HMH on young and adult SHRs exerted a preventive and therapeutic effects since it led to:
• The attenuation of the normal increases of SBP in young growing SHRs;
• The significant reduction of SBP in adult SHRs;
• The significant reduction of the plasma ACE and renin activities in both young and adult SHRs.
|Hempseed and bitter vegetable (HB)||Evaluation of the beneficial effect of the HB diet on chronic diseases and on the slowing of the aging process.||15-month-old C57BL/6 female mice (n = 10) fed low CHO, low SFA, and high PUFA content-HB diets containing hempseed and bitter vegetable (Sonchus oleraceus) (2:1) or control (western diet), ad libitum until only 20% of the mice in one group survived.||The HB diet is capable of promoting health and longevity since it:
• Significantly increased the mice lifespan;
• Improved the spatial learning and memory, and the locomotory activity;
• Exerted beneficial effects on hepatic steatosis, hepatotoxicity, and plasma lipid profiles including the normalization of the size, weight, and colour of the liver and the reduction of hepatic lipid accumulation and of the ALT, AST, and TG levels.
• Provided protective effects against the aging-related abnormalities in spleen morphology and inflammation;
• Increased the antioxidant defences and decreased the oxidative stress;
• Decreased the systemic inflammation by lowering the plasma level of the inflammatory cytokines (i.e., TNF-α, IL-1β, MCP-1 and IL-6), and by increasing the plasma level of anti-inflammatory IL-10;
• Improved the gut microbiota profile leading to a significant decrease in the gut levels of E. coli and a significant increase in the gut levels of Bifidobacterium and Lactobacillum species after 11 weeks of dietary intervention;
• Increased the sensitivity to insulin;
• Increased the hepatic expression of genes associated with longevity (i.e., AMPK, Sirt1, Nrf-1, and FOXO3).
|Hempseed oil and Evening primrose oil (HSO/EPO)||Evaluation of the MS’ therapeutic effect of co-supplementation with HSO/EPO.||14 days of HSO/EPO oral administration on adult female C57BL/6 (n = 6) EAE mice (MS model)||The HSO/EPO dietary treatment can exert a beneficial effect on MS treatment since it is able to:
• Act as an immunomodulator, down-regulating the mRNA expression of mTORC1 (which promotes Th1 and Th2 cells differentiation) and of the pro-inflammatory cytokines IFN- in lymph node;
• Exert an anti-inflammatory action through increasing the mRNA expression of mTORC2 (which promotes Th2 cells differentiation) and of the anti-inflammatory cytokines IL-10 in lymph nodes;
• Reduce the infiltration of the inflammatory cells in brain;
• Promote the re-myelination of neurons’ myelin sheath.
ACE: angiotensin I-converting enzyme; AD: Alzheimer Disease; ALA: α-Linolenic Acid; ALT: Alanine Transaminase; AMPK: AMP-activated protein kinase; ApoE KO: Apolipoprotein E Knockout; AST: Aspartate Aminotransferase; CAT: Catalase; CHO: Carbohydrate; CVD: Cardiovascular Disease; EAE: Experimental Autoimmune Encephalomyelitis; FOXO3: Forkhead box O3; GLA: γ- linolenic acid; GOT: glutamic oxaloacetic transaminase; HDL: High Density Lipoprotein; IFN-γ: Interferon γ; LA: Linoleic Acid; LDL: Low Density Lipoprotein; MCP-1: Monocyte Chemoattractant Protein 1; MS: Multiple Sclerosis; mTORC1: mTOR Complex 1; mTORC2: mTOR Complex 2; rf-1: Nuclear respiratory factor 1; NTRs: Normotensive Rats; PGD: Prostaglandin D; PGE: Prostaglandin E; PUFA: Polyunsaturated Fatty Acid; SBP: Systolic Blood Pressure; SFA: Saturated Fatty Acid; SHRs: Spontaneously Hypertensive Rats; Sirt1: Sirtuin 1; SOD: Superoxide dismutase; TC: Total Cholesterol; TG: Triglyceride; IL: Interleukin; TGs: Triglycerides; TNF-α: Tumor Necrosis Factor α; TPx: Total Peroxide.
4.2. Human Studies
Although the studies about hempseeds and hempseed products dietary supplementation in animals are relatively abundant in scientific literature, only a few papers ( Table 12 ) have faced the issue of the hempseeds and derivatives dietary supplementation in human nutrition and its effects on human health, and all of the few investigations performed to date, were carried out exclusively with hempseed oil as a supplement.
Literature studies on the effect of hempseed oil dietary supplementation on humans.
|Supplement Type||Purpose||Experimental Design||Results||Ref.|
|Cold-pressed hempseed oil||Evaluation of the effect of dietary hempseed oil and olive oil on plasma lipid profiles, TEWL, skin quality, and dermal medication usage in patients with atopic dermatitis.||Controlled, randomized single-blind crossover study, based on two intervention periods of 8-weeks last, separated by a 4-weeks washout period. Patients (n = 20) with a diagnosis of atopic dermatitis were randomly divided into two groups. Every patient of each group orally consumed 30 mL/day of olive or hempseed oils.
• Inclusion criteria: BMI < 30 Kg/m 2 ; 25–60 years old.
• Exclusion criteria: assumption of lipid-lowering, anti-hypertensive or asthma medications, nutrient supplements, steroid-containing skin creams, oral cyclosporine, and use of solarium during the study and in the previous month.
|A relatively short period of hempseed oil dietary consumption significantly improved skin quality and the atopic symptomology of the patients without any negative side effects or adverse reactions.
The dietary treatment significantly increased the plasma level of LA, ALA, and GLA; significantly decreased the TEWL values and patients’ skin dryness, itchiness, and dermal medication usage.
|Cold-pressed under nitrogen atmosphere hempseed oil||Evaluation and comparison of the effects of dietary hempseed oil and flaxseed oil on the profile of serum lipids, fasting serum total and lipoprotein lipid concentrations, plasma glucose and insulin concentrations, and hemostatic factors in healthy volunteers.||Controlled, randomized single-blind crossover study, based on two intervention periods of 4-weeks last, separated by a 4-weeks washout period. Male (n = 8) and female (n = 6) healthy volunteers were randomly divided into two groups. Every volunteer of each group orally consumed 30 mL/day of flax or hempseed oils.
• Inclusion criteria: BMI < 30 Kg/m 2 ; 25–60 years old; fasting serum concentration of TG < 3.5 mmol/L; fasting serum concentration of TC 5.0–7.5 mmol/L; fasting plasma glucose < 6.0 mmol/L.
• Exclusion criteria: assumption of lipid-lowering, anti-hypertensive medications and nutrient supplements during the study and in the previous month.
|In healthy subjects, 4-weeks daily of orally ingestion of hempseed oil:
• Reduced the total plasma TGs concentration;
• Significantly decreased the TC/HDL-C ratio, lowering the risk of coronary heart diseases;
• Significantly changed the FA composition of serum TG and CE, increasing the LA, ALA, and GLA amounts and decreasing the OA content, whereas the AA and DHA amount did not differ;
• Did not modify the plasma glucose, insulin, and hemostatic factor like fibrinogen, FVIIa, and PAI-1.
|Hempseed oil capsule||Evaluation and comparison of the effects of the hempseed, flaxseed, and fish dietary oils on cardiovascular parameters (lipid profile, LDL oxidation, inflammatory markers and platelet aggregation) in healthy volunteers.||Double-blinded, placebo controlled clinical trial. Male (n = 34) and female (n = 54) healthy volunteers were randomly divided into 4 groups (placebo, fish oil, flaxseed oil, and hempseed oil). The volunteers of each group were orally daily supplemented with 2 capsules each containing 1 g of the relative treatment for 12 weeks.
• Inclusion criteria: fasting TC levels • Exclusion criteria: usage of aspirin; ibuprofen; and/or other non-steroidal, anti-inflammatory medications as well as thyroid, anticoagulant, or lipid-lowering medication and the presence of menopause or chronic illness.
|2 × 1g hempseed oil capsule daily supplementation, administrated for 12 weeks did not significantly affect the ALA and LA plasma levels; TC, TG, LDL, and HDL amounts, or inflammatory (CRP, and TNF-α) and platelet aggregation analyzed markers (collagen and thrombin-induced platelet aggregation).|||
|Hempseed oil soft capsule||Evaluation of the role of hempseed oil in the modulation of hyperlipidaemia and CVD risk in children and adolescents.||Randomized, controlled, two-arm parallel-group study. Children and adolescents (n = 36) with diagnosis of primary hyperlipidemia were randomly divided into two groups. Each subject of the test group was dietary supplemented with one hempseed oil soft capsule containing 3 g of oil for 8 weeks. The other group was used as control (without control).
• Inclusion criteria: assessment of primary hyperlipidaemia; 6–16 years old.
• Exclusion criteria: diagnosis of secondary hyperlipidaemia, and/or renal, endocrine, lipid, neurologic, onco-hematologic disorders requiring drug treatment; BMI > 85th percentile; smokers.
|The 8-weeks daily intake of 3 g of hempseed oil:
• Did not affect the levels of TC, LDL-C, HDL-C and TGs;
• Did not change the values of body weight, BMI, and blood pressure;
• Significantly modified the RBC FAs composition increasing the total n-3 PUFAs, n-3 LCPUFAs, and n-6 LCPUFAs, and decreasing the n-6/n-3 PUFAs ratio as well as the SFAs and MUFAs.
|Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation||Evaluation of the therapeutic and protective effect of the Hot-natured diet co-supplemented with HSO/EPO or of the HSO/EPO dietary co-supplementation on MS patients.||Double blind, randomized trial. Female (n = 42) and male (n = 23) patients with diagnosis of RMSS were randomly divided into three groups. Each group (A, B, and C) was subjected to a Hot-natured diet co-supplemented with 18–21 g of HSO/EPO (9:1) (group A) or to 18–21 g olive oil supplementation (group B), or to 18–21 g of HSE/EPO (9:1) co-supplementation (group C) for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
|6 months of Hot-natured diet co-supplemented with HSO/EPO or of HSO/EPO co-supplementation significantly improved the MS clinical condition and inflammatory status of the patients, without any adverse effects.
• Both treatments significantly improved the degree of Th2/Th1 ratio and the value of EDSS and of relapse rate;
• Both treatments significantly increased the level of anti-inflammatory IL-4 cytokine;
• Only the Hot-natured diet co-supplemented with HSO/EPO significantly decreased the level of pro-inflammatory IFN-γ and IL-17 cytokines;
• The co-supplementation of HSO/EPO led to a decreasing (but not statistically significant) trend in the level of IFN-γ and IL-17 cytokines.
|Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation||Evaluation of the Hot-natured diet co-supplemented with HSO/EPO in patients with RRMS on the type and level of produced cytokines.||Females (n = 16) and males (n = 7) patients with diagnosis of RRMS were subjected to a Hot-natured dietary regimen co-supplemented with 18–21 g of HSE/EPO (9:1), for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
|6 months of Hot-natured diet co-supplemented with HSO/EPO had a beneficial effect in RRMS patients by decreasing the Th1 cells and by promoting the Th2 cell responses. This dietary treatment led to:
• A significant improvement of EDSS;
• A significant decrease of the production of the pro-inflammatory cytokines (IFN-γ and IL-17);
•A significant increase of the production of anti-inflammatory IL-4.
|Hempseed oil and evening primrose oil (HSO/EPO, 9:1) co-supplementation||Investigation of the effect of the Hot-natured diet co-supplemented with HSO/EPO or of the solely HSO/EPO dietary co-supplementation on MS patient’s liver dysfunction.||Double blind, randomized trial. Female (n = 42) and male (n = 23) patients with diagnosis of RMSS were randomly divided into three groups. Each group (A, B, and C) was subjected to a Hot-natured diet co-supplemented with 18–21 g of HSO/EPO (9:1) (group A) or to 18–21 g olive oil supplementation (group B), or to 18-21 g of HSE/EPO (9:1) co-supplementation (group C) for 6 months.
• Inclusion criteria: diagnosis of RRMS (EDSS < 6); 14–55 years old.
• Exclusion criteria: diagnosis of secondary or primary progressive MS; pregnancy; corticosteroid treatment; and diagnosis of other chronic neurological and inflammatory diseases such as cancer, rheumatic diseases, and heart diseases.
|6 months of Hot-natured diet co-supplemented with HSO/EPO or of HSO/EPO co-supplementation significantly improved the MS patients’ liver dysfunction, without any adverse effects.
• Both treatments significantly improved the EDSS value;
• Both treatments significantly decrease the AST enzyme serum level;
• Only the Hot-natured diet co-supplemented with HSO/EPO significantly decreased the ALT and GGT enzyme serum levels.
ALA: α-linolenic Acid; ALT: (SGPT) alanine-aminotransferase; AST: (SGOT) aspartate- aminotransferase; BMI: Body Mass Index; CVD: Cardiovascular Disease; EDSS: Extended Disability Status Score; FA: Fatty Acid; Cholesteryl ester; FVIIa: coagulation Factor VIIa; GGT: gamma-glutamyl transferase; GLA: γ-Linolenic Acid; HDL-C: High Density Lipoprotein-Cholesterol; LA: Linoleic Acid; LCPUFAs: Long Chain Polyunsaturated Fatty Acids; LDL-C: Low Density Lipoprotein-Cholesterol; MS: Multiple Sclerosis; MUFAs: Monounsaturated Fatty Acids; OA: Oleic Acid; PAI-1: Plasminogen activator inhibitor-1; PUFAs: Polyunsaturated Fatty Acids; RBC: Red Blood Cell; RRMS: Relapsing-Remitting Multiple Sclerosis; SDA: Stearidonic Acid; SFAs: Saturated Fatty Acids; TC: Total Cholesterol; TEWEL: trans-epidermal water loss; TG: Triglyceride.
One of the first studies which investigated the beneficial effect of hempseed oil dietary supplementation was that of Callaway and co-workers  in which a 8-week oral consumption of 30 mL/day of hempseed oil in patients with diagnosis of atopic dermatitis, was adopted to evaluate the potential ability of this oil to ameliorate the patients’ symptomatology and medicinal usage. The results of this research highlighted that, contrarily to the olive oil treatment, used as comparison, the hempseed dietary assumption can effectively improve the skin quality and the pathology’s symptoms leading to decrease of skin dryness, itchiness, and dermal medication usage by patients. The authors attributed these findings to the increase in the GLA, SDA, and LA plasma levels as a result of the hempseed oil supplementation. Indeed, both GLA and SDA have anti-inflammatory action which can be beneficial for atopic dermatitis. Particularly, GLA has been shown able to decrease the production of the pro-inflammatory leukotriene B4 (LTB4) by polymorphonuclear neutrophils (PMN), through increasing the plasma level of its biological metabolite, namely the anti-inflammatory DGLA which can directly suppress the LTB4 PMN’s production in the skin. Furthermore, SDA can increase the level of EPA in both erythrocytes and plasma phospholipids contributing to the anti-inflammatory effect, whereas, the increase of the LA plasma level can raise the ceramide amount in the skin’s stratum corneum, reducing the loss of moisture and improving the skin’s dryness, since LA acts as precursor of ceramide 1, an important component of the skin’s lipid lamellar sheet. Finally, the total plasma PUFAs amount of the patients significantly increased after the oral daily assumption of hempseed oil, and this can have facilitated the formation of new skin cells by dermal stem cells, contributing to the obtained amelioration of atopic dermatitis.
Other works employed the hempseed oil as a dietary treatment/supplementation to explore its potential cardiovascular benefits on humans. In this regard, Schwab and colleagues  observed that 4-week daily supplementation of 30 mL of hempseed oil was able to reduce the total TGs plasma level and to induce significant changes in the composition of serum cholesteryl-esters (CEs) and TGs of healthy volunteers. Particularly, the content of LA, ALA, and GLA increased whilst the OA concentration significantly decreased after the hempseed oil treatment. In contrast, the proportion of AA and DHA in both TGs and CEs did not change after hempseed oil intake as well as the plasma glucose, insulin, and haemostatic factors, including fibrinogen, coagulation factor VIIa (FVIIa), and plasminogen activator inhibitor-1 (PAI-1). Interestingly, the hempseed oil treatment led to reduction of the TC/HDL-cholesterol ratio which is considered an important index to predict the risk of coronary heart disease. Contrarily, Kaul and colleagues  found that the daily assumption of 2 capsules, each containing 1 g of hempseed oil, in healthy volunteers for 12 weeks neither significantly affected any blood lipid parameters (i.e., the TGs, TC, LDL, and HDL plasma levels), nor induced any changes in the LA and ALA plasma concentrations as well as in the inflammatory and platelet aggregation markers, namely TNF-α and C-Reactive Protein (CRP), and collagen and thrombin-induced platelet aggregation, respectively. The authors hypothesized that these findings could be due to a limited and low gastrointestinal absorption of hempseed oil’s LA and ALA, or to the fact that a larger dosage and a longer experimental period may be necessary to obtain significant changes in the evaluated parameters. It is also important to note that these studies have been performed on healthy subjects, and therefore, they do not exclude potential beneficial actions in a specific pathological status. Furthermore, this evidence also introduces the importance and the necessity of identifying the appropriate dosage and vehicle/matrix that will have benefits in healthy people too as a preventive tool. In the context of the usage of hempseeds or their products for a specific pathological target groups, a recent report of Del Bo’ and colleagues  explored the effects of hempseed oil supplementation in the modulation of hyperlipidaemia and CVDs risk in children and adolescents (6–16 years old) with primary hyperlipidaemia. In more detailed, the test group was daily supplemented with one hempseed oil soft capsule containing 3 g of oil, which provided 700 mg of ALA, 1400 mg of LA, 30 mg of SDA, and 100 mg of GLA, with 2.3 g total PUFAs and a PUFAs/SFAs ratio of 7.7:1. As a consequence of this treatment, it has been shown that, although the hempseed oil supplementation after 8 weeks did not significantly change the plasma lipid profile of the volunteers, it was able to improve the red blood cell (RBC) FAs composition, significantly increasing the total n-3 PUFAs, including the LC-n-3 PUFAs EPA, DPA, and DHA and decreasing the n-6/n-3 PUFAs ratio, as well as the total amount of SFAs and MUFAs. Considering that an altered FAs composition in RBCs has been shown to be positively related with coronary heart disease, atherosclerosis-related diseases, arterial hypertension, and dyslipidaemia, and that SFAs have been reported to have hypercholesterolemic activity in adults, the observed effect of hempseed oil supplementation could have a contribution in counteracting the negative consequences of hyperlipidaemia on the cardiovascular system. Interestingly, in this work was also noted that the dietary intake of higher ALA amounts led to an increase in the RBCs’ LC-n-3 PUFAs derived by the ALA conversion (EPA, DPA, and DHA) in comparison to the control group, and this evidence could indicate that hempseed oil supplementation may stimulate the endogenous conversion of ALA into its biologically active derivatives. According to the authors and in agreement with Kaul and colleagues , the lack of differences between the control and the test group on the serum lipid markers, may be dependent on the food matrix/vehicle used and/or the length of the intervention. This evidence has highlighted again the importance to understand the molecular mechanisms through which hempseed components can exert their beneficial effect on human health, the level of each functional component needed in order to obtained an effective and clinically detectable action, and the more suitable matrix able to maximize the gastrointestinal bioavailability and structurally preservation of these components in the human body.
Finally, another three literature works about the hempseed oil dietary supplementation in humans have been performed on patients affected by MS [147,148,149]. As described in the previous subsection (Section 4.1), the same authors have used an MS mouse model in order to understand the molecular mechanisms underlying the beneficial effects of the co-supplementation of hempseed oil and evening primrose oil on this neurodegenerative, immune-mediated pathology [141,142]. In previous works performed on humans, these authors observed that the co-supplementation of hempseed oil and evening primrose oil in a 9:1 ratio, used alone, or in association to a Hot-natured diet, was able to ameliorate the inflammatory status of MS patients, thus exerting a beneficial effect on this pathological condition. In particular, the authors explained that MS is a Th1-mediated autoimmune disease, which therefore, is characterized by an unbalance Th1/Th2 immune responses and high levels of pro-inflammatory IL-6, IFN-γ and IL-17 cytokines. This latter cytokine is produced by the Th17 cells which, hence, are involved in the development of the pathology, together with Th1 cells [147,148]. A Hot-natured diet is characterized by the consumption of foods with low cholesterol, hydrogenated, trans, and saturated FAs; a plenty of fruits and vegetables, nuts and seeds without additives, olive and grapes oils as the main oils of the diet, fish and seafood, and unrefined carbohydrates and dairy products with honey; contrarily, it excludes the consumption of sugar and refined carbohydrates, alcohol, and smoke. It has been shown that the consumption of the Hot-natured diet is related to a deviation of the immune system toward the Th2 responses. In addition, both hempseed oil and evening primrose oil possess anti-inflammatory features, related to the high PUFAs content and the perfectly balanced n-6/n-3 PUFAs ratio of the former and to the about 9% of GLA content of the latter. Based on all this evidence, Rezapour-Firouzi and co-workers in their studies [147,148] decided to adopt the hot-natured diet co-supplemented with 18–21 g of hempseed oil and evening primrose oil in a 9:1 ratio, as a potential useful dietary intervention for the treatment and attenuation of MS. The authors found that both types of dietary intervention (i.e., the Hot-natured co-supplemented with hempseed oil and evening primrose oil, and the co-supplementation of hempseed oil and evening primrose oil alone) for 6 months have exerted an effective anti-inflammatory action, leading to a significant increase in the IL-4 cytokine level on MS patients and to an improvements of the degree of the Th2/Th1 ratio, the expanded disability status scale (EDSS), and the relapse rate, which are all indexes of the disease severity, and thus performed a beneficial action in the patients, without exhibiting any side effects [147,148,149]. However, only the Hot-diet associated with the hempseed and evening primrose oils co-supplementation resulted in having also the ability to significantly decreased the level of the pro-inflammatory IFN-γ and IL-17 cytokines. Indeed, contrarily, the hempseed oil and evening primrose oil co-supplementation alone showed a decreased trend in the level of these cytokines, which though, was not statistically significant, at least after 6 months of the treatment . In a later report, the same authors  also demonstrated that both Hot-natured diet co-supplemented with hempseed and evening primrose oils and the co-supplementation of hempseed and evening primrose oils alone were able to improve the liver function in the MS patients, which generally showed a serious liver injury also as a consequence of the drug treatment, but the former dietary intervention was more efficient than the latter.
In conclusion, in addition to the fact that there is still a lack of studies about the effects of whole hempseed dietary intake on either healthy human subjects or patients with a specific pathological status, to date, the few works present in the scientific literature refer exclusively to hempseed oil supplementation and they are rather inconclusive and not very comparable due to the employment of different types of experimental designs, as well as different dosages, experimental periods, and administration methods of the supplement. Therefore, it appears necessary to deepen and expand the research and the knowledge in this area.
5. Hempseed Foods
In the field of food technology, due to their unique nutritional quality and composition, hempseeds have been exploited as ingredient or means to ameliorate the nutritional and healthy grade of food, in order to obtain healthy and potentially functional foods. In this context, the first efforts in the employment of these seeds by the food industry concerned their use as a means to increase the quality of animal derived food products, namely the use of hempseed or hempseed’s derivatives (i.e., hempseed oil or flour/cake/meal) as livestock feed supplement to ameliorate the quality composition of animal-based food products (e.g., meat, eggs, and milk). Only later, hempseeds and their derivatives have also been used as ingredient to directly enrich daily-consumed foods (e.g., bakery products).
5.1. Hempseed Products as Livestock Supplement
As a means to increase the quality of animal-derived food products, hempseeds and hempseed derivatives, especially hempseed oil, were used as supplements of the laying hens or broiler chickens’ normal diets to obtain eggs or meat enriched with n-3 PUFAs, including the n-3 long chain PUFAs (LCPUFAs) biologically active in humans, like EPA and DHA, due to the ability of the laying hens or broiler chickens to endogenously convert dietary ALA into these LCPUFAs and to deposit them into egg yolk or muscle tissues. In this context, several experiments were performed to assess either the safety of hempseed or hempseed derivatives as feed ingredients in poultry diets as well as their efficacy as a means to nutritionally ameliorate the FAs profile of egg yolk and meat, as an alternative to other n-3 PUFAs sources such as flaxseed, flaxseed oils, or marine oils, and microalgae products. Overall, these studies demonstrated that the performance of laying hens and broiling chickens, including feed intake, egg weight, egg production, feed conversion ratio, body weight, or weight gain, was not affected [150,151,152,153] or was ameliorated  by the dietary supplementation with hempseeds (up to 30%) or hempseed oil (up to 12%), and therefore, these products can be included in the bird’s diet without compromising their safety and efficacy. Interestingly, the hens’ performance was more positive if hempseeds were subjected to a heat treatment (specifically 120 °C for 60 min) performed before to supplement the hens’ diet . The safety of the inclusion of these supplementary products to poultry diet was further confirmed by the absence of the markers of hepatic and muscular damage after the hempseed product supplementation [151,154]. In addition, literature reports agree that the inclusion of hempseed products to the poultry diet effectively improved the nutritional value of the eggs and meat and obtained food products with higher total n-3 PUFAs amount, higher PUFA/SFA ratio, and a better-balanced n-6/n-3 PUFAs ratio in comparison to the poultry food products obtained by animals fed a normal diet. More specifically, it has been demonstrated that the total n-3 PUFAs and the individual n-3 PUFA ALA, as well as the n-3 LCPUFAs biologically active in humans, namely EPA, DPA (Docosapentaenoic Acid), and DHA, were increased in both poultry eggs [150,152,153,156,157,158,159,160] and meat (thigh and breast)  as the inclusion of the hemp products rose and the n-6/n-3 PUFAs ratio, normally high in common eggs, was reduced [152,157,158,161]. Neijat and colleagues  found that, as a consequence of the dietary hempseed and hempseed oil supplementation to the laying hens’ control diet (wheat-barley-soybean meal-based), the ALA content increased in a dose-dependent manner and this increase was higher in the TGs than in the phospholipids (PLs) that, therefore, seem to be less responsive in ALA enrichment in comparison to TGs. The authors found also an increase in the total amount of n-3 LCPUFAs synthesized from ALA (i.e., EPA, DPA, and DHA) in response to the increase in the ALA dietary intakes, reflecting the endogenous synthesis from ALA in hens’ liver and the subsequent deposition in egg yolk. However, contrarily to ALA, this growth did not occur in a dose-dependent fashion for LCPUFAs, such as DHA, which in fact, was accumulated mainly in PLs, until a saturation level [156,157]. Regarding this, it is important to consider that the conversion of ALA to DHA occurs through the sequential actions of the enzymes ∆-6 desaturase encoded by the fatty acid desaturase 2 (FADS2) gene, elongase encoded by the elongase 5 (ELOVL5) gene, and ∆-5 desaturase encoded by the fatty acid desaturase 1 (FADS1) gene. Gakhar and co-workers  by evaluating the effect of the consumption of hempseeds or hempseed oil by hens on the expression of these three main biosynthetic genes involved in the PUFAs metabolism found that the FADS1 and FADS2 expressions were reduced by the increasing inclusion of hempseed products in laying hens’ diets, thus providing a possible explanation to the DHA saturation in the egg yolk of hens supplemented with hempseed products. Interestingly, Jing and colleagues  showed that the increase in the n-3 PUFAs ALA, EPA, DPA, and DHA occurred both in the egg yolk and in the meat of laying hens’ and broiler chickens fed a hempseed oil supplemented diet, but this increase took place to a different extent based on the food product. Indeed, in comparison to the respective control, the enrichment efficiency for total n-3 PUFAs, ALA, and EPA appeared to be higher in egg yolk than in chicken meat. Furthermore, the DPA amount was higher than DHA in meat, contrarily to egg yolk, where the DHA level was higher than DPA even without supplementation, and after hempseed oil supplementation, the difference between DPA and DHA content in egg yolk or meat became more evident. This finding was attributed to a differential expression and activity of FADS2 and ELOVL5 enzymes that are involved in the conversion of DPA to DHA rather than an effect of the supplementation. In particular, based on the results, it was hypothesized that these enzymes may be low in the muscle tissues of chicken and thus, inhibiting the metabolism of DPA to DHA. Interestingly, Mierliță and colleagues  found that the egg yolk produced by hens fed a diet supplemented with whole hempseeds contained a higher ALA and EPA amount and a more remarkable decrease in n-6/n-3 PUFAs ratio in comparison with the egg yolk produced by hens fed a diet supplemented with hempseed cake. Hence, the authors concluded that whole hempseeds supplementation was more effective in ameliorating the nutritional quality of egg yolk than the hempseed cake one.
With regard to the effect of hempseed products supplementation on the n-6 PUFAs content of the poultry eggs and meat, Shahid and co-workers  found an increase in the total n-6 PUFAs amount of egg yolk, whereas, Neijat and others  observed that, although the level of n-6 LA was higher especially in the TGs, in comparison to the control, the n-6 AA amount decreased as the hemp dietary inclusion increased, reflecting the metabolic competition of n-3 ALA and n-6 LA for the ∆-6 desaturase enzyme, responsible to their conversion in the corresponding LCPUFAs, with the greater affinity of n-3 ALA than n-6 LA, and a consequent favour of n-3 PUFAs metabolism. Similar data was found also by Mierliță and colleagues . Furthermore, it has been also observed that among, n-6 PUFAs, the hempseed products supplementation led to an enrichment of eggs and meat with the GLA [150,161], conferring to these food products a further unique features related to the biological anti-inflammatory and anti-proliferative properties of GLA that have important implications for human health. Similar GLA-enrichment was also shown in the muscle of ducks fed a 15-20% hempseed cake-supplemented diet .
Regarding MUFAs and SFAs, literature publications agree that the MUFAs content, mainly OA, decreased with the increase of the level of the hempseed products to the diet, probably due to the inhibition effect of a PUFAs-rich diet on the activity of ∆-9 desaturase, which is essential for the conversion of PA to OA [150,153,155,157]. Whereas, about the effect on SFAs there are some contrasting results. Some authors found a reduction in the SFAs [155,158], as well as in the cholesterol amount  in egg yolk after hempseed supplementation. Other researchers [153,157] showed that the overall levels of SFAs and cholesterol of egg yolk were not influenced by a dietary treatment with hempseeds, hempseed oil, or hempseed cake.
Similar findings about the positive effect of the hempseed or derivative dietary supplementation on the nutritional quality of egg yolk and meat were also shown for quails . In this case, 6-week supplementation with up to 20% whole hempseeds, allowed to obtain n-3 PUFAs enriched quail eggs with a reduction of MUFAs—OA in particular—and SFAs—PA in particular—as an additional advantage. In the same study, the quality of the meat of the 5-week whole hempseed supplemented quails was also analysed, and a decrease in thawing and cooking loss were observed, which are both negative indicators for meat quality, with the increase of the dietary hempseed amount, demonstrating that hempseeds supplementation can ameliorate also the meat quality other than the eggs FA profile. In addition to the safety for animals and the efficacy in obtaining more nutritionally beneficial food products, the inclusion of hempseed products into the poultry diet was tested also for the potential negative impacts on the sensory characteristics of the resultant products. Indeed, it was found that dietary supplement as flaxseed or fish oils can compromise the sensory quality of the poultry meat and eggs due to the presence of fish smell/taste. Instead, Goldberg and colleagues  demonstrated that the inclusion of up to 20% hempseed or up to 10% hempseed oil in the poultry’s diet did not have any adverse effects on the eggs’ sensory quality. Similar results were obtained by Konca and co-workers  for eggs produced by hens supplemented with 15% raw or heat-treated whole hempseeds for 12 weeks.
Hempseeds supplementation in animals’ feed has been shown to be a useful tool also to improve the yield, the quality, and the nutritional value of some milks, such as the goat and sheep ones, and in particular, to positively modify the milk’s FAs content. This by increasing the total concentration of LCPUFAs, n-3 PUFAs, and conjugated linoleic acids (CLAs), and concomitantly by decreasing the concentration of SFAs and the n-6/n-3 PUFAs ratio, with a putative beneficial effect on human health [164,165,166]. Mierliță and colleagues  found also an increase in the tocopherol amount and an improvement of total antioxidant capacity of milk obtained from sheep fed a diet supplemented with hempseed (180 g/day) or hempseed cake (480 g/day), in comparison to that obtained by sheep fed a control diet (hay diet completed with high-energy concentrate and sunflower meal), thus demonstrating that despite the increase of the PUFAs content in milk, the safety of this product was not negatively affected by lipid oxidation. The same authors also showed that, between hempseeds and hempseed cake supplementation, the latter was more effective in ameliorating the quality and the nutritional value of the milk, as it was resulted in a significantly lower atherogenic index and a higher hypocholesterolemic/hypercholesterolemic index. Cozma and colleagues  found a reduction in the lactose content of the milk produced by goat fed a diet supplemented with hempseed oil (93 g/day). Contrarily, Iannaccone and co-workers  showed an up-regulation in the genes involved in lactose biosynthesis, based on the results of a RNA sequencing analysis of the whole-blood transcriptome of lactating sheep fed either a control diet or a 5% hempseed supplemented diet, and this result was in accordance with the increase in the lactose amount found in the resulting milk.
5.2. Hempseed Products as Ingredient for Enriched/Fortified Foods
As a means to directly enrich or fortify daily foods, hempseeds and their derivatives have been assessed as an ingredient added to daily consumed foods, including bakery products such as bread, cookies, crackers, and energy bars, as well as meat and meat products.
Regarding the enrichment of bread with hempseed or derivatives, some works have evaluated the impact on the nutritional, structural, and textural characteristics of both dough and bread, consequentially to the addition of hempseeds or their derivatives. About this, from a technological/rheological point of view, the main issue of the usage of non-conventional ingredient in the bakery industry, in order to fortify the bakery products is their adverse effect on the dough rheological and baking properties, mainly as a result of the dilution of wheat gluten proteins. Consequently, this can negatively affect the end product quality (volume, texture, crumb and crust properties, and colour) that may ultimately affect lowering the consumers’ acceptability. Studies about the enrichment of the bread dough with hempseed flour agree that the addition of hempseed flour in the wheat flour significantly reduced the dough’s water absorption, stability, strength, and starch gelatinization, in a proportional manner to the level of hemp flour added as a consequence of the dilution of gluten amount in the dough [166,169,170]. Pojić and colleagues , and Švec and others  found that the decrease in the water absorption of the bread dough had a negative impact also on the time required for dough development, but nevertheless, the dough’s stability and strength were not significantly affected by the addition of up to 10% of hempseed flour. Pojic and others  also noted that the increase in the hempseed flour content up to 20%, negatively affected both the dough’s stability and strength.
The changes in the dough’s rheological properties, resulting in the addition of hempseed flour, led to a negative impact on the bread quality. In this regard, Pojic and colleagues  showed that the bread volume was significantly impaired as the level of hemp flour increased. This result was found also by Hrušková and co-workers  and by Švec and colleagues  for bread enriched with 10%, 15%, or 20% of hempseed flour, and was confirmed also by Mikulec and others  for bread containing 15%, 30%, or 50% of hempseed flour, as well as by Wang and colleagues  for bread enriched with 5%, 10%, or 15% extruded hemp-rice flour (EHR), made by the extrusion of the whole hempseeds (30%) together with the rice flour (70%). According to the authors, the decrease in the bread’s volume could be due to the partial replacement of wheat flour with a non-glutinous one, that may dilute the gluten protein of wheat flour and prevent its extension, or to the increased content of fibre, which reduces the ability to retain fermentation gases. However, Wang and colleagues  showed that the addition of 15% of EHR led to a significantly increase of the bread volume in comparison to 10% EHR-containing bread. The researchers attributed this evidence to the higher fat content present in the 15% of EHR. This hypothesis was later confirmed by another work of the same authors  in which the properties of the dough and the bread made from extruded and non-extruded hemp-rice flour were compared. The obtained results showed that the presence of whole hempseeds in the bread dough did not impair the specific bread volume in comparison with the control. A similar finding was noted also by Švec and co-workers  who found that the volume of the bread enriched with whole hempseeds powder (i.e., ground whole hempseeds) was higher than those obtained for the breads enriched with other defatted hempseed products (i.e., hempseed flour or hempseed protein concentrates). This fact has been attributed to the interactions between lipids and proteins and to the influence of the fat in terms of enhancing dough expansion during proofing . The addition of hempseed flour to the wheat flour also changed the physical and rheological properties of the bread’s crust and crumb. The color of both of them became darker after the hempseed flour addition [166,169,172,173]. Švec and colleagues  asserted that the 5% enrichment has conferred a pleasant coffee brown colour, which intensified to dark brown by increasing the amount of hempseed flour, whereas, Wang and co-workers  observed a significantly decreased in the lightness of both crust and crumb only for the breads enriched with an EHR amount of at least 10%, since the 5%-EHR bread did not show any significant colour’s differences compared to the control bread. Similar changes in the crust and crumb bread’s colour were observed by Wang and colleagues  also after the addition of whole hempseeds powder. Interestingly, in this paper, the authors noted that the hempseed extrusion process and the extrusion temperature can further emphasize the lack of the lightness. Regarding the textural properties of bread crumb, Pojic and co-workers  found that the presence of hempseed flour as an ingredient of the bread’s mixture significantly decreased the crumb cohesiveness and increased the crumb chewiness and hardness. Analogously, Mikulec and others  found an increase in the hardness of the crumb after the addition of hempseed flour, on the baking day. Contrarily, Wang and colleagues  showed that the 15% EHR-bread displayed significantly lower hardness compared to the samples enriched with a lower EHR amount (i.e., 5% and 10%), whereas, in their later publications , the same authors observed no significantly differences on the crumb hardness in the whole hempseeds powder-containing breads, and this might be attributed to the influence of hemp oil, which probably enhanced crumb texture and crust tenderness. Interestingly, Pojic and colleagues  found that the presence of hempseed flour up to 10% in bread formulation did not significantly affect the elasticity and the resilience of the crumb, unlike the addition of 20% of hempseed flour.
Concerning the nutritional quality of the hempseed flour or whole hempseed powder-enriched bread, it has been demonstrated that the addition of hempseed product significantly ameliorated the bread nutritional quality, since it proportionally increased the total protein [166,169,170,171,172] and fat  contents, as well as the total, soluble, and insoluble dietary fibre . About this, it is interesting to note that Švec and colleagues  showed that the increase in the dietary fibre was higher if the enrichment was made with whole hempseed powder rather than hempseed flour. Furthermore, Pojic and co-workers  found that the hempseed flour enrichment also led to an increase in the content of the macro-elements, especially of Mg and Ca and of the micro-elements such as Mn, Cu, and above all, Fe and Zn. At the same time, the Na amount, the complex carbohydrates, and total metabolizable energy of the bread significantly decreased. This nutritional improvement was more marked for the 20% hempseed flour-enriched bread. Also, an increase in the total phenolic content was observed by Mikulec and others  as a consequence of adding the hempseed flour, and the most abundant polyphenols included epicatechin, ferulic acid, and protocatechuic acid. However, according to Švec and co-workers , the addition of 20% of hemp product (i.e., hempseed flour or whole hempseeds powder) has conferred a less acceptable, partially bitter taste to the bread; by contrast, the addition of 10% hempseed product did not have any negative impact on the sensorial parameters. Mikulec and co-workers  found that also the 15% addition level of hempseed flour had an overall acceptability. Therefore, also considering that the negative impact of the presence of the hempseed flour on the bread quality seems to be attenuated with 10% enrichment, the literature generally agrees that the 10% or 15%-substitution level of hempseed flour should accomplish requirements in terms of providing the balance between bread quality, sensorial, and nutritional properties.
Since hempseed is naturally gluten-free, it could be potentially employed as an ingredient to improve the poor nutritional value of the gluten-free products. To date, only a few papers in the literature investigated this issue by evaluating the impact of replacing to a certain extent, the main ingredient of the gluten-free recipe with hempseed derivatives, mainly hempseed flour or proteins. For example, Korus and colleagues assessed the effects of replacing 10% or 20% of gluten-free starch corn with hempseed proteins or flour in the dough of gluten-free bread , and the consequences of the substitution with 20%, 40%, or 60% of hempseed flour in the preparation of gluten-free cookies  on the rheological, qualitative, sensorial, and nutritional properties of the relative food products. Nutritionally, both studies highlighted that the addition of hempseed product led to significantly improvement of the nutritional value of the gluten-free food, since it rose, at high extent, the amount of total proteins and total dietary fibre, including soluble and insoluble, with higher increase especially in the insoluble fraction as well as fat and minerals [175,176]. Moreover, for the biscuits, it has shown that the carbohydrate content and the energy value of the products decreased proportionally to the level of substitution. Furthermore, the authors also found an enrichment in the antioxidant profile of the hempseed flour-substituted cookies that had significantly higher values of total phenolic (up to 2-fold higher) and flavonoid (up to 2-fold higher) compounds compared to the control, with a resulting rise in the total antioxidant capacity (up to 3-fold higher) . Hence, from a nutritional point of view, either hempseed flour or proteins may be considered valuable ingredients for the formulation of improved gluten-free products. Regarding the rheological properties of the bread’s and cookies’ dough, the authors showed that for the bread mixture, the substitution of corn starch with hempseed flour resulted in a weakening of dough structure, which became more susceptible to deformation; contrarily, the substitution with hempseed proteins reinforced the dough structure. These differences have been attributed to the differences in the interaction and the binding between the hempseed components and water in the dough. Indeed, the authors explained that proteins absorbed more water, and hence, the addition of hempseed proteins could prevent the fulfil hydration of all dough component, thus resulting in dough strengthening. By contrast, hempseed flour contains other components besides proteins, and these significantly modified water binding, thus differently influencing the rheological properties of final dough . For the cookies’ dough, the authors observed a significant increase in the overall hydration properties of the mixture, demonstrated by the higher values of water absorption, water retention, and oil absorption capacity in comparison to the control. These findings were associated to the increase of both the protein (4-fold higher) and total fibre content (20-fold higher) in the dough, which significantly affected the hydration properties of the biscuits’ blend . In addition, contrary to what was observed for the enrichment with hempseed flour of gluten-containing bread, in this case, the addition of hempseed flour led to a significant increase in the quality of the gluten-free bread, as well as an improvement in the bread sensory acceptability, nutritional quality, and storage. Particularly, the authors found an increase in the bread volume, resulting in the addition of both hempseed products. This increase was more evident with raising amounts of hempseed products in the dough, and it was more pronounced in the case of hempseed proteins addition. This is probably due to the absence of gluten proteins, and so, hempseed proteins can act as surface-active and foaming agents, thus allowing to retain and stabilize the gas bubbles in the dough and bread. Interestingly, the bread volume was shown to be negatively related to the crumb hardness that, therefore, was the lowest in the control bread and the highest in the 20% hempseed protein-enriched bread. The limited hardness in the enriched bread was maintained also during the storage, thus limiting the bread’s aging. Contrarily, in the biscuits, the volume decreased after the hempseed flour substitution, whereas the cookies hardness increased, reaching the highest value in the 60% hempseed flour enriched cookies . In both bread and biscuits, the colour of crumb and cookies became darker after the hempseed product substitution as the substitution level increased; this was found to positively affect the product sensory acceptability [175,176]. Moreover, for the gluten-free bread, either the enrichment with hempseed flour or hempseed protein conferred an aroma and taste considered better than the control, nevertheless the taste acceptability was significantly reduced by 20% hempseed flour , whereas, as regard the biscuits, the sensory panel highlighted a significant reduction in the sensorial acceptability of the hempseed flour cookies than the control one, especially at a high level (60%) of substitution .
Similar results about the water absorption properties, colour, and nutritional and antioxidant changes after the addition of hempseed flour in the mixture, were obtained by Radocaj and colleagues  for gluten-free crackers in which brown rice flour was partially substituted with 10%, 20%, 30%, or 40% of hempseed flour. In this work, the authors underlined the possible employment of hempseed flour as a functional ingredient usable to mix with other functional raw materials such as green tea leaves, as it was done in this study, to enhance the nutritional and healthy values of daily food and to develop potentially functional foods, accessible also to the coeliac people. Indeed, with this report, the researchers demonstrated that the addition of hempseed flour is the direct responsible to some nutritional improvement that was even better than those observed for other fortified or enriched products. For example, the authors demonstrated that the addition of hempseed flour permitted to obtained crackers with a content of proteins, fibre, and minerals higher than that found for crackers enriched with pulse flour. Moreover, the addition of hemp flour led to enforcement of the crackers with essential FAs that lack in other analogous products. This remark was in line with the findings by Norajit and colleagues , who investigated the effects of the addition of hempseed flour, or whole hempseeds powder, at three different levels (20%, 30%, or 40%), on the nutritional quality and the antioxidant activity of rice flour bars. Interestingly, comparing the nutritional and functional differences (i.e., antioxidant activity) between the rice bars enriched with hempseed flour and that enriched with whole hempseeds powder, the authors showed that the rice bar with whole hempseeds powder had significantly higher total phenolic and flavonoid contents, as well as better antioxidant properties, than the rice bar blended with hempseed flour.
A few studies investigated the incorporation of whole hempseeds or derivatives products (i.e., de-hulled hempseed, hempseed flour, and hempseed proteins) in meat products in order to ameliorate their nutritional value. In this context, Zając and Świątek  used the whole hempseeds as added ingredients of liver pâtés with the aim to improve its FA profile. Actually, although the total fat content of the tested pâtés did not significantly change, its FA profile was significantly better since MUFAs and SFAs decreased compared to the control whilst the PUFAs increased. Moreover, the total n-3 PUFAs was almost 6-fold higher than the control product, and even though its level was too low to label the product as a source of n-3 PUFAs accordingly to the EU regulation 1924/2006, nevertheless, its significantly higher amount conferred it a better nutritional value in comparison with the traditional pâtés. The authors also assessed the texture and sensorial properties of the experimental product and demonstrated that the addition of whole hempseeds significantly raised the hardness, chewiness, and the adhesiveness of the pâtés without significantly changed its cohesiveness. Despite these texture variations, the inclusion of whole hempseed did not modify the sensory parameters compared to the control.
Zając and colleagues  also investigated the effects of the incorporation of 5% of either whole hempseeds, de-hulled hempseeds, hempseed flour, or hempseed proteins in pork loaves, on nutritional quality, sensorial acceptability, and physical features of the obtained product. From a nutritional point of view, the obtained data showed that, among all hempseed additives, only the whole hempseeds have led to a significant increase in protein, ash, and total fibre content, without significantly changing the total fat amount, whereas, hempseed flour and proteins were the additives that have led to the highest enrichment in the amounts of K, Mn, and Fe, and of Ca, Mg, and Zn, respectively, even though a significant increase in the macro- and micro-elements in comparison to the control, was observed also for the others hempseed additives, in spite of in a minor extent. Furthermore, predictably, only the inclusion of whole hempseeds and de-hulled hempseeds led to a significant improvement in the FAs profile, through decreasing the total MUFAs and SFAs, increasing the total PUFAs, both n-3 PUFAs (4-times and 3-times higher in whole and de-hulled hempseeds enriched sample, respectively) and n-6 PUFAs (2-times higher) and decreasing the n-6/n-3 PUFAs ratio. The improvement of the FA profile of the pork loaves enriched with whole or de-hulled hempseeds, led these samples to have also the lowest thrombogenicity and atherogenicity index. Hence, overall, these two enriched products appeared to be healthier and nutritionally better in comparison to the other enriched pork loaves. Nevertheless, a Thiobarbituric Acid Reactive Sunstances (TBARS) analysis showed that the de-hulling process made the pork loaves enriched with de-hulled hempseeds more prone to oxidation during the storage in comparison to the other samples, probably due to the removal of the hull, that as previously said, it has shown to be the hempseed fraction where most of polyphenols are located [74,92,100]. However, among all evaluated samples, the de-hulled hempseeds enriched one was the sample which has received the higher consumers’ acceptance, even though, interestingly, the authors found that the consumers’ willingness to buy the meat enriched with hempseed products increased after providing the information about the healthy ingredient and therefore, highlighted the importance to furnish the right awareness to consumers about the hempseed’s health benefits.
Finally, hempseed proteins have been also used as an additive for yogurt by Dabija and colleagues  with the aim to fortify it and to obtain a new daily product with high nutritional value. In this study, the authors found that among different tested vegetable source proteins (i.e., hempseed proteins, pea proteins, gluten wheat, soy proteins, and pumpkins flour proteins), hempseed proteins have been shown to be those with the lowest syneresis value, which is an index of the expulsion grade of serum, considered as a negative acceptable parameter. This could be related to the high fibre content of hempseed proteins that improved the viscosity and reduced the serum separation levels, as it was confirmed by the rheological analysis. Moreover, the addition of hempseed proteins also induced a reduction in the pH value and an increase in the acidity of the fortified yogurt. Both features can be related to an improvement of the growth of the bacteria present in the yogurt. In addition to these positive changes, no significant differences were found about the acceptance of the fortified sample with hempseed proteins in comparison to the control sample.
Hence, in view of the above, it is clear that there are efforts by researchers to understand the structural, nutritional, and functional roles of the hempseeds and derivative utilization in the development of new heathier and nutritionally improved foods, also for specific intended groups of people such as coeliac ones. However, further investigations are needed for a better comprehension of the most appropriate hempseed product types, matrices, and dosages in order to develop a food product with a greater improvement of nutritional and functional properties, without negatively affecting the physical and sensorial properties of the food product. In-depth investigations are also necessary to identify the most functional hempseed’s compounds, their molecular mechanisms, and their targets in order to comprehend the most adequate concentration of the functional compounds and the vehicle/matrix most suitable to preserve their structure and functionality into the gastrointestinal tract to maximize their bioavailability in the human body and to allow the compounds to reach the target sites. Only in this way, the regular ingestion of the appropriate quantity of food product could actually exert a preventive and beneficial clinically detectable effect, as required in order to claim a food as a functional food.
Due to the optimal nutritional composition and to the functional properties of hempseeds, some researchers investigated on one hand, the effects of hempseed dietary supplementation on health and in specific pathological condition, through animal models and humans studies and, on other hand, the possibility to used hempseeds in the food industry as livestock feed supplement to ameliorate the nutritional quality of animal-derived food products, and as ingredient to enrich or fortify daily foods. Overall, the studies performed on animal models have highlighted that there is some evidence about the protective and beneficial effects of hempseeds dietary supplementation especially on inflammatory and chronic-degenerative diseases such as CVDs and neurodegenerative ones, whereas, from the human studies some benefits for the atopic dermatitis treatment, certain blood parameters, and inflammatory responses modulation were emerged following the hempseed oil dietary intake. Nevertheless, the papers present in the scientific literature concerning this issue, are still few and rather inconclusive, referring only to hempseed oil, and is not very comparable due to the employiment of different types of experimental designs, as well as different dosages, experimental periods, and administration methods of the supplement. Finally, the studies respecting the adoption of hempseeds or derivatives in the food industries showed that these products could effectively ameliorate the FAs profile of some animal foods like eggs, milk, and meat, when they are used as livestock feed supplement, whereas when they are employed as ingredients of enriched or fortified foods, many changes occurred in both the rheological and sensorial acceptability of the enriched/fortified products and, often, they were not positively in spite of the improvement of the nutritional quality. Therefore, further investigations are needed to expand the research and knowledge about the potential use of the hempseed or derivatives for the development of functional foods. Particularly, it is necessary to understand what are the most functional hempseed’s compounds, their molecular mechanisms, and their targets, in order to comprehend the most adequate concentration of the functional compounds and the vehicle/matrix most suitable to preserve their structure and functionality into the gastrointestinal tract, and to maximize their bioavailability in the human body. Furthermore, it is also required to identify the best compromise between the functionality and the rheological and sensorial properties, taking into account that a certain reduction of sensorial acceptability could be tolerable by consumers informed about the beneficial effects of the fortified/enriched products in comparison to the common counterpart.
Conceptualization, B.F.; writing—original draft preparation, B.F.; writing–review and editing, all of the authors. All authors have read and agreed to the published version of the manuscript.
Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Industrial hemp (Cannabis sativa L., Cannabaceae) is an ancient cultivated plant originating from Central Asia and historically has been a multi-use crop valued for its fiber, food, and medicinal uses. Various oriental and Asian cultures kept records of its production and numerous uses. Due to the similarities between industrial hemp (fiber and grain) and the narcotic/medical type of Cannabis, the production of industrial hemp was prohibited in most countries, wiping out centuries of learning and genetic resources. In the past two decades, most countries have legalized industrial hemp production, prompting a significant amount of research on the health benefits of hemp and hemp products. Current research is yet to verify the various health claims of the numerous commercially available hemp products. Hence, this review aims to compile recent advances in the science of industrial hemp, with respect to its use as value-added functional food ingredients/nutraceuticals and health benefits, while also highlighting gaps in our current knowledge and avenues of future research on this high-value multi-use plant for the global food chain.
Industrial hemp (Cannabis sativa L., Cannabaceae) is a versatile herbaceous crop that has been used for fiber, food, and medicinal purposes [1,2]. The cultivation of hemp dates back to China around 2700 BC and is believed to have then expanded across Asia, making its way to Europe 2000–2200 years ago [3,4]. Historically, a multitude of products has been derived from the seeds, fiber, and wooden core of the hemp plant . As a traditional fiber crop, hemp is said to have lined the spine of the first copy of the Bible and set Columbus’s sails with canvas and rope [3,4,5]. As a multi-use crop, hemp is considered one of the oldest plants cultivated to provide nutritional and medicinal benefits [2,6]. The hemp seed, be it raw, cooked, or pressed into oil, has been well documented as a primitive source of fiber, protein, and fat, with high nutritional value [3,6]. Furthermore, properties of hemp have been used to aid in treating and preventing ailments for thousands of years in traditional oriental medicine [3,4]. In recent years, the interest in investigating the potential use of industrial hemp in food and nutraceuticals has been growing ( Figure 1 ).
Number of abstracts in the CAB international database in the last 20 years. The search with the keywords (A) Cannabis sativa + Food, (B) Cannabis sativa + Protein, (C) Cannabis sativa + Oil, (D) Cannabis sativa + Cannabidiol.
Most researchers consider that Cannabis has only one species, C. sativa L. In the 1970s, Small and Cronquist  separated it into two subspecies: subsp. indica, with relatively high amounts of the psychoactive constituent delta-9-tetra-hydrocannabinol (THC), and subsp. sativa, with low amounts of THC. The two subspecies can be further broken down into wild and domesticated varieties; under subsp. sativa, var. sativa is domesticated and var. spontanea is wild, and under subsp. indica, var. indica is domesticated and var. kafiristanica is wild . According to these systematics, the modern industrial hemp varieties would belong to subsp. sativa, and most medical Cannabis (also called “marijuana”) varieties would belong to subsp. indica. However, there are numerous hybrids blurring the line. A contradiction to the above observation has also been reported . Hemp and medical Cannabis strains with 100% C. indica ancestry possessed higher genetic variance than strains with 100% C. sativa ancestry. Another study using Random Amplified Polymorphic DNA markers of hemp and medical Cannabis also indicated that hemp aligns more with C. indica than C. sativa . Hillig  also strongly opposed the C. sativa classification of hemp due to many Asian hemp accessions exhibiting more commonalities with C. indica. Apart from indicating a high admixture between the C. sativa and C. indica genetic pools, these results also suggest that the genetic lineage analysis did not conform to the currently recognized classification, and we may have to revisit the taxonomy of these species to better reflect new genetic information coming to light.
1.2. Sex Expression
Hemp is typically a dioecious, obligate cross-pollinated species with a diploid genome (2n = 20), although monoecious types have been bred. It is genetically complex and therefore has significant variability in phenotype and sex expression [11,12]. Also, research has shown significant intra- and inter-cultivar karyotype variation among eight monoecious and two dioecious cultivars . Plants may be entirely female, entirely male, or a gradient of intermediate .
1.3. The Genetic Basis of the Difference between Hemp and Medical Cannabis
Industrial hemp and medical Cannabis have primarily been differentiated by their levels of THC production. The cannabinoids (THC and cannabidiol [CBD, Figure 2 ]) profile and the morphology of the plant are determined by the interaction of genetics and the environment. Genetically, medical Cannabis possesses the BT allele that encodes for tetra-hydrocannabinolic acid synthase, while hemp produces the BD allele encoding for canabidiolic acid (CBDA) synthase . Furthermore, van Bakel et al.  studied the transcriptome of female flowers from hemp and medical Cannabis, concluding that there was an up-regulation in the entire THC production pathway in medical Cannabis compared to hemp. This difference translates to producing upwards of 10% THC in many medical Cannabis samples, whereas most hemp samples have a total THC level of 0.3% or less . Some preliminary studies indicated 27% genetic variation between hemp and medical Cannabis samples using Amplified Fragment Length Polymorphisms and genetic variance in certain genomic regions [18,19].
Chemical structures of selected biologically active compounds of industrial hemp. (A) Linoleic acid (omega-6 polyunsaturated fatty acid [PUFA]), (B) alpha-Linolenic acid (omega-3 PUFA), (C) Tocopherol, (D) Cannabidiol (CBD), (E) Cannabisin A, and (F) Caffeoyltyramine.
Recent research indicates genome-wide differences that are not confined to the THC biosynthetic pathway . A principal component analysis plot of 81 medical Cannabis and 43 hemp samples obtained from 14,301 single-nucleotide polymorphisms indicated a clear genetic structural difference between hemp and medical Cannabis samples. The hemp samples were more heterogenous than medical Cannabis, indicating the hemp samples came from a wide genome pool, whereas the medical Cannabis samples had a relatively narrow genetic base . Though there are known genetic structural differences, a detailed examination of the genes involved in differentiation, and their corresponding phenotype changes, will provide more input into the genetic basis of the differences between hemp and medical Cannabis. Hemp is resurging in cultivation and production, so care must be taken to conserve the genetic diversity to ensure the long-term survival of the crop.
This review surveys the composition of hemp (both the major nutritive components and the bioactive phytochemicals), as well as their collective health benefits. The aim of this paper is to provide a comprehensive review of hemp seed as a source of value-added or functional food ingredients that is inclusive of its constituents and the role they play in the prevention and treatment of disorders and diseases.
2. Hemp Industrial Products
There are various industrial or economic products of hemp. Industrial hemp comprises fiber and oilseed hemp. Fiber hemp is currently considered a niche crop and is grown in temperate regions. Hemp seed (grain) and its derivatives have also gained popularity among consumers and have multiple uses.
It is estimated that the hemp market entails more than 25,000 products, ranging from textiles, clothing, rope, home furnishings, industrial oils, cosmetics, to food and pharmaceuticals [4,20,21]. The durability and high strength properties of the cellulose-rich fiber from the stalk make it a valuable product for rope, paper, construction, and reinforcement materials [1,3,4,22]. Hemp seeds have high nutritional value and pharmacological properties [2,22]. Within the last decade, hemp seed products have expanded to include a range of food and beverages, nutritional supplements, alternative protein sources, and pharmaceuticals [2,20]. In fact, hemp seed’s utility as a functional food ingredient is currently witnessing a revival of old medicinal applications, as its metabolites have shown potent biological activities .
2.1. Crop Production
The cultivation of industrial hemp is more efficient and less environmentally degrading than that of many other crops . Hemp can be grown under a variety of agro-ecological conditions and has a capacity to grow quickly, especially after the first 4–5 weeks after emergence, making it an excellent candidate for carbon sequestration [4,5,23]. Hemp grows best in sandy loam with good water retention and drainage at temperatures between 16–27 °C, in nutrient balanced soil (especially nitrogen, phosphorus, potassium, magnesium, copper, and others). The planting density depends on the type of crop. Fiber hemp does well in high density to encourage stalk growth, but oilseed and CBD hemp should be planted farther apart to encourage greater branching and flower yields . Densely seeded fiber varieties may reach 5–6 m tall, while some recent grain varieties may only reach 1–1.2 m tall. Many multiple-use or resin cultivars are intermediate in height. Industrial hemp is either harvested for the stalk or seeds, whereas the flowering buds are collected from the narcotic type cultivars [18,23,24,25]. Selection for a specific final product (fiber, seeds, or products from the inflorescences) is reflected in the plant architecture of available varieties and clones . However, architecture also strongly depends on plant density, day length, and nutrients and moisture available in the soil .
As a fiber crop, hemp provides a high yield; it produces 250% more fiber than cotton and 600% more fiber than flax, from the same acreage [5,21]. Due to the fast-growing, dense canopy, fiber hemp is a natural weed suppressor and could be grown without herbicides; it also suppresses levels of fungi and nematodes in the soil and can be grown without fungicides or pesticides [5,21,23,24]. Hemp contributes to the maintenance of soil quality by its anchored roots, which prevent soil erosion and nutrient leaching, may extract nutrients from deeper soil layers, and are effective for phytoremediation by absorbing heavy metal contaminants from the soil and storing them within the plant. The continual shedding of leaves through the growing season adds moist organic matter to the soil [1,4,21]. Because of the functions in improving the soil quality, hemp is a prime candidate to be used for crop rotation programs to improve the yield of the main crop . Despite the historical functionality of this multi-purpose crop, global hemp production declined in the 19th century, and still only comprises about 0.5% of the total production of natural fibers .
2.2. History of Hemp Production
Industrial hemp has been grown as a commodity fiber crop in North America since the mid-18th century until the 1930s. Hemp fell under the umbrella of “marijuana” in the 1930s, and its production was prohibited in Canada under the Narcotics Control Act [3,22,24]. Industrial hemp production acreage and industry rapidly declined in the USA following the Marihuana (SIC) Tax Act of 1937 . However, with the onset of WWII, prohibition was lifted temporarily, when imports of other sources of fiber were unavailable . As an important historical note, hemp was of such necessity to the war effort that the United States Department of Agriculture (USDA) produced an educational video “Hemp for Victory” to encourage farmers to grow hemp . The prohibition was then renewed after the war, and investments in the industry dwindled and were deferred to other crops [3,21,27]. Hemp production generally ceased in North America but continued to a limited extent in Eastern Europe, China, Soviet Union, France, and Spain, where industrial hemp was not prohibited . Hemp production decreased in Europe and the Americas in the late 19th century due to several factors including the replacement of sail ships with steamships, the availability of abaca fiber and rope, and the availability of other less expensive and softer fibers such as cotton. In addition, synthetic fibers such as polyester, nylon, and acrylic were invented in the 1930s and 1940s, and became major fiber competitors after WWII . In 1998, the 60-year hemp production ban was revoked, and under a closely monitored Industrial Hemp Regulation Program, hemp cultivation commenced in Canada .
In terms of prohibition, industrial hemp was guilty by its association with medical Cannabis . As mentioned above, both hemp and medical Cannabis belong to the same plant species Cannabis sativa L. but are cultivated differently and vary in their phytochemical constituents . In North America and most of Europe, the industrial hemp must not contain more than 0.3% THC in dried herbage [2,17,20,24]. In some countries such as France, this limit was set at 0.2% THC. In the USA, the 2014 Farm Bill permitted “Institutions of higher education” and state agriculture departments to grow hemp under a pilot program if state law permitted it; however, some production aspects were still subject to Drug Enforcement Administration oversight . Before this, all hemp subspecies and varieties were considered Schedule I controlled substances. The 2018 Farm Bill legalized the production of hemp as an agricultural commodity, removed hemp from the list of controlled substances, and listed it as a covered commodity crop under crop insurance .
Currently, fiber and grain hemp are minor crops around the world. However, in the last few years, the production of CBD has made hemp one of the most high-value crops. CBD hemp is becoming a major commodity crop in some states in the USA. Moreover, the increased use of Cannabis in the western world as a psychoactive modulatory drug has changed the public perception of hemp.
2.3. Industrial Hemp Market
Globally, the industrial hemp market remains in China, where approximately half of the world’s fiber hemp supply is produced . The resurgence of interest in hemp crop can be attributed to the demand for sustainable agricultural practices, along with the recognition of hemp’s superior fiber content and nutritional profile. Primarily in central and western Canada, 340 cultivation licenses were issued to farmers who grew more than 39,000 acres of industrial hemp in 2011 [24,32]. In 2018, there were over 77,000 acres used for hemp production . Since the beginning of state pilot programs to produce industrial hemp in the USA in 2014, the total acreage has increased from 0 to over 90,000, and the number of license holders increased from 292 to 3852 by 2018 . Since the implementation of the 2018 Farm Bill, the acreage has increased even further, to over 146,000 by the end of 2019. Future economic prospects for the crop are unclear; there is competition for land with other crops as well as with medical Cannabis, which can pose an issue due to its ability to crossbreed with hemp, causing issues with the THC content in both crops. There is also global competition; production is increasing rapidly in many places and may exceed demand, driving down profits for hemp .
3. Hemp Seed Composition
When hemp cultivars are grown primarily for fiber, harvesting is done at the flowering stage, and seeds are not collected. Recently, the production of industrial hemp for the seed has gained interest due to the macronutrients and phytochemicals. Hemp seed is a balanced health product with bioactive components that have the capacity to aid health beyond that of basic nutrition [2,3].
The major constituents of hemp seed include easily digestible protein (20–25%), polyunsaturated fatty acid (PUFA), abundant lipids (25–35%), and carbohydrates (20–30%) high in insoluble fiber ( Table 1 ) [2,3,6,22,35,36,37]. Hemp seed protein is well-suited for human and animal consumption, consisting mainly of high-quality, easily digestible proteins edestin, and albumin, which are abundant with essential amino acids [2,3,6,22]. The rich source of PUFA, linoleic acid (LA; omega-6) and alpha-linolenic acid (ALA; omega-3), is favorable and regarded as balanced for human nutrition at a ratio of 3:1 [2,22,38,39]. LA concentrations range from 64 to 72% of the total fatty-acid composition. This range can be a result of the variation of different hemp cultivars, cultivation techniques, as well as processing and storage conditions. These fatty acids must be acquired from the diet, as they are needed for proper nutrition but cannot be synthesized endogenously [2,22,35,40,41]. Nutritional recommendations indicate that 15–20% of daily caloric intake should come from fats, and approximately one-third of these fats should be essential fatty acids in a 3:1 ratio. It is estimated that this dietary goal can be met with three tablespoons of hemp seed oil [42,43].
Important major and minor constituents of hemp seed and hemp seed oil.
|Hemp seed||Carbohydrate||20–30 † ; 27.6 †||[3,35]|
|Crude fat||25–35 † ; 33.2 † ; 30.4 † ; 31.1 †||[2,35,36,37]|
|Crude protein||20–25 † ; 24.8 † ; 24.9 † ; 24.0 † ; 27.3 †||[2,3,35,36,37]|
|Neutral detergent fiber||37.2 † ; 32.1 † ; 38.1 †||[2,36,37]|
|Acid detergent fiber||23.5 † ; 29.6 †||[2,36]|
|Ash||5.6 † ; 5.8 † ; 4.8 † ; 5.9 †||[2,3,36,37]|
|Hemp seed oil||Cannabidiol (CBD)||10 ‡ ; 4.18–243.68 ‡||[43,44]|
|Linoleic acid (omega-6 PUFA)||52–62 § ; 53.4 § ; 16.84 † ; 56.2 ¶ ; 56.07 §||[2,41,43,44,45]|
|Alpha-linolenic acid (omega-3 PUFA)||12–23 § ; 15.1 § ; 6.8 † ; 17.2 ¶ ; 15.98 §||[2,41,43,44,45]|
|Beta-tocopherol||6 ‡ ; 1.6 ‡ ; 0.64 ‡||[41,45,46]|
|Gamma-tocopherol||733 ‡ ; 216.8 ‡ ; 91.57 ‡||[41,45,46]|
|Alpha-tocopherol||34 ‡ ; 18.2 ‡ ; 19.74 ‡||[41,45,46]|
|Delta-tocopherol||25 ‡ ; 12.0 ‡ ; 2.09 ‡||[41,45,46]|
† , % Hemp seed fresh weight; ‡ , mg/kg Hemp seed oil; § , % Total fatty acids; ¶ , % Hemp seed oil. PUFA, polyunsaturated fatty acid.
3.2. Phytocannabinoids and Endocannabinoid System
Hemp flowers and herbage contain valuable phytocannabinoids, which are naturally occurring cannabinoids that are unique to the Cannabis plant . All industrial hemp varieties contain THC, CBD, and other cannabinoids, although the concentrations in some varieties are very low to non-detectable. In northern latitudes, industrial hemp has a particularly high content of CBD and low content of THC [43,47]. CBD content is higher than THC, and CBD can be detected at relatively low levels in hemp seed oil ( Table 1 ). This is because the production and storage of CBD and THC are in the glandular structures of the plant. The wide range of CBD content detected ( Table 1 ) is primarily due to the amount of resin retained by the seed coat during processing, as well as the varying hemp varieties and their associated cultivation conditions [1,25,43,44]. However, the presence of CBD, even in trace amounts, is speculated to provide certain health benefits [1,3,43,44].
The biosynthesis of CBD begins with the polyketide pathway and the plastidal 2-C-methyl-D-erythritol 4-phosphate pathway, which lead to the synthesis of olivetolic acid and geranyl diphosphate, respectively. These precursors undergo condensation to form cannabigerolic acid (CBGA), which is then converted to cannabidiolic acid (CBDA). Decarboxylation of CBDA occurs spontaneously or with the addition of heat to form CBD [1,43,47]. The health benefits of hemp are primarily focused around CBD; however, over 100 cannabinoids are reported to present in Cannabis species . These phytocannabinoids can be classified into 11 different classes, namely: (−)-delta-9-trans-tetrahydrocannabinol (Δ9-THC), (−)-delta-8-trans-tetrahydrocannabinol (Δ8-THC), cannabigerol (CBG), cannabichromene (CBC), CBD, cannabinodiol (CBND), cannabielsoin (CBE), cannabicyclol (CBL), cannabinol (CBN), cannabitriol (CBT) and miscellaneous-type cannabinoids. Recently, besides THC and CBD, 30 other cannabinoids from commercial hemp seed oil have been identified using high-resolution mass spectrometry .
The endocannabinoid system of humans is an endogenous signaling system consists of endocannabinoids, enzymes involved in their synthesis and degradation, cannabinoid receptors, and other associated elements [50,51]. The system is modulated by diet, sleep, exercise, stress, among many others. The endocannabinoids are fatty-acid-derived neurotransmitters that act as signal molecules of coordinating intercellular communication across all physiological systems. One of the primary functions of the system is to restore homeostasis following cellular stressors. The two most studied endocannabinoids are anandamide-N-arachidonylethanolamine (AEA) and 2-arachidonylglycerol (2-AG). Phytocannabinoids are recognized as pharmacologically active compounds, which function by interacting with the endocannabinoid system in humans [1,52]. Cannabinoid receptors are 7-transmembrane-domain G-protein-coupled receptors. Two cannabinoid receptors have been identified: the central CB1 receptor and the peripheral CB2 receptor . The CB1 receptor is primarily present in the brain and spinal cord but also found on certain cells of the immune system, adipose tissues, liver, muscle, reproductive cells, kidney, and lungs. CB1 mediates the release of neurotransmitters such as acetylcholine, noradrenaline, dopamine, gamma-aminobutyric acid (GABA), and glutamate. The CB2 receptor is expressed mainly in the cells in the periphery, in the organs of the immune system and have a role in the release of cytokines and the modulation of immune cell migration [53,54,55] but not psychoactivity . The diversified physiological effects of endocannabinoids take place when they bind to and activate these receptors.
The pharmacology or interaction of THC and CBD with the endocannabinoid system is not yet fully understood and seems complicated. THC has been shown to provide most of the psychoactive effects through the CB1 receptor as an agonist; however, under certain conditions, THC act as an antagonist of the CB1 receptor and also shown to interact with CB2 receptor [54,55]. Interaction of THC with CB1 receptor inhibits ongoing neurotransmitter release; however, repeated administration of THC may nullify its effect as well as the action of endocannabinoids . In contrast, CBD has minimal direct activity at CB1 and CB2 receptors; therefore, no psychoactive activity similar to THC. Though CBD has a very low affinity for CB1 and CB2 receptors, CBD can bind these receptors . CBD antagonizes synthetic agonists of CB1 and CB2 receptors and can be considered to be a negative allosteric modulator of CB1 and CB2 receptors. Moreover, recent findings also indicate that CBD exhibits various dose-dependent physiological responses. Though the low doses (30 mg oral) has no intoxicating effects, high doses (300 mg oral) increased somnolence and reduced anxiety . Moreover, the biological activity of CBD seems to be complex due to its complex pharmacological actions, such as inhibition of endocannabinoid reuptake and increasing the activity of serotonin 5-HT1A receptors, binding to non-cannabinoid receptors such as transient receptor potential vanilloid 1 (TRPV1), peroxisome proliferator-activated receptor-γ (PPARγ), and the orphan receptor G protein-coupled receptor 55 (GPR55) [51,55,57]. CBD has recently received increasing interest since chronic administration of CBD has shown potential therapeutic properties such as antiepileptic, anxiolytic, antipsychotic, neuroprotective activities, and benefits against disorders of motility and epilepsy [55,56,58].
3.3. Hemp Seed Oil
Hemp seed oil contains tocopherol isomers beta-tocopherol, gamma-tocopherol, alpha-tocopherol, and delta-tocopherol, with the gamma-tocopherol derivative present in the highest quantity ( Table 1 ) [2,41,45]. Tocopherols are natural antioxidants that can reduce the risk of oxidative degeneration related disorders [2,41]. In addition, terpenes and polyphenols have been detected, which contribute to the odor/flavor and intrinsic antioxidant activity, respectively [1,2]. Among phenolic compounds, flavonoids, such as flavanones, flavonols, flavanols, and isoflavones were the most abundant . The reported phytochemical contents of hemp seed oil vary due to a broad range of existing hemp cultivars, which are grown and processed under diverse conditions.
4. Potential Health Benefits
Numerous health benefits and potential therapies are reported for hemp seed. Hemp seed delivers a desirable ratio of omega-6 to omega-3 PUFA ( Figure 2 ), which can improve cardiovascular health, reduce osteoporosis symptoms, and diminish eczema conditions. CBD exerts pharmacological properties that make it a potential therapeutic agent for central nervous system diseases, such as epilepsy, neurodegenerative diseases, and multiple sclerosis (MS) [1,59].
4.1. Cardiovascular Health
The dietary intervention of hemp seed for cardiovascular health has been examined. Schwab et al.  supplemented the human diet with 30 mL of hemp seed oil daily for four weeks and detected positive changes in the serum lipid profile. Another study also noted that rats fed a 5% or 10% hemp seed-supplemented diet for 12 weeks experienced an elevation in plasma LA and ALA levels . After the diet, post-ischemic heart performance was assessed; the heart’s ability to recover from ischemia-reperfusion insult appeared to be directly related to the hemp seed’s PUFA. Richard, Ganguly, Steigerwald, Al-Khalifa, and Pierce  also found that the integration of hemp seed into the rat diet significantly increased plasma LA and ALA levels. As a result, platelet aggregation was inhibited and slowed to a lower rate. The diminished likelihood of clot formation has implications for reducing the incidences of myocardial infarctions and strokes . Prociuk et al.  reported similar findings after examining the effect of dietary hemp seed for eight weeks in rabbits. Elevated plasma levels of PUFAs indirectly decreased the risk of platelet aggregation and myocardial infarction and provided better defense against hypercholesterolemia . Other issues caused by hypercholesteremia that were improved by supplementing hemp seed, including decreased cholesterol, low-density lipoprotein, and triglyceride levels, increased high-density lipoprotein levels, lower plaque, and fat deposition, and lower arterial wall damage .
Since the first study exhibiting the anti-cancer effects of Cannabis phytochemicals by Munson, Harris, Friedman, Dewey, and Carchman , there have been major advances in understanding the mechanisms and targeting action of cannabinoids. Evidence suggests that phyto-, endo-, and synthetic cannabinoids contain properties that aid in the treatment of the brain, prostate, breast, skin, pancreas, and colon cancer. Both in vitro and in vivo models suggest cannabinoids play a role in regulating cellular mechanisms causing anti-proliferative, anti-metastatic, anti-angiogenic, and pro-apoptotic responses [66,67]. These findings have major implications in oncology, as it has been well established that most cancers originate from uncontrolled or improperly managed cellular growth .
Phytocannabinoids demonstrate the potential to inhibit cell growth and induce apoptosis in gliomas. Massi et al.  tested the effect of introducing CBD to U87 and U373 human glioma cell lines. In vitro treatment resulted in a reduction in mitochondrial oxidative metabolism and glioma cell viability. It was also confirmed that CBD induced apoptosis. When a CB2 receptor antagonist was introduced to the glioma cell lines, the antiproliferative effect of CBD was hindered, revealing its mechanism of action . Vaccani, Massi, Colombo, Rubino, and Parolaro  also looked at the implications of CBD on the U87 glioma cell line, where an anti-metastatic result was observed due to the inhibition of cell migration. Cannabinoids have also been found to prevent the differentiation and proliferation of glioma stem-like cells, which may help treat the difficult-to-eliminate nature of gliomas .
The treatment of prostate and breast cancers with CBD have also been explored. Sarfaraz et al.  found that androgen-responsive human prostate carcinoma cells treated with CBD exhibited a pro-apoptotic response, inhibited cell growth, and a lowered secretion of prostate-specific antigen, which is typically elevated in cancerous cells . Of several natural cannabinoids tested, a CBD extract provided the most potent cytotoxic effects against breast cancer cells, with significantly lower damage to healthy cells . CBD induced apoptosis in a breast cancer cell line via the activation of the overexpressed CB2 receptor [70,71].
Other studies have explored cannabinoid therapy in skin, pancreas, and colon cancers. Blázquez et al.  evaluated cannabinoid receptor agonists in mice and found that the activation of these receptors decreased the growth, proliferation, angiogenesis, and metastasis of melanomas. Through similar actions, cannabinoids induced apoptosis in pancreatic tumor cell lines, and the effects were lessened when the CB2 receptors were blocked . Promising results were found in vivo by Ferro et al. , where mice with pancreatic ductal adenocarcinoma treated with gemcitabine and CBD survived nearly three times as long as mice treated only with gemcitabine or with a vehicle. This was achieved through interference with the G-coupled protein receptor GPR55, resulting in the prevention of growth and cell cycle arrest . Cianchi et al.  investigated the activation of the cannabinoid receptors in colorectal cancer and demonstrated similar apoptotic mechanisms to pancreatic and melanoma cancers.
The strategic elimination of these cancer cells, while inflicting limited harm to normal cells, shows potential for CBD mediation. Although the range of cancers therapeutically affected by cannabinoids is promising, further investigations are required to interpret the growth-inhibitory action of CBD. The results presented here reinforce that much of the CBD effect is mediated through the activation of CB2 receptors and that the possible application of CBD in cancer cytotoxicity is vast.
4.3. Diseases of the Central Nervous System
Several phytocannabinoids have exhibited the ability to mediate symptoms of neurodegenerative diseases and reduce compromising damage. Hypoxic-ischemic (HI) brain injury results when the brain is deprived of oxygen and can lead to neurological impairments such as epilepsy, developmental delay, as well as reduced motor and cognitive function. Castillo, Tolón, Fernández-Ruiz, Romero, and Martinez-Orgado  found that CBD enhanced neuroprotection in mice that experienced induced HI by oxygen and glucose withdrawal. Pazos et al.  tested rats that underwent HI injury and subsequently received CBD treatment; the common measures of HI damage, infarct volume, and histological evaluation indicated CBD provided neuroprotection. Later, Pazos et al.  studied HI in a pig model by reducing carotid blood flow and then administering CBD treatment . The neuroprotective action was attributed to the prevention of an increase in excitotoxicity, oxidative stress, and inflammation, and CB2 receptors were associated with these effects [77,78]. Treatment with CBD prevents emotional and cognitive impairments, injury to white matter, degeneration of hippocampus tissue, and glial cell response decrease that result from brain ischemia, as well as promotes recovery through hippocampus dendritic cell reconstruction and neurogenesis in mice that already have brain ischemia .
The most prevalent neurological disease, epilepsy, has also benefited from CBD. Jones et al.  examined seizure activity and found that CBD exerted anticonvulsant properties. Jones et al.  reconfirmed these findings using an acute pilocarpine model of temporal lobe seizure and the penicillin model of the partial seizure. Both studies found a decrease in both the severity and mortality of the seizures [80,81]. Intervention with CBD is even beneficial to people who have treatment-resistant epilepsy; adverse events, severity, and frequency of seizures were significantly and sustainably reduced with long-term treatment .
Several clinical studies have outlined the cannabinoid treatment of spasticity, pain, and hindered bladder control symptoms associated with MS patients. A novel cannabinoid therapy, THC/CBD oromucosal spray (Sativex™), has been introduced to patients suffering from neuropathic pain that can be difficult to manage with normal pharmaceuticals. A placebo-controlled study found that the spray was able to lessen MS-induced neuropathic pain . The same spray was evaluated for symptomatic relief and was found to cause a decline in spasticity occurrence and severity, and had limited adverse side effects on cognition . This could be due to the critical part CBD plays in diminishing the psychoactive effects of THC. A similar spray provided to MS patients effectively reduced pain and sleep disturbance . When MS patients were provided with THC/CBD extract capsules, daily self-reports of spasm frequency, mobility, and ability to fall asleep were favorably impacted in the active treatment group .
Limited research has been done on CBDs effect on Parkinson’s disease symptoms, though the current evidence suggests it can improve the non-mobility related symptoms, there is contradicting evidence on its effects on mobility and cognition symptoms . Further studies need to be conducted to determine the true extent of CBD treatment on Parkinson’s disease.
The mechanisms by which CBD exerts its neuroprotective effects are not entirely understood; however, CBD is noted for its antioxidant and anti-inflammatory properties [76,80]. Since the activation of CB1 receptors is consequently associated with psychoactive ramifications and potentially neurodegenerative symptoms upon long-term activation, the investigation of CBD is increasingly important for neurological disorders. At present, CBD used therapeutically, either alone or in combination with THC, aids in the treatment and symptomatic relief of several neurodegenerative disorders.
4.4. Rheumatoid Arthritis
In traditional Chinese folk medicine, hemp seed oil has been used to relieve chronic knee pain in patients with rheumatoid arthritis (RA) and improve blood circulation . RA is an autoimmune inflammatory disease primarily characterized by synovial tissue inflammation and hyperplasia . Jeong et al.  concluded that hemp seed oil promotes the production of reactive oxygen species (ROS), storage of lipids, production of endoplasmic reticulum stress markers, which act as anti-rheumatoid factors in downstream processes, and improved blood circulation, providing additional relief to RA patients. Hammell et al.  found that CBD can positively impact pain caused by arthritis. A rat model was used to examine topical application of CBD: joint swelling, pain scores, synovial membrane thickness, infiltration of immune cells, and inflammation biomarkers were all significantly reduced in a dose-dependent manner . A CBD-based oil was used to treat another kind of arthritis: osteoarthritis in dogs . Dogs receiving treatment exhibited significantly less pain compared to those without treatment, allowing these dogs to be more comfortable and active . Clinical studies on RA patients will provide clarity on the mechanism and biochemistry behind the benefits of hemp seed oil in reducing and ameliorating the symptoms of RA.
4.5. Dermatitis and Skin Diseases
Hemp seed oil can be an effective cure to eczema, as well as a host of other skin related ailments . Hemp seed oil is composed of more than 80% PUFA, and is rich in tocopherols [3,41]. These constituents point to hemp seed oil’s beneficial effects in reducing and eradicating skin diseases, including eczema . A clinical study by Callaway et al.  found participants who had a regular dietary intake of hemp seed oil had significantly fewer symptoms of eczema, including skin dryness and itchiness, and they used dermatitis medicine less often. Allergic contact dermatitis has shown preliminary evidence to be mediated through intervention with the endocannabinoid system, making treatment with CBD a promising solution . The presence of high levels of essential PUFAs improves the atopic symptoms of dermatitis [93,96].
4.6. Mental Health and Sleep Disorders
Concentrated CBD from hemp has been shown in both pre-clinical and clinical studies to possess anxiolytic or antianxiety characteristics due to its ameliorating effect on limbic and paralimbic areas of the brain [97,98]. Importantly, the anxiolytic effects of CBD are only induced with low concentrations; high concentrations may cause anxiogenic or panicogenic effects . Treatment doses need to be selected carefully to ensure only anxiolytic benefits are felt by the individual. Other anxiety-related disorders also benefit from treatment with CBD, including post-traumatic stress disorder (PTSD) and depression, as well as addiction recovery [99,100,101]. The endocannabinoid system is involved in learning, emotional responses (including those related to trauma), and regulation of emotional behavior; therefore, this system is an important target for the treatment of PTSD . Using experimental animal models, CBD has been effectively used to treat the development of adverse associations at all steps of the process, including immediately after trauma to prevent the development of PTSD. CBD has been able to help in the extinction process of adverse memories in humans, as well as treat the anxiety-related symptoms accompanying PTSD without causing side effects . In male and female genetically depressive mice, CBD had anti-depressant properties as well as reduced the exhibition of anhedonia . In patients at high risk of psychosis, CBD was able to partially normalize function in regions of the brain associated with psychosis . When administered to sober heroin-addicted individuals, CBD reduced cue-induced cravings and anxiety with short-term 3-day administration, as well as had prolonged benefits up to 1 week after the final treatment dose .
CBD has been shown to have therapeutic effects in favorably modifying REM sleep behaviors that may be altered due to insomnia . A study conducted on people experiencing anxiety and sleep issues found that CBD improved sleep quality in the first month, but it did not remain constant throughout the remainder of the study period . There are contradictions in the literature, where some studies have found, as discussed, that CBD can improve sleep; however, there are other studies that find treatment with CBD can improve wakefulness during the day . The mechanisms behind sleep cycle regulation by CBD need to be more thoroughly explored to determine how it can be used to improve both sleep and wakefulness.
Comprehensive research on this topic is required to understand the broad-spectrum effects of hemp-seed-derived CBD-based nutraceuticals on anxiety . Data is especially lacking on the differences between sexes in response to treatment; most pre-clinical studies used only male animals, and clinical studies that include females have yet to evaluate sex-differentiated responses . Males and females experience anxiety differently, and they respond to psychotropics differently, so this is an important knowledge gap to fill with further studies . There is also limited research on CBD treatment for the other anxiety-related disorders discussed above. There are contradictions within the literature on the true benefit of CBD on the treatment of addictions, some of the conflicts are due to the type of drug at the center of the addiction, but there is also lacking consensus within drug types .
4.7. Additional Health Benefits
There are other areas of treatment using hemp products that have been explored less extensively than those discussed above. The hemp seed oil has been documented to be therapeutic for constipation problems . Furthermore, mice trials have shown that hemp seed consumption leads to improved memory and learning-induced by chemical drugs [111,112].
CBD has suppressive effects on the immune system, including inflammatory response reduction, cellular and humoral immunity suppression, and induction of apoptosis in some lymphocytes; these effects are beneficial for treating inflammatory diseases [113,114]. Type 1 diabetes is an example of an inflammatory-based disease that can benefit from CBD preemptive treatment; non-obese diabetic mice receiving CBD had delayed development of diabetes, and had significantly lower activation of leukocytes than mice receiving control vehicle . Zhou, Wang, Ji, Lou, and Fan  demonstrated anti-neuroinflammatory properties of hemp seed using an experimental mouse model.
Another area of research on the benefits of hemp is pain management. It has been theorized that some pain conditions, including fibromyalgia, migraine, and irritable bowel syndrome, are caused by an endocannabinoid deficiency . Due to this theory, targeting the endocannabinoid system with CBD is a common treatment for symptomatic relief of these conditions . Cannabis has also commonly been used to treat other chronic pain that is not suspected to be caused by an endocannabinoid deficiency; it is the most common reason for medicinal Cannabis usage in the USA [118,119]. Cannabinoids act in many ways to produce an analgesic effect, including preventing the release of neurotransmitters from presynaptic neurons, altering the sensitivity of postsynaptic neurons, activating pain inhibiting pathways, and reducing neural inflammation .
The major limitation for the treatment of all previously discussed health conditions is the lack of long-term studies. There has virtually been no research examining the long-term effects, especially of hemp-derived CBD-based treatments. Short-term data shows that it has been well-tolerated and results in minimal adverse side effects . The cannabinoids and terpenes in Cannabis work synergistically together to provide the discussed health benefits in addition to the flavonoids present . In the future, investigations should be conducted to understand the synergistic effect of all the phytochemicals in addition to validating the health benefits of minor constituents of hemp seed.
5. Food and Nutraceutical Applications
Consumers have become increasingly interested in the way their diet can address health deficits and wellbeing. Over a decade ago, two thirds of grocery shoppers reported that their purchases were highly influenced by the pursuit of preventing, managing, or treating a specific health condition . Since then, food scientists have targeted such consumer demands by investigating and advertising additional health benefits and bioactive properties that functional foods provide. In recent years, some unconventional plant-derived oils, such as hemp seed oil, have earned a reputation for providing not only cooking and alimentary services but also providing medicinal and nutraceutical potential . Hemp seed oil is currently advertised primarily as a natural health product for body care purposes, as oil for salad dressings, or to be taken directly as a dietary supplement. The hemp seed oil has a strong susceptibility to rancidity with heat and prolonged storage, which reduces its use as cooking oil [40,120,121]. Because hemp prohibition was only lifted about 20 years ago, only recently that hemp seed has been investigated for its applications in the food and nutraceutical industry for its benefits beyond basic nutrition.
5.1. Hemp Seed in Food Products
In addition to the primary use of hemp seed as oil, it has been used in the milled form as a source of vegetable protein and dietary fiber, facilitating its incorporation into food products such as energy bars, flavored yogurt, baked goods, and more [36,122,123]. Shim [124,125] patented a process of making bread and confectionary from hemp seed oil and hemp seeds, respectively. Guang and Wenwei  patented hemp seed flours to be used in functional foods that aid in the prevention of certain diseases by increasing the levels of high-density lipoprotein (HDL) and stabilizing the levels of other glycerides and lipoproteins. A seasoning sauce from fermented hemp seeds was developed by Metz and Selg-Mann , while Steinbach  developed a process for producing pralines and chocolates from hemp seed and hemp seed oil. A process was developed for obtaining hemp milk that did not change color or develop bitterness when subjected to pasteurization . Hemp seed as a powder and an additive has been used as a source of protein [130,131]. Furthermore, Guang and Wenwei  developed a process for using hemp protein powder in treating anemia. Though the most popular part of the hemp plant to ingest is the seeds, sprouts, leaves, and flowers can also be consumed raw in juice or salads . The inclusion of juice obtained from hemp in alcoholic beverages is speculated to have digestive benefits .
Frassinetti et al.  examined hemp seeds and sprouts to be rich in beneficial bioactive compounds with both in vitro and ex vivo antioxidant activities. Furthermore, these compounds exhibited an antimutagenic effect on Saccharomyces cerevisiae. The main polyphenols identified in seeds and sprouts exhibiting antioxidant activities were cannabisin A, B, C, and caffeoyltyramine ( Figure 2 ). The two primary compounds identified in sprouts that provide nutraceutical benefits were linoleic acid and gluconic acids, which act as intermediaries in the production of vitamin C . Terpenes, which are also found in hemp, have anti-inflammatory and some antiallergic properties, can treat pain, prevent the production of ROS, and act as potent antioxidants . Due to the presence of a wide variety of nutrients, including high levels of PUFA and essential amino acids, hemp seeds are praised for providing adequate quantities of different nutrients to satisfy human dietary requirements [136,137].
5.2. Advancement in the Extraction of Oil and Cannabinoids from Hemp Seed
There are numerous methods for extraction of hemp seed oil, including cold press, supercritical CO2 extraction, solvent extraction with isopropanol, hexane, dimethyl ether, and numerous pretreatments. However, all of these methods possess different advantages and disadvantages depending on the end use of the product and the extraction fraction in question .
Cold-pressed oils from seeds have become more commercially popular since they are viewed as natural and safe products to be used in food [120,139]. Cold-pressing passes the raw seed material through a conventional screw press, without the addition of harsh chemical solvents or high heat treatments [40,120]. This process retains more of the beneficial components of the seeds, including valuable PUFA and bioactive substances, while minimizing degradative changes in the oil [40,120,121,139]. One notable disadvantage of cold-pressed oil is the low yield potential of 60–80% of extractable oil .
Soxhlet extraction is the conventional method of extraction; the selected solvent is heated to reflux and floods the solid material, extracting the desired compounds, including volatile compounds . Many solvents have been successfully used to extract hemp seed oil with high yields. N-hexane and petroleum ether , dimethyl ether , ethanol  and isopropanol  have been used and optimized with regards to extraction time, temperature, and other extraction conditions.
Another method optimized recently is supercritical fluid extraction, most commonly using CO2. Using the response surface method, Da Porto, Decorti, and Tubaro  and Da Porto, Voinovich, Decorti, and Natolino  optimized supercritical CO2 extraction of hemp oil; they observed fatty-acid compositions and oxidative stability at different stages of the extraction process while varying the parameters to obtain maximum efficiency of extraction. In addition, Aladić et al.  and Tomita et al.  further refined the processing temperature, pressure, and time to determine how these conditions affect the constituency of hemp oil, especially focusing on fatty acids, tocopherol, and pigment content. Supercritical CO2 using n-propane as a solvent, reduces the extraction pressure and preserves the physical and nutritional properties of hemp seed oil .
There have been many innovations in hemp seed oil extraction. Optimized procedures to extract hemp seed oil rich in CBD by supercritical CO2 are well established [149,150]. To remove pigments and waxes prior to supercritical CO2 extraction, crushed silicon sand and ultrasonic-assisted extraction, respectively, can be used [151,152]. Procedures to extract hemp seed oil free of THC have also been developed to satisfy regulatory requirements and societal concerns. Separation techniques such as chromatographic columns, and stabilization reactions such as oxidation with heat and isomerization with UV light, have been reported [153,154]. Dynamic maceration with ethanol for 45 min is an efficient method to extract non-THC cannabinoids from hemp seed oil . New methods using ultrasonication-assisted extraction are also gaining interest due to minimal intervention with the product and shorter extraction time [156,157]. Similarly, the response surface method has been used to optimize the microwave-assisted extraction of cannabinoids, which also provides a shorter extraction time . Recently, many advances have been made to combine different techniques, such as supercritical fluid extraction, ultrasonication, and microwave-assisted extraction, to increase efficiency . Hemp seed oil extracted through the above methods are different in yield, physical properties, and chemical composition. Furthermore, the cost is also an important factor in the selection of the extraction method. Considering an initial economic cost-benefit analysis, supercritical CO2 extraction is most efficient, followed by Soxhlet extraction and ultrasonication . In terms of scale-up extraction, ultrasonication and Soxhlet extraction are the best methods, while the desirable omega-6 PUFA/omega-3 PUFA ratio can be achieved by the Soxhlet extraction method . Selecting the most appropriate method of extraction depends on the end use and desired bioactives in the final products.
5.3. Methods of Enhancing Oxidative Stability of Hemp Seed Oil
To maintain oxidative stability, it is necessary to monitor the fatty-acid profiles throughout the extraction process to standardize temperature, pressure, and particle size required for supercritical CO2 extraction of hemp seed oil [145,146]. Hemp seed oil can maintain oxidative stability through the presence of tocopherols and polyphenols. Tocopherols effectively stop or slow down the lipoperoxidative radical chain reactions by preventing the oxidation of PUFAs . Furthermore, phytosterol concentrations of approximately 15% also have excellent oxidative prevention functions . Among them, b-sitosterol, campesterol, and D5–avenasterol can withstand high temperatures and reinforce the plasma membranes of eukaryotic cells. Storage studies must be conducted for hemp seed oil while observing the changes in composition and antioxidant activity.
Some research has been done in improving oxidative stability and adhesion of hemp seed oil to surfaces such as skin or hair. A method of saponizing and quarternizing fatty acids  resulted in the minimization of oxidation and crosslinking of released essential fatty acids. Many cosmetic formulations of hemp seed oil were prepared with this method to improve adherence to skin. Maintenance of the antioxidant properties of the oil helps regulate oxidative stability as well. Temperature and pressure play a major role in altering oxidative stability; however, there is no universal standard that specifies the optimal conditions for maintaining oxidative stability as it varies greatly between extraction procedures. Hence, it is more likely that optimization at the local process level will help maintain the oxidative stability of hemp seed oil.
5.4. Microencapsulation Technologies
To increase the bioavailability and protect unstable food constituents, such as PUFAs, from oxidation, different types of microencapsulation techniques have been used for plant-based oils . Spray drying , freeze-drying , fluidized bed coating , centrifugal extrusion , complex coacervation [167,168], ionotropic gelation , liposome entrapment , and electrospraying  are the most predominant methods used for microencapsulation. Hemp seed oil is a prime candidate for these interventions to increase its nutritional value and benefits. The selection of the shell coating material to protect the core substance during microencapsulation depends on the microencapsulation method, the nature of the core material, the end use of the product, its physicochemical characteristics, and possible interactions with the core material .
Nanoencapsulation is remarkable in improving the low water solubility, bioavailability, volatility, and stability of high-value oils . Belščak-Cvitanović et al.  concentrated and encapsulated the bioactive compounds extracted from hemp fiber processing waste, also called hemp fiber meal. Hemp fiber meal can be used for isolation of essential amino acids, especially arginine, by using food grade enzymes for polysaccharide digestion; the resulting polysaccharide fragments can be subjected to ultrafiltration and removed to concentrate the protein content, making it a superior isolate compared to other hemp protein products .
Considerable evidence of the potential health benefits of hemp seed oil has been uncovered in the past two decades; however, additional investigations are required to use hemp seed oil as a functional food ingredient. The value-added hemp food sector is growing; with increased consumer awareness and product innovation, the health applications of hemp seed oil are expected to expand [24,42].
6. Future Prospects and Conclusions
Since ancient times, hemp has been cultivated to provide nutritional and medicinal benefits. Although the government regulations repressed the cultivation and scientific inquiry of industrial hemp in the past, under recent legalization with stringent production regulations, hemp has proven to hold viable, value-added food and nutraceutical applications ( Figure 3 ). Recently, many studies have demonstrated that the nutrient and bioactive composition of hemp contributes to the prevention and treatment of several ailments suggesting its potential as a valuable functional food ingredient. This review sought to highlight these advances in understanding the medical, nutritional, and nutraceutical benefits of industrial hemp. The ease of production and suitability to many climatic and geographical locations are assets to the expansion of this industrial crop. Due to its versatility, breeding of hemp is underway in many universities and breeding centers across North America and Europe to develop high-yielding varieties for both fiber and oil seed production. This will help standardize varieties across different growing regions, thus maintaining quality and reducing disease and insect pressure. The controversial association of industrial hemp with medical Cannabis has also slowed expansion efforts. Therefore, breeding of hemp to clearly differentiate it from medical Cannabis may accelerate its development and consumer acceptance, as well as ease regulatory barriers of the crop.
Advanced value-added technologies can drive value-added innovation to make use of industrial hemp to introduce a wide array of functional food ingredients and nutraceuticals.
A lot of advances have also been made in the extraction technologies of hemp seed oil and its nutraceutical benefits. However, there is still no industry consensus on the best methods of extraction, as it depends on the scale of production and end-use. The development of standardized processing guidelines for hemp seed and hemp seed oil will help ensure stringent quality control. There are opportunities in food innovation through the incorporation of hemp seed oil and its constituents, especially PUFA and CBD, in mainstream value-added and supplemented food products. Also, there is potential for the use of hemp processing byproducts in various food, feed, and industrial applications.
For innovation of novel hemp-derived food ingredients and nutraceuticals requires precise identification and quantification of major bioactives and standardization of the products. The analytical methods required for bioactives such as CBD need to be standardized. To ensure the authenticity and safety of hemp-derived food and nutraceuticals, it is important to quantify the amount of THC in the final product and includes it in the label. For example, in North America and most of Europe, to classify as industrial hemp, THC content should not exceed 0.3% on a dry weight basis. If the regulatory agencies could make a requirement for declaring THC content, that will help the food and nutraceutical industry to stay away from complicated regulatory issues around medical Cannabis. Since the impact of CBD is dose-dependent, an acceptable limit of CBD to be determined for inclusion in the labels of nutraceuticals and dietary supplements. The manufacturers should be aware that CBD content may change from batch-to-batch due to the variations of sources of materials, growing conditions, and manufacturing. Future investigations should also be aimed at quantification of trace cannabinoids other than THC and CBD and exploring their pharmacological effects. The pharmacokinetics of these bioactives, when incorporated in different food matrices, need to be understood. The inclusion of the content of omega-3 PUFA and omega-6 PUFA and their ratio in the label is useful for consumers to recognize the benefits of hemp oil and other value-added food products.
Most of the health benefits-associated research of industrial hemp has been conducted under pre-clinical conditions. However, due to the possibility of concentrating bioactive phytochemicals during the manufacturing process, the industry should pay attention to the dosing to optimize the potential health benefits and avoid possible safety concerns. There is a need to conduct appropriately designed, randomized, placebo-controlled, double-blind clinical studies on the effects of hemp-derived functional food ingredients and products, dietary supplements, and nutraceuticals on the promotion of human health. The hemp seed oil has potential as a nutraceutical due to the desired ratio of omega-6 PUFA to omega-3 PUFAs, and the bioactive CBD. Future research should focus on exploring other bioactive phytochemicals of industrial hemp, such as polyphenols and isoprenoids. The contribution of polyphenols and isoprenoids of hemp to the sensory quality, shelf life, and health benefits of the final products still to be understood. Overall, the hemp industry is starting to flourish across the globe. Regulatory agencies need to distinguish industrial hemp from medical Cannabis (marijuana), so the economic potential of industrial hemp as a sustainable source of value-added functional food ingredients and nutraceutical products can be realized.
Authors wish to thank the Natural Sciences and Engineering Research Council (NSERC) of Canada for their support to train highly qualified personnel. Authors also appreciate the encouragement and in-kind support by the Global Hemp Innovation Center at Oregon State University, Corvallis, OR 97331, USA.
Conceptualization: H.P.V.R.; writing—original draft preparation: A.D., S.K.K., B.M.; writing—review and editing: H.P.V.R. and V.D.Z.; visualization: H.P.V.R. and V.D.Z.; supervision: H.P.V.R. All authors have read and agreed to the published version of the manuscript.
This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit organization. APC was sponsored by MDPI.
Conflicts of Interest
The authors declare no conflict of interest.
1. Andre C.M., Hausman J.F., Guerriero G. Cannabis sativa: The plant of the thousand and one molecules. Front. Plant Sci. 2016; 7 :19. doi: 10.3389/fpls.2016.00019. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Vonapartis E., Aubin M.P., Seguin P., Mustafa A.F., Charron J.B. Seed composition of ten industrial hemp cultivars approved for production in Canada. J. Food Composit. Anal. 2015; 39 :8–12. doi: 10.1016/j.jfca.2014.11.004. [CrossRef] [Google Scholar]
3. Callaway J.C. Hempseed as a nutritional resource: An overview. Euphytica. 2004; 140 :65–72. doi: 10.1007/s10681-004-4811-6. [CrossRef] [Google Scholar]
4. Struik P.C., Amaducci S., Bullard M.J., Stutterheim N.C., Venturi G., Cromack H.T.H. Agronomy of fibre hemp (Cannabis sativa L.) in Europe. Ind. Crops Prod. 2000; 11 :107–118. doi: 10.1016/S0926-6690(99)00048-5. [CrossRef] [Google Scholar]
5. Ranalli P., Venturi G. Hemp as a raw material for industrial applications. Euphytica. 2004; 140 :1–6. doi: 10.1007/s10681-004-4749-8. [CrossRef] [Google Scholar]
6. Matthäus B., Brühl L. Virgin hemp seed oil: An interesting niche product. Eur. J. Lip. Sci. Technol. 2008; 110 :655–661. doi: 10.1002/ejlt.200700311. [CrossRef] [Google Scholar]
7. Small E., Cronquist A. A practical and natural taxonomy for Cannabis. Taxon. 1976; 25 :405–435. doi: 10.2307/1220524. [CrossRef] [Google Scholar]
8. Sawler J., Stout J., Gardner K.M., Hudson D., Vidmar J., Butler L., Page J.E., Myles S. The genetic structure of marijuana and hemp. PLoS ONE. 2015; 10 :e0133292. doi: 10.1371/journal.pone.0133292. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Piluzza G., Delogu G., Cabras A., Marceddu S., Bullitta S. Differentiation between fiber and drug types of hemp (Cannabis sativa L.) from a collection of wild and domesticated accessions. Genet. Resour. Crop Evol. 2013; 60 :2331–2342. doi: 10.1007/s10722-013-0001-5. [CrossRef] [Google Scholar]
10. Hillig K.W. Genetic evidence for speciation in Cannabis (Cannabaceae) Genet. Resour. Crop Evol. 2005; 52 :161–180. doi: 10.1007/s10722-003-4452-y. [CrossRef] [Google Scholar]
11. Faux A.M., Berhin A., Dauguet N., Bertin P. Sex chromosomes and quantitative sex expression in monoecious hemp (Cannabis sativa L.) Euphytica. 2014; 196 :183–197. doi: 10.1007/s10681-013-1023-y. [CrossRef] [Google Scholar]
12. Schultes R.E., Klein W.M., Plowman T., Lockwood T.E. Cannabis: An example of taxonomic neglect. [(accessed on 15 July 2020)]; Bot. Museum Leaflets Harvard Univ. 1974 23 :337–367. Available online: https://www.biodiversitylibrary.org/page/7467406#page/359/mode/1up [Google Scholar]
13. Razumova O.V., Alexandrov O.S., Divashuk M.G., Sukhorada T.I., Karlov G.I. Molecular cytogenetic analysis of monoecious hemp (Cannabis sativa L.) cultivars reveals its karyotype variations and sex chromosomes constitution. Protoplasma. 2016; 253 :895–901. doi: 10.1007/s00709-015-0851-0. [PubMed] [CrossRef] [Google Scholar]
15. De Meijer E.P.M., Bagatta M., Carboni A., Crucitti P., Moliterni V.M.C., Ranalli P., Mandolino G. The inheritance of chemical phenotype in Cannabis sativa L. Genetics. 2003; 163 :335–346. [PMC free article] [PubMed] [Google Scholar]
16. Van Bakel H., Stout J.M., Cote A.G., Tallon C.M., Sharpe A.G., Hughes T.R., Page J.E. The draft genome and transcriptome of Cannabis sativa. Genome Biol. 2011; 12 :R102. doi: 10.1186/gb-2011-12-10-r102. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
17. Russo E.B. History of cannabis and its preparations in saga, science, and sobriquet. Chem. Biodiver. 2007; 4 :1614–1648. doi: 10.1002/cbdv.200790144. [PubMed] [CrossRef] [Google Scholar]
18. Datwyler S.L., Weiblen G.D. Genetic variation in hemp and marijuana (Cannabis sativa L.) according to amplified fragment length polymorphisms. J. Forensic Sci. 2006; 51 :371–375. doi: 10.1111/j.1556-4029.2006.00061.x. [PubMed] [CrossRef] [Google Scholar]
19. Hakki E.E., Kayis S.A., Pinarkara E., Sag A. Inter simple sequence repeats separate efficiently hemp from marijuana (Cannabis sativa L.) Electron. J. Biotechnol. 2007; 10 doi: 10.2225/vol10-issue4-fulltext-4. [CrossRef] [Google Scholar]
20. Johnson R. Hemp as an Agricultural Commodity. [(accessed on 22 June 2018)]; Available online: https://fas.org/sgp/crs/misc/RL32725.pdf
21. Mass E. Hemp: The new, old fiber makes a comeback for clothes, fabrics, and home furnishings. Nat. Life. 2009; 127 :36. [Google Scholar]
22. Tang C.H., Ten Z., Wang X.S., Yang X.Q. Physicochemical and functional properties of hemp (Cannabis sativa L.) protein isolate. J. Agric. Food Chem. 2006; 54 :8945–8950. doi: 10.1021/jf0619176. [PubMed] [CrossRef] [Google Scholar]
23. Adesina I., Bhowmik A., Sharma H., Shahbazi A. A review on the current state of knowledge of growing conditions, agronomic soil health practices and utilities of hemp in the United States. Agriculture. 2020; 10 :129. doi: 10.3390/agriculture10040129. [CrossRef] [Google Scholar]
24. Agriculture and Agri-Food Canada Canada’s Industrial Hemp Industry. [(accessed on 10 January 2020)]; 2016 Available online: http://www4.agr.gc.ca
26. Campiglia E., Radicetti E., Mancinelli R. Plant density and nitrogen fertilization affect agronomic performance of industrial hemp (Cannabis sativa L.) in Mediterranean environment. Ind. Crops Prod. 2017; 100 :246–254. doi: 10.1016/j.indcrop.2017.02.022. [CrossRef] [Google Scholar]
27. Shahzad A. Hemp fiber and its composites—A review. J. Comp. Mater. 2012; 46 :973–986. doi: 10.1177/0021998311413623. [CrossRef] [Google Scholar]
28. Deitch R. Hemp: American History Revisited. Algora Publishing; New York, NY, USA: 2003. [Google Scholar]
29. Robinson B.B., Evans R. Hemp for Victory [Motion Picture] United States Department of Agriculture; Washington, DC, USA: 1942. [Google Scholar]
30. Agricultural Act of 2014. (U.S.C. 2014, c.7). § 5940. [(accessed on 10 January 2020)]; Available online: https://www.congress.gov/bill/113th-congress/house-bill/2642/text
31. United States Department of Agriculture Hemp and Farm Bill Programs. [(accessed on 10 January 2020)]; 2019 Available online: https://www.farmers.gov/manage/hemp?utm_medium=email&utm_source=govdelivery
32. Health Canada Cultivation Licenses. [(accessed on 10 January 2020)]; 2011 Available online: http://www.hc-sc.gc.ca/
34. Mark T., Shepherd J., Olson D., Snell W., Proper S., Thornsbury S. Economic Viability of Industrial Hemp in the United States: A Review of State Pilot Programs. [(accessed on 10 January 2020)]; Available online: https://www.ers.usda.gov/webdocs/publications/95930/eib-217.pdf?v=4149.6
35. Deferne J.L., Pate D.W. Hemp seed oil: A source of valuable essential fatty acids. J. Int. Hemp Assoc. 1996; 3 :4–7. [Google Scholar]
36. House J.D., Neufeld J., Leson G. Evaluating the quality of protein from hemp seed (Cannabis sativa L.) products through the use of the protein digestibility-corrected amino acid score method. J. Agric. Food Chem. 2010; 58 :11801–11807. doi: 10.1021/jf102636b. [PubMed] [CrossRef] [Google Scholar]
37. Silversides F.G., Lefrancois M.R. The effect of feeding hemp seed meal to laying hens. Br. Poult. Sci. 2005; 46 :231–235. doi: 10.1080/0071660500066183. [PubMed] [CrossRef] [Google Scholar]
38. Ditrói K., Kleiner D., Böszörményi A., Szentmihályi K., Fébel H. The alimentary impact of the hemp seed. Acta Aliment. 2013; 42 :410–416. doi: 10.1556/AAlim.42.2013.3.14. [CrossRef] [Google Scholar]
39. Schultz C.J., Lim W.L., Khor S.F., Neumann K.A., Schulz J.M., Ansari O., Skewes M.A., Burton R.A. Consumer and health-related traits of seed from selected commercial and breeding lines of industrial hemp, Cannabis sativa L. J. Agric. Food Res. 2020; 2 :100025. doi: 10.1016/j.jafr.2020.100025. [CrossRef] [Google Scholar]
40. Dimić E., Romanić R., Vujasinović V. Essential fatty acids, nutritive value and oxidative stability of cold pressed hempseed (Cannabis sativa L.) oil from different varieties. Acta Aliment. 2009; 38 :229–236. doi: 10.1556/AAlim.2008.0035. [CrossRef] [Google Scholar]
41. Kriese U., Schumann E., Weber W.E., Beyer M., Brühl L., Matthäus Oil content, tocopherol composition and fatty acid patterns of the seeds of 51 Cannabis sativa L. genotypes. Euphytica. 2004; 137 :339–351. doi: 10.1023/B:EUPH.0000040473.23941.76. [CrossRef] [Google Scholar]
42. Alberta Agriculture and Forestry Industrial Hemp Enterprise. [(accessed on 12 May 2020)]; 2015 Available online: www.agriculture.alberta.ca/publications
43. Leizer C., Ribnicky D., Poulev A., Dushenkov S., Raskin I. The composition of hemp seed oil and its potential as an important source of nutrition. J. Nutraceut. Funct. Med. Foods. 2000; 2 :35–53. doi: 10.1300/J133v02n04_04. [CrossRef] [Google Scholar]
44. Petrović M., Debeljak Ž., Kezić N., Džidara P. Relationship between cannabinoids content and composition of fatty acids in hempseed oils. Food Chem. 2015; 170 :218–225. doi: 10.1016/j.foodchem.2014.08.039. [PubMed] [CrossRef] [Google Scholar]
45. Oomah B.D., Busson M., Godfrey D.V., Drover J.C.G. Characteristics of hemp (Cannabis sativa L.) seed oil. Food Chem. 2002; 76 :33–43. doi: 10.1016/S0308-8146(01)00245-X. [CrossRef] [Google Scholar]
46. Smeriglio A., Galati E.M., Monforte M.T., Lanuzza F., D’Angelo V., Circosta C. Polyphenolic compounds and antioxidant activity of cold-pressed seed oil from finola cultivar of Cannabis sativa L. Phytother. Res. 2016; 30 :1298–1307. doi: 10.1002/ptr.5623. [PubMed] [CrossRef] [Google Scholar]
47. Russo E.B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 2011; 163 :1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
48. Grof C.P. Cannabis, from plant to pill. Br. J. Clin. Pharmacol. 2018; 84 :2463–2467. doi: 10.1111/bcp.13618. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
49. Citti C., Linciano P., Panseri S., Vezzalini F., Forni F., Vandelli M.A., Cannazza G. Cannabinoid profiling of hemp seed oil by liquid chromatography coupled to high-resolution mass spectrometry. Front. Plant Sci. 2019; 10 :120. doi: 10.3389/fpls.2019.00120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
50. Corroon J., Felice J.F. The endocannabinoid system and its modulation by cannabidiol (CBD) Alter. Ther. Health Med. 2019; 25 :6–14. [PubMed] [Google Scholar]
51. Kumar A., Premoli M., Aria F., Bonini S.A., Maccarinelli G., Gianoncelli A., Memo M., Mastinu A. Cannabimimetic plants: Are they new cannabinoidergic modulators? Planta. 2019; 249 :1681–1694. doi: 10.1007/s00425-019-03138-x. [PubMed] [CrossRef] [Google Scholar]
52. Mastinu A., Premoli M., Ferrari-Toninelli G., Tambaro S., Maccarinelli G., Memo M., Bonini S.A. Cannabinoids in health and disease: Pharmacological potential in metabolic syndrome and neuroinflammation. Horm. Mol. Biol. Clin. Investig. 2018; 36 :1–15. doi: 10.1515/hmbci-2018-0013. [PubMed] [CrossRef] [Google Scholar]
53. Massi P., Vaccani A., Ceruti S., Colombo A., Abbracchio M.P., Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther. 2004; 308 :838–845. doi: 10.1124/jpet.103.061002. [PubMed] [CrossRef] [Google Scholar]
54. Sánchez C., de Ceballos M.L., Del Pulgar T.G., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Cajal S.R.Y., Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. [(accessed on 12 May 2020)]; Cancer Res. 2001 61 :5784–5789. Available online: https://cancerres.aacrjournals.org/content/61/15/5784 [PubMed] [Google Scholar]
55. Freeman A.M., Petrilli K., Lees R., Hindocha C., Mokrysz C., Curran H.V., Saunders R., Freeman T.P. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci. Biobehav. Rev. 2019; 107 :696–712. doi: 10.1016/j.neubiorev.2019.09.036. [PubMed] [CrossRef] [Google Scholar]
56. Premoli M., Aria F., Bonini S.A., Maccarinelli G., Gianoncelli A., Della Pina S., Tambaro S., Memo M., Mastinu A. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019; 224 :120–127. doi: 10.1016/j.lfs.2019.03.053. [PubMed] [CrossRef] [Google Scholar]
57. VanDolah H.J., Bauer B.A., Mauck K.F. Clinicians’ guide to cannabidiol and hemp oils. Mayo Clin. Proc. 2019; 94 :1840–1851. doi: 10.1016/j.mayocp.2019.01.003. [PubMed] [CrossRef] [Google Scholar]
58. White C.M. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J. Clin. Pharmacol. 2019; 59 :923–934. doi: 10.1002/jcph.1387. [PubMed] [CrossRef] [Google Scholar]
59. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorgan. Med. Chem. 2015; 23 :1377–1385. doi: 10.1016/j.bmc.2015.01.059. [PubMed] [CrossRef] [Google Scholar]
60. Schwab U.S., Callaway J.C., Erkkilä A.T., Gynther J., Uusitupa M.I., Järvinen T. Effects of hemp seed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors. Eur. J. Nutr. 2006; 45 :457–470. doi: 10.1007/s00394-006-0621-z. [PubMed] [CrossRef] [Google Scholar]
61. Al-Khalifa A., Maddaford T.G., Chahine M.N., Austria J.A., Edel A.L., Richard M.N., Ander B.P., Gavel N., Kopilas M., Ganguly R., et al. Effect of dietary hempseed intake on cardiac ischemia-reperfusion injury. Am. J. Physiology. Integr. Comp. Physiol. 2007; 292 :R1198–R1203. doi: 10.1152/ajpregu.00661.2006. [PubMed] [CrossRef] [Google Scholar]
62. Richard M.N., Ganguly R., Steigerwald S.N., Al-Khalifa A., Pierce G.N. Dietary hemp seed reduces platelet aggregation. J. Thromb. Haemost. 2007; 5 :424–425. doi: 10.1111/j.1538-7836.2007.02327.x. [PubMed] [CrossRef] [Google Scholar]
63. Prociuk M.A., Edel A.L., Richard M.N., Gavel N.T., Ander B.P., Dupasquier C.M., Pierce G.N. Cholesterol-induced stimulation of platelet aggregation is prevented by a hempseed-enriched diet. Can. J. Physiol. Pharmacol. 2008; 86 :153–159. doi: 10.1139/Y08-011. [PubMed] [CrossRef] [Google Scholar]
64. Kaushal N., Dhadwal S., Kaur P. Ameliorative effects of hempseed (Cannabis sativa) against hypercholesterolemia associated cardiovascular changes. Nutr. Metab. Cardiovasc. Dis. 2020; 30 :330–338. doi: 10.1016/j.numecd.2019.09.006. [PubMed] [CrossRef] [Google Scholar]
65. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., Carchman R.A. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. 1975; 55 :597–602. doi: 10.1093/jnci/55.3.597. [PubMed] [CrossRef] [Google Scholar]
66. Alexander A., Smith P.F., Rosengren R.J. Cannabinoids in the treatment of cancer. Cancer Lett. 2009; 285 :6–12. doi: 10.1016/j.canlet.2009.04.005. [PubMed] [CrossRef] [Google Scholar]
67. Sarfaraz S., Afaq F., Adhami V.M., Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005; 65 :1635–1641. doi: 10.1158/0008-5472.CAN-04-3410. [PubMed] [CrossRef] [Google Scholar]
68. Vaccani A., Massi P., Colombo A., Rubino T., Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol. 2005; 144 :1032–1036. doi: 10.1038/sj.bjp.0706134. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
69. Dumitru C.A., Sandalcioglu I.E., Karsak M. Cannabinoids in glioblastoma therapy: New applications for old drugs. Front. Mol. Neurosci. 2018; 11 :159. doi: 10.3389/fnmol.2018.00159. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
70. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 2006; 318 :1375–1387. doi: 10.1124/jpet.106.105247. [PubMed] [CrossRef] [Google Scholar]
71. Pellati F., Borgonetti V., Brighenti V., Biagi M., Benvenuti S., Corsi L. Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Res. Int. 2018; 2018 :1–15. doi: 10.1155/2018/1691428. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
72. Blázquez C., Carracedo A., Barrado L., Real P.J., Fernández-Luna J.L., Velasco G., Malumbres M., Guzmán M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006; 20 :2633–2635. doi: 10.1096/fj.06-6638fje. [PubMed] [CrossRef] [Google Scholar]
73. Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M., Velasco G., Iovanna J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006; 66 :6748–6755. doi: 10.1158/0008-5472.CAN-06-0169. [PubMed] [CrossRef] [Google Scholar]
74. Ferro R., Adamska A., Lattanzio R., Mavrommati I., Edling C.E., Arifin S.A., Fyffe C.A., Sala G., Sacchetto L., Chiorino G., et al. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene. 2018; 37 :6368–6382. doi: 10.1038/s41388-018-0390-1. [PubMed] [CrossRef] [Google Scholar]
75. Cianchi F., Papucci L., Schiavone N., Lulli M., Magnellic L., Vinci M.C., Messerini L., Manera C., Ronconi E., Romagnani P., et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res. 2008; 14 :7691–7700. doi: 10.1158/1078-0432.CCR-08-0799. [PubMed] [CrossRef] [Google Scholar]
76. Castillo A., Tolón M.R., Fernández-Ruiz J., Romero J., Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol. Dis. 2010; 37 :434–440. doi: 10.1016/j.nbd.2009.10.023. [PubMed] [CrossRef] [Google Scholar]
77. Pazos M.R., Cinquina V., Gómez A., Layunta R., Santos M., Fernández-Ruiz J., Martínez-Orgado J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology. 2012; 63 :776–783. doi: 10.1016/j.neuropharm.2012.05.034. [PubMed] [CrossRef] [Google Scholar]
78. Pazos M.R., Mohammed N., Lafuente H., Santos M., Martínez-Pinilla E., Moreno E., Valdizán E.M., Romero J., Pazos A., Franco R., et al. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT(1A) and CB2 receptors. Neuropharmacology. 2013; 71 :282–291. doi: 10.1016/j.neuropharm.2013.03.027. [PubMed] [CrossRef] [Google Scholar]
79. Mori M.A., Meyer E., Soares L.M., Milani H., Guimarães F.S., de Oliveira R.M.W. Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2017; 75 :94–105. doi: 10.1016/j.pnpbp.2016.11.005. [PubMed] [CrossRef] [Google Scholar]
80. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Therap. 2010; 332 :569–577. doi: 10.1124/jpet.109.159145. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Jones N.A., Glyn S.E., Akiyama S., Hill T.D., Hill A.J., Weston S.E., Burnett M.D., Yamasaki Y., Stephens G.J., Whalley B.J., et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012; 21 :344–352. doi: 10.1016/j.seizure.2012.03.001. [PubMed] [CrossRef] [Google Scholar]
82. Szaflarski J.P., Bebin E.M., Cutter G., DeWolfe J., Dure L.S., Gaston T.E., Kankirawatana P., Liu Y., Singh R., Standaert D.G., et al. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy Behav. 2018; 87 :131–136. doi: 10.1016/j.yebeh.2018.07.020. [PubMed] [CrossRef] [Google Scholar]
83. Langford R.M., Mares J., Novotna A., Vachova M., Novakova I., Notcutt W., Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 2013; 260 :984–997. doi: 10.1007/s00415-012-6739-4. [PubMed] [CrossRef] [Google Scholar]
84. Wade D.T., Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. J. 2004; 10 :434–441. doi: 10.1191/1352458504ms1082oa. [PubMed] [CrossRef] [Google Scholar]
85. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65 :812–819. doi: 10.1212/01.wnl.0000176753.45410.8b. [PubMed] [CrossRef] [Google Scholar]
86. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., Schnelle M., Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. J. 2004; 10 :417–424. doi: 10.1191/1352458504ms1048oa. [PubMed] [CrossRef] [Google Scholar]
87. Ferreira-Junior N.C., Campos A.C., Guimarães F.S., Del-Bel E., Zimmermann P.M.D.R., Junior L.B., Hallak J.E., Crippa J.A., Zuardi A.W., Brum L. Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Bras. J. Psychiatry. 2020; 42 :218–224. doi: 10.1590/1516-4446-2019-0460. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
88. Cho H. Dongeubogam—Naekyeong and Oehyeong. Yeo Gang Publishing Company; Seoul, Korea: 2005. pp. 1–1279. [Google Scholar]
89. Choy E. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012; 51 (Suppl. S5):v3–v11. doi: 10.1093/rheumatology/kes113. [PubMed] [CrossRef] [Google Scholar]
90. Jeong M., Cho J., Shin J.-I., Jeon Y.-J., Kim J.-H., Lee S.-J., Kim E.-S., Lee K.-H. Hempseed oil induces reactive oxygen species- and C/EBP homologous protein-mediated apoptosis in MH7A human rheumatoid arthritis fibroblast-like synovial cells. J. Ethnopharmacol. 2014; 154 :745–752. doi: 10.1016/j.jep.2014.04.052. [PubMed] [CrossRef] [Google Scholar]
91. Hammell D.C., Zhang L.P., Ma F., Abshire S.M., McIlwrath S.L., Stinchcomb A.L., Westlund K.N. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur. J. Pain. 2016; 20 :936–948. doi: 10.1002/ejp.818. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
92. Gamble L.J., Boesch J.M., Frye C.W., Schwark W.S., Mann S., Wolfe L., Brown H., Berthelsen E.S., Wakshlag J.J. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front. Vet. Sci. 2018; 5 :165. doi: 10.3389/fvets.2018.00165. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
93. Callaway J., Schwab U., Harvima I., Halonen P., Mykkänen O., Hyvönen P., Järvinen T. Efficacy of dietary hempseed oil in patients with atopic dermatitis. J. Dermatol. Treat. 2005; 16 :87–94. doi: 10.1080/09546630510035832. [PubMed] [CrossRef] [Google Scholar]
94. Harbridge L.S. Dietary n-6 and n-3 fatty acids in immunity and autoimmune disease. Proc. Nutr. Soc. 1998; 57 :555–562. doi: 10.1079/pns19980081. [PubMed] [CrossRef] [Google Scholar]
95. Karsak M., Gaffal E., Date R., Wang-Eckhardt L., Rehnelt J., Petrosino S., Starowicz K., Steuder R., Schlicker E., Cravatt B., et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 2007; 316 :1494–1497. doi: 10.1126/science.1142265. [PubMed] [CrossRef] [Google Scholar]
96. Okuyama H., Kobayashi T., Watanabe S. Dietary fatty acids –the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan. Prog. Lipid Res. 1996; 35 :409–457. doi: 10.1016/S0163-7827(96)00012-4. [PubMed] [CrossRef] [Google Scholar]
97. Whiting P., Wolff R.F., Deshpande S., Di Nisio M., Duffy S., Hernandez A.V., Keurentjes J.C., Lang S.H., Misso K., Ryder S., et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015; 313 :2456–2473. doi: 10.1001/jama.2015.6358. [PubMed] [CrossRef] [Google Scholar]
98. Wright M., Di Ciano P., Brands B. Use of cannabidiol for the treatment of anxiety: A short synthesis of preclinical and clinical evidence. Cannabis Cannabinoid Res. 2019; 10 :1–6. doi: 10.1089/can.2019.0052. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
99. Blessing E.M., Steenkamp M.M., Manzanares J., Marmar C.R. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015; 12 :825–836. doi: 10.1007/s13311-015-0387-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
100. Bitencourt R.M., Takahashi R.N. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: From bench research to confirmation in human trials. Front. Neurosci. 2018; 12 :502. doi: 10.3389/fnins.2018.00502. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
101. Shoval G., Shbiro L., Hershkovitz L., Hazut N., Zalsman G., Mechoulam R., Weller A. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology. 2016; 73 :123–129. doi: 10.1159/000443890. [PubMed] [CrossRef] [Google Scholar]
102. Shbiro L., Hen-Shoval D., Hazut N., Rapps K., Dar S., Zalsman G., Mechoulam R., Weller A., Shoval G. Effects of cannabidiol in males and females in two different rat models of depression. Physiol. Behav. 2019; 201 :59–63. doi: 10.1016/j.physbeh.2018.12.019. [PubMed] [CrossRef] [Google Scholar]
103. Bhattacharyya S., Wilson R., Appiah-Kusi E., O’Neill A., Brammer M., Perez J., Murray R.M., Allen P., Bossong M.G., McGuire P.K. Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial. JAMA Psychiatry. 2018; 75 :1107. doi: 10.1001/jamapsychiatry.2018.2309. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
104. Hurd Y.L., Spriggs S., Alishayev J., Winkel G., Gurgov K., Kudrich C., Oprescu A.M., Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am. J. Psychiatry. 2019; 176 :911–922. doi: 10.1176/appi.ajp.2019.18101191. [PubMed] [CrossRef] [Google Scholar]
105. Bonini S.A., Premoli M., Tambaro S., Kumar A., Maccarinelli G., Memo M., Mastinu A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol. 2018; 227 :300–315. doi: 10.1016/j.jep.2018.09.004. [PubMed] [CrossRef] [Google Scholar]
106. Shannon S., Lewis N., Lee H., Hughes S. Cannabidiol in anxiety and sleep: A large case series. Perman. J. 2019; 23 :18–41. doi: 10.7812/TPP/18-041. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
107. Murillo-Rodríguez E., Sarro-Ramírez A., Sánchez D., Mijangos-Moreno S., Tejeda-Padrón A., Poot-Aké A., Guzmán K., Pacheco-Pantoja E., Arias-Carrión O. Potential effects of cannabidiol as a wake-promoting agent. Curr. Neuropharmacol. 2014; 12 :269–272. doi: 10.2174/1570159X11666131204235805. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
108. Crippa J.A., Zuardi A.W., Martín-Santos R., Bhattacharyya S., Atakan Z., McGuire P., Fusar-Poli P. Cannabis and anxiety: A critical review of the evidence. Hum. Psychopharmacol. 2009; 24 :515–523. doi: 10.1002/hup.1048. [PubMed] [CrossRef] [Google Scholar]
109. Prud’homme M., Cata R., Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: A systematic review of the evidence. Subst. Abuse Res. Treat. 2015; 9 :33–38. doi: 10.4137/SART.S25081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
110. Cheng C.W., Bian Z.X., Zhu L.X., Wu J.C.Y., Sung J.J.Y. Efficacy of a Chinese herbal proprietary medicine (hemp seed pill) for functional constipation. Am. J. Gastroenterol. 2011; 106 :120–129. doi: 10.1038/ajg.2010.305. [PubMed] [CrossRef] [Google Scholar]
111. Lin Z.M., Chen L.M., Liang Z.M., Xia X. The effect of different extractants from hemp seed in mice with Alzheimer’s disease. Pharmacol. Clin. Chin. Materia Med. 2016; 32 :130–134. doi: 10.13412/j.cnki.zyyl.2016.06.035. [CrossRef] [Google Scholar]
112. Luo J., Yin J.H., Wu H.Z., Wei Q. Extract from Fructus cannabis activating calcineurin improved learning and memory in mice with chemical drug-induced dysmnesia. [(accessed on 12 May 2020)]; Acta Pharmacol. Sin. 2003 24 :1137–1142. Available online: https://pubmed.ncbi.nlm.nih.gov/14627499/ [PubMed] [Google Scholar]
113. Booz G.W. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic. Biol. Med. 2011; 51 :1054–1061. doi: 10.1016/j.freeradbiomed.2011.01.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
114. Nichols J.M., Kaplan B.L.F. Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 2020; 5 :12–31. doi: 10.1089/can.2018.0073. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
115. Lehmann C., Fisher N.B., Tugwell B., Szczesniak A., Kelly M., Zhou J. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clin. Hemorheol. Microcir. 2016; 64 :655–662. doi: 10.3233/CH-168021. [PubMed] [CrossRef] [Google Scholar]
116. Zhou Y., Wang S., Ji J., Lou H., Fan P. Hemp (Cannabis sativa L.) seed phenylpropionamides composition and effects on memory dysfunction and biomarkers of neuroinflammation induced by lipopolysaccharide in mice. ACS Omega. 2018; 3 :15988–15995. doi: 10.1021/acsomega.8b02250. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
117. Russo E.B. Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016; 1 :154–165. doi: 10.1089/can.2016.0009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
118. Baron E.P. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, Headache, and pain: An update on current evidence and cannabis science. Headache. 2018; 58 :1139–1186. doi: 10.1111/head.13345. [PubMed] [CrossRef] [Google Scholar]
119. Vučković S., Srebro D., Vujović K.S., Vučetić Č., Prostran M. Cannabinoids and pain: New insights from old molecules. Front. Pharmacol. 2018; 9 :1259. doi: 10.3389/fphar.2018.01259. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
120. Parker T.D., Adams D.A., Zhou K., Harris M., Yu L. Fatty acid composition and oxidative stability of cold-pressed edible seed oils. J. Food Sci. 2006; 68 :1240–1243. doi: 10.1111/j.1365-2621.2003.tb09632.x. [CrossRef] [Google Scholar]
121. Uluata S., Özdemir N. Antioxidant activities and oxidative stabilities of some unconventional oilseeds. J. Am. Oil Chem. Soc. 2012; 89 :551–559. doi: 10.1007/s11746-011-1955-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
122. Montserrat-de la Paz S., Marín-Aguilar F., García-Giménez M.D., Fernández-Arche M.A. Hemp (Cannabis sativa L.) seed oil: Analytical and phytochemical characterization of the unsaponifiable fraction. J. Agric. Food Chem. 2014; 62 :1105–1110. doi: 10.1021/jf404278q. [PubMed] [CrossRef] [Google Scholar]
123. Small E., Marcus D. Hemp: A new crop with new uses for North America. In: Janick J., Whipkey A., editors. Trends in New Crops and New Uses. ASHS Press; Alexandria, VA, USA: 2002. pp. 284–326. [Google Scholar]
124. Shim J.S. Manufacturing Method of Bread Containing Blue Ginseng Seed. No. 100927544 B1. [(accessed on 10 January 2020)]; South Korea Patent. 2009 Available online: https://patents.google.com/patent/KR100927544B1/en
125. Shim J.S. Method for Manufacturing Confectionery Containing Blue Ginseng. No. 100969163 B1. [(accessed on 10 January 2020)]; South Korea Patent. 2010 Available online: https://patents.google.com/patent/KR100969163B1/en
126. Guang H., Wenwei C. Application of Powder of Whole Cannabis Sativa Seeds for Preparing Functional Food with Adjuvant Therapy of Lowering Blood Fat. No. 100998414 B. [(accessed on 12 May 2020)]; China Patent. 2010 Available online: https://patents.google.com/patent/CN100998414B/en
127. Metz M., Selg-Mann K. Production of a Food Seasoning, e.g., Useful as a Substitute for Soy Sauce, by Two-Stage Fermentation of Hemp Seeds. No. 10002389 A1. [(accessed on 12 May 2020)]; Germany Patent. 2005 Available online: https://patents.google.com/patent/DE10002389A1/en
128. Steinbach W. Hemp Pralines. No. 19746830 C1. [(accessed on 12 May 2020)]; Germany Patent. 1999 Available online: https://patents.google.com/patent/DE19746830C1/en
129. Berghofer E., Pollmann K., Traby M., Frenkenberger C. Method for Producing Hemp Milk. No. 2505350 C. [(accessed on 12 May 2020)]; Canada Patent. 2012 Sep 25; Available online: https://patents.google.com/patent/CA2505350C/en
130. Ge Z., Wu R. Hempseed Protein Drink and Producing Method Thereof. No. 1054034 C. [(accessed on 12 May 2020)]; China Patent. 2000 Available online: https://patents.google.com/patent/CN1054034C/en
131. Guang H., Hua Y. Hempseed Protein Powder and Its Preparing Method and Use. No. 1294833 C. [(accessed on 12 May 2020)]; China Patent. 2007 Available online: https://patents.google.com/patent/CN1294833C/en
132. Guang H., Wenwei C. Application of Fructus Cannabis Protein in Preparation of Health Food for Relieving Nutritional Anemia. No. 100433990 C. [(accessed on 12 May 2020)]; China Patent. 2008 Available online: https://patents.google.com/patent/CN100433990C/en
133. Cerino P., Buonerba C., Cannazza G., D’Auria J., Ottoni E., Fulgione A., Di Stasio A., Pierri B., Gallo A. A review of hemp as food and nutritional supplement. Cannabis Cannabinoid Res. 2020; 10 :1–9. doi: 10.1089/can.2020.0001. [CrossRef] [Google Scholar]
134. Bisterfeld von Merr G. Method of Obtaining Hemp Plant Juice and Use of Same for the Production of Beverages. No. 8778418 B2. [(accessed on 12 May 2020)]; USA Patent. 2014 Jul 15; Available online: https://patents.google.com/patent/US8778418B2/en
135. Frassinetti S., Moccia E., Caltavuturo L., Gabriele M., Longo V., Bellani L., Giorgi G., Giorgetti L. Nutraceutical potential of hemp (Cannabis sativa L.) seeds and sprouts. Food Chem. 2018; 262 :56–66. doi: 10.1016/j.foodchem.2018.04.078. [PubMed] [CrossRef] [Google Scholar]
136. Mihoc M., Pop G., Alexa E., Radulov I. Nutritive quality of Romanian hemp varieties (Cannabis sativa L.) with special focus on oil and metal contents of seeds. Chem. Central J. 2012; 6 :122–134. doi: 10.1186/1752-153X-6-122. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
137. Werz O., Seegers J., Schaible A.M., Weinigel C., Barz D., Koeberle A., Allegrone G., Pollastro F., Zampieri L., Grassi G., et al. Cannaflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lypoxygenase. Pharm. Nutr. 2014; 2 :53–60. doi: 10.1016/j.phanu.2014.05.001. [CrossRef] [Google Scholar]
138. Devi V., Khanam S. Comparative study of different extraction processes for hemp (Cannabis sativa) seed oil considering physical, chemical and industrial-scale economic aspects. J. Clean. Prod. 2019; 207 :645–657. doi: 10.1016/j.jclepro.2018.10.036. [CrossRef] [Google Scholar]
139. Prescha A., Grajzer M., Dedyk M., Grajeta H. The antioxidant activity and oxidative stability of cold-pressed oils. J. Am. Oil Chem. Soc. 2014; 91 :1291–1301. doi: 10.1007/s11746-014-2479-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
140. Da Porto C., Decorti D., Natolino A. Separation of aroma compounds from industrial hemp inflorescences (Cannabis sativa L.) by supercritical CO2 extraction and on-line fractionation. Ind. Crops Prod. 2014; 58 :99–103. doi: 10.1016/j.indcrop.2014.03.042. [CrossRef] [Google Scholar]
141. Kostić M.D., Joković N.M., Stamenković O.S., Rajković K.M., Milić P.S., Veljković V.B. Optimization of hempseed oil extraction by n-hexane. Ind. Crops Prod. 2013; 48 :133–143. doi: 10.1016/j.indcrop.2013.04.028. [CrossRef] [Google Scholar]
142. Subratti A., Lalgee L.J., Jalsa N.K. Liquified dimethyl ether (DME): A green solvent for the extraction of hemp (Cannabis sativa L.) seed oil. Sustain. Chem. Pharm. 2019; 12 :100144. doi: 10.1016/j.scp.2019.100144. [CrossRef] [Google Scholar]
143. Bomgardner M. Entrepreneurs get in on the ground floor with CBD from hemp. Chem. Eng. News. 2018; 96 :32. [Google Scholar]
144. Grijó D.R., Piva G.K., Osorio I.V., Cardozo-Filho L. Hemp (Cannabis sativa L.) seed oil extraction with pressurized n-propane and supercritical carbon dioxide. J. Supercrit. Fluids. 2019; 143 :268–274. doi: 10.1016/j.supflu.2018.09.004. [CrossRef] [Google Scholar]
145. Da Porto C., Decorti D., Tubaro F. Fatty acid composition and oxidation stability of hemp (Cannabis sativa L.) seed oil extracted by supercritical carbon dioxide. Ind. Crops Prod. 2012; 36 :401–404. doi: 10.1016/j.indcrop.2011.09.015. [CrossRef] [Google Scholar]
146. Da Porto C., Voinovich D., Decorti D., Natolino A. Response surface optimization of hemp seed (Cannabis sativa L.) oil yield and oxidation stability by supercritical carbon dioxide extraction. J. Supercrit. Fluids. 2012; 68 :45–51. doi: 10.1016/j.supflu.2012.04.008. [CrossRef] [Google Scholar]
147. Aladić K., Jarni K., Barbir T., Vidović S., Vladić J., Bilić M., Jokić S. Supercritical CO2 extraction of hemp (Cannabis sativa L.) seed oil. Ind. Crops Prod. 2015; 76 :472–478. doi: 10.1016/j.indcrop.2015.07.016. [CrossRef] [Google Scholar]
148. Tomita K., Machmudah S., Quitain A.T., Sasaki M., Fukuzato R., Goto M. Extraction and solubility evaluation of functional seed oil in supercritical carbon dioxide. J. Supercrit. Fluids. 2013; 79 :109–113. doi: 10.1016/j.supflu.2013.02.011. [CrossRef] [Google Scholar]
149. Zongbing P. Be Rich in the Industrial Hemp Extraction of Essential Oil Equipment of Cannabidiol. No. 204111719 U. [(accessed on 17 June 2020)]; China Patent. 2015 Available online: https://patents.google.com/patent/CN204111719U/en
150. Mueller A. Method for Producing an Extract from Cannabis Plant Matter, Containing a Tetrahydrocannabinol and a Cannabidiol and Cannabis Extracts. No. 8895078 B2. [(accessed on 17 June 2020)]; USA Patent. 2014 Available online: https://patents.google.com/patent/US8895078B2/en
151. Keliang L., Qingtao T., Yazhong G., Zhonghua M., Huisen L. Ultrasonic Assisted Supercritical CO2 Hemp Seed Oil Extraction Method. No. 102676290 B. [(accessed on 17 June 2020)]; China Patent. 2013 Available online: https://patents.google.com/patent/CN102676290B/en
152. Horska I. Transport and Absorption Agents and the Method of Its Manufacture from Hems. No. 602004007164 T2. [(accessed on 17 June 2020)]; Germany Patent. 2008 Available online: https://patents.google.com/patent/DE602004007164T2/en
153. Webster G.R.B., Sarna L.P. Cannabinoid Extraction Method. No. 6403126 B1. [(accessed on 17 June 2020)]; USA Patent. 2002 Jun 11; Available online: https://patents.google.com/patent/US6403126B1/en
154. Raderman J.M. Method for Modifying THC Content in a Lipid-Based Extract of Cannabis. No. 9259449 B2. [(accessed on 17 June 2020)]; USA Patent. 2016 Available online: https://patents.google.com/patent/US9259449B2/en
155. Brighenti V., Pellati F., Steinbach M., Maran D., Benvenuti S. Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp) J. Pharm. Biomed. Anal. 2017; 143 :228–236. doi: 10.1016/j.jpba.2017.05.049. [PubMed] [CrossRef] [Google Scholar]
156. Teh S.S., Birch E.J. Effect of ultrasonic treatment on the polyphenol content and antioxidant capacity of extract from defatted hemp, flax and canola seed cakes. Ultrason. Sonochem. 2014; 21 :346–353. doi: 10.1016/j.ultsonch.2013.08.002. [PubMed] [CrossRef] [Google Scholar]
157. Teh S.S., Niven B.E., Bekhit A.E.D.A., Carne A., Birch E.J. The use of microwave and pulsed electric field as a pretreatment step in ultrasonic extraction of polyphenols from defatted hemp seed cake (Cannabis sativa) using response surface methodology. Food Bioprocess Technol. 2014; 7 :3064–3076. doi: 10.1007/s11947-014-1313-y. [CrossRef] [Google Scholar]
158. Chang C.W., Yen C.C., Wu M.T., Hsu M.C., Wu Y.T. Microwave-assisted extraction of cannabinoids in hemp nut using response surface methodology: Optimization and comparative study. Molecules. 2017; 22 :1894. doi: 10.3390/molecules22111894. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
159. Chen T., He J., Zhang J., Zhang H., Qian P., Hao J., Li L. Analytical characterization of hempseed (seed of Cannabis sativa L.) oil from eight regions in China. J. Diet. Suppl. 2010; 7 :117–129. doi: 10.3109/19390211003781669. [PubMed] [CrossRef] [Google Scholar]
160. Crescente G., Piccolella S., Esposito A., Scognamiglio M., Fiorentino A., Pacifico S. Chemical composition and nutraceutical properties of hempseed: An ancient food with actual functional value. Phytochem. Rev. 2018; 17 :733–749. doi: 10.1007/s11101-018-9556-2. [CrossRef] [Google Scholar]
161. Pierce D., Brooks G. Quaternized Hemp Seed Oil. No. 6063369. [(accessed on 17 June 2020)]; USA Patent. 2000 Available online: https://patents.google.com/patent/US6063369A/en
162. Timilsena Y.P., Wang B., Adhikari R., Adhikari B. Advances in microencapsulation of polyunsaturated fatty acids (PUFAs)-rich plant oils using complex coacervation: A review. Food Hydrocoll. 2017; 69 :369–381. doi: 10.1016/j.foodhyd.2017.03.007. [CrossRef] [Google Scholar]
163. Arslan S., Erbas M., Tontul I., Topuz A. Microencapsulation of probiotic Saccharomyces cerevisiae var. boulardii with different wall materials by spray drying. LWT—Food Sci. Technol. 2015; 63 :685–690. doi: 10.1016/j.lwt.2015.03.034. [CrossRef] [Google Scholar]
164. Anwar S.H., Kunz B. The influence of drying methods on the stabilization of fish oil microcapsules: Comparison of spray granulation, spray drying, and freeze drying. J. Food Eng. 2011; 105 :367–378. doi: 10.1016/j.jfoodeng.2011.02.047. [CrossRef] [Google Scholar]
165. Anwar S.H., Weissbrodt J., Kunz B. Microencapsulation of fish oil by spray granulation and fluid bed film coating. J. Food Sci. 2010; 75 :E359–E371. doi: 10.1111/j.1750-3841.2010.01665.x. [PubMed] [CrossRef] [Google Scholar]
166. Desai K.G.H., Park H.J. Recent developments in microencapsulation of food ingredients. Dry. Technol. 2005; 23 :1361–1394. doi: 10.1081/DRT-200063478. [CrossRef] [Google Scholar]
167. Timilsena Y.P., Adhikari R., Barrow C.J., Adhikari B. Microencapsulation of chia seed oil using chia seed protein isolate-chia seed gum complex coacervates. Int. J. Biol. Macromol. 2016; 91 :347–357. doi: 10.1016/j.ijbiomac.2016.05.058. [PubMed] [CrossRef] [Google Scholar]
168. Wang B., Adhikari B., Barrow C.J. Optimisation of the microencapsulation of tuna oil in gelatin–sodium hexametaphosphate using complex coacervation. Food Chem. 2014; 158 :358–365. doi: 10.1016/j.foodchem.2014.02.135. [PubMed] [CrossRef] [Google Scholar]
169. Belščak-Cvitanović A., Bušić A., Barišić L., Vrsaljko D., Karlović S., Špoljarić I., Vojvodic A., Mršić G., Komes D. Emulsion templated microencapsulation of dandelion (Taraxacum officinale L.) polyphenols and β-carotene by ionotropic gelation of alginate and pectin. Food Hydrocoll. 2016; 57 :139–152. doi: 10.1016/j.foodhyd.2016.01.020. [CrossRef] [Google Scholar]
170. Mozafari M.R., Johnson C., Hatziantoniou S., Demetzos C. Nanoliposomes and their applications in food nanotechnology. J. Lip. Res. 2008; 18 :309–327. doi: 10.1080/08982100802465941. [PubMed] [CrossRef] [Google Scholar]
171. Coghetto C.C., Brinques G.B., Ayub M.A.Z. Probiotics production and alternative encapsulation methodologies to improve their viabilities under adverse environmental conditions. Int. J. Food Sci. Nutr. 2016; 67 :929–943. doi: 10.1080/09637486.2016.1211995. [PubMed] [CrossRef] [Google Scholar]
172. Augustin M.A., Hemar Y. Nano- and micro-structured assemblies for encapsulation of food ingredients. Chem. Soc. Rev. 2009; 38 :902–912. doi: 10.1039/B801739P. [PubMed] [CrossRef] [Google Scholar]
173. Prakash B., Kujur A., Yadav A., Kumar A., Singh P.P., Dubey N.K. Nanoencapsulation: An efficient technology to boost the antimicrobial potential of plant essential oils in food system. Food Contr. 2018; 89 :1–11. doi: 10.1016/j.foodcont.2018.01.018. [CrossRef] [Google Scholar]
174. Belščak-Cvitanović A., Vojvodić A., Bušić A., Keppler J., Steffen-Heins A., Komes D. Encapsulation templated approach to valorization of cocoa husk, poppy and hemp macrostructural and bioactive constituents. Ind. Crops Prod. 2018; 112 :402–411. doi: 10.1016/j.indcrop.2017.12.020. [CrossRef] [Google Scholar]
175. Malomo S.A., Aluka R.E. Conversion of a low protein hemp seed meal into a functional protein concentrate through enzymatic digestion of fibre coupled with membrane ultrafiltration. Innovat. Food Sci. Emerg. Technol. 2015; 31 :151–159. doi: 10.1016/j.ifset.2015.08.004. [CrossRef] [Google Scholar]
Articles from Molecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)